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Abstract 
 
 
 
 
Introduction: Medication non-adherence is prevalent in Parkinson’s disease (PD). 
However, factors associated with non-adherence are unknown. Despite 
interventions to improve medication adherence being investigated in long-term 
conditions, few studies have focused on PD. Adherence Therapy (AT) is a novel, 
patient-centred approach to maximising adherence that has shown benefit in other 
chronic conditions. 
 
Aim: To investigate the efficacy of AT for improving medication adherence and 
quality of Life (QoL) in people with PD. 
 
Methods: To achieve the above aim I conducted a systematic review to identify 
factors associated with medication non-adherence, followed by a Cochrane 
systematic review on interventions for improving medication adherence in PD. I 
then tested the efficacy of AT in PD in a randomised controlled trial (RCT). Semi-
structured interviews were used to explore patients’ experiences of receiving AT. 
 
Results: Mood disorders, cognition, poor symptom control/QoL, younger 
age/longer disease duration, regimen complexity/polypharmacy, risk taking 
  
behaviours, poor knowledge of PD/education, lack of spouse/partner, low income, 
desire to maintain employment and gender were identified as factors associated 
with non-adherence in PD. Only one study previously investigated an intervention 
(didactic educational material) for improving medication adherence in PD, 
according to my Cochrane systematic review.  
 
Seventy-six patients and 46 spouse/carers completed the RCT (CAAT-PARK). At 
week-12 follow-up the active treatment group significantly improved in adherence 
and QoL compared to the treatment as usual group. Thematic analysis of interviews 
from 10 patients and 3 spouse/carers suggested that positive effects and attributes 
of AT may be important for the success of AT. Furthermore, the findings suggested 
that the mechanism of AT may be bi-directional and associated with improved 
confidence and self-efficacy.  
 
Conclusions: Adherence Therapy improved medication adherence and QoL in PD. 
A larger pragmatic trial to test the efficacy and cost effectiveness of Adherence 
Therapy with a control group placebo intervention is required. ISRCTN07830951
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Parky’s Time 
 
 
 
“Parky is running around my brain what is he doing there 
He whizzes round from dawn to dusk and doesn’t seem to care 
He makes my life quite hard to plan and leaves me feeling down 
He twits my face this way and that and makes me wear a frown 
Levodopa is the answer, so all the experts say 
To put this right I have to take some medicine each day 
Through studies made it has been proved it’s most important to 
Not just take them every day, but at the right time too. 
My morning medications, starts off with good intent 
The sequence that I follow, is time I think well spent 
The importance of adherence, is there for all to see 
It soothes the highs and the lows you see, and leaves me tremor free 
It may be sometimes tiresome, for a clock to rule my day 
But all in all it helps me live my life a better way” 
 
Trial Participant: B181 (CRTU 052) 
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CHAPTER 1 
 
 
The Necessity of This Work 
 
 
Background 
The Structure and Aim of This Thesis 
 
 
 
1.1 Background 
Parkinson’s disease (PD) is a degenerative, neurological disorder that greatly 
impacts on Quality of Life (QoL). The diagnosis of PD is made based on four key 
symptoms: rigidity, bradykinesia (slowness of movement), postural instability and 
resting tremor (Hughes et al., 1992). Alongside motor dysfunction, many people 
with PD experience a wide variety of non-motor symptoms which can be both 
highly prevalent and problematic (Chaudhuri et al., 2006, Poewe, 2008).       
 
The symptoms of PD are controllable, although management becomes considerably 
more complex as the condition progresses. Not only do slowness, rigidity and gait 
problems respond to treatment, but many non-motor symptoms can also be relieved 
by PD medications. Healthcare professionals responsible for managing PD have the 
potential to substantially improve the QoL of patients. Although not all symptoms 
of PD can be sufficiently managed, anti-parkinsonian medication affords the 
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patient an optimal QoL, allowing many individuals to remain in the mainstream of 
their lives for many years post diagnosis (Ahlskog, 2009). 
 
Medication management for PD, however, is not straight forward and is 
complicated by a multitude of factors. There are various pharmaceutical 
formulations (drugs) available for use with the same therapeutic indications and 
overlapping pharmacodynamics. Many drugs can induce unique side effects, which 
may often be confused with the worsening symptoms of PD (Fahn, 1989). Despite 
a vast body of research, disparity remains in the literature concerning what is the 
best therapeutic approach to adopt at different stages of disease severity (Schapira, 
2007). Furthermore, controversy between expert opinions regarding when to 
initiate certain treatments remains topical and continues to be a source of debate 
(Schapira and Obeso, 2006).  
 
Obscuring management decisions further is the fact that PD is progressive, with 
new problems appearing over the course of the disease that can alter the therapeutic 
focus. This can result in continuous amendment of doses and class of medications 
used to control the symptoms. What’s more, as PD is mainly a condition prevalent 
in older people, age related comorbidities add further to the burden on QoL. In 
light of the aforementioned factors, it is evident that successful medical 
management of a person with PD is a complex and on-going pursuit, particularly as 
the disease progresses. 
 
As with all chronic diseases, adherence to medication is paramount for achieving 
effective symptom control; drugs do not have the desired therapeutic effect if they 
3 
 
are not taken as the prescriber intended (Rigby, 2007). However, reports from the 
World Health Organization (WHO) and the National Institute for Health and Care 
Excellence (NICE) in the UK suggest that a third to half of all medications 
prescribed to people with long term conditions are not taken as recommended 
(WHO, 2003, NICE, 2009).  
 
In PD more than half of people take two to four anti-parkinsonian medications 
three to four times daily (Leoni et al., 2002, Tan et al., 2005). This is because 
multiple drug classes are needed to adequately control symptoms as PD progresses 
(Schapira et al., 2009a). Adding further prescriptions often parallels dose 
escalation, resulting in complex polypharmacy (Kulkarni et al., 2008). Therefore, 
not surprisingly, medication adherence is poor in people with PD (Bainbridge and 
Ruscin, 2009). 
 
Whilst not taking prescribed medication as recommended will result in ill managed 
symptoms in many chronic conditions, the ramifications of non-adherence in PD 
are acutely problematic (Grosset et al., 2005b, Kulkarni et al., 2008, Grosset, 
2010). For example, sub-optimal medication adherence in PD can result in the 
‘wearing-off’ of the treatment effect which can increase motor dysfunction 
(Grosset et al., 2005b, Kulkarni et al., 2008, Grosset, 2010). Researchers have 
shown sub-optimal medication adherence to be associated with poor symptom 
control, increased unplanned hospital visits for PD related problems and a poorer 
overall prognosis (Kulkarni et al., 2008).  
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Aside from sub-optimal medication taking, people may also over medicate on anti-
parkinsonian therapy. This can result in severe motor complications such as peak 
dose motor fluctuations, dyskinesia (uncoordinated movements) and can even lead 
to psychosis (Lim et al., 2009, O'Sullivan et al., 2009). Although medication 
adherence is important in all chronic diseases, due to the intricate relationship 
between medication taking and both immediate and long-term symptom 
management, it is clear that sound adherence in PD is essential. 
 
The reasons for non-adherence are likely to be multi-dimensional. Consequentially, 
there is a need for greater understanding of the factors that are associated with 
medication non-adherence in PD. With an increased understanding of why patients 
may not adequately adhere to medication regimens, an intervention that specifically 
aims to enhance adherence behaviour can be investigated. A targeted therapy that 
acknowledges factors associated with sub-optimal medication taking may result in 
overall improvement in rates of adherence. As various motor and non-motor 
symptoms of PD are sensitive to anti-parkinsonian therapies, improved medication 
adherence may enhance overall function. Consequentially, improved adherence to 
medication could theoretically benefit QoL. 
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1.2 The Aim & Structure of This Thesis 
The main aim of the work presented in this thesis was to investigate the efficacy of 
an intervention for improving medication adherence in patients with PD. From this 
aim, several specific objectives were developed as presented below: 
 
1. To identify from the existing literature which factors are associated with 
medication non-adherence in people with PD. 
 
2. To identify from the literature which interventions have been investigated 
previously that aimed specifically to improve adherence to medication in PD. 
 
3. To develop a novel intervention aimed at improving medication adherence in 
people with PD. 
 
4. To investigate the efficacy of this novel intervention. 
 
5. To evaluate patient acceptability and to investigate the potential underlying 
mechanism of the adherence enhancing intervention. 
   
This thesis is presented in three parts. Part one contains Chapters 2, 3 and 4. In 
Chapter 2 I provide an introduction to PD, including an overview of the medication 
used to manage the common symptoms in both early and later stages of the disease. 
I then discuss the importance of medication adherence in PD, the prevalence of 
non-adherence and the associated consequences. 
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In Chapter 3 I present the rationale and findings of a systematic review identifying 
factors associated with medication non-adherence in people with PD. The 
development of a novel quality appraisal tool for assessing risk of bias is also 
discussed. Having highlighted factors associated with non-adherence in PD, in 
Chapter 4 I provide the rationale and findings of a Cochrane systematic review 
investigating interventions used to improve medication adherence in PD. 
 
Part 2 commences with Chapter 5 where I discuss the common psychological 
theories of behaviour change. The underlying principles of, and the evidence base 
for, the disciplines of motivational interviewing and cognitive behavioural therapy 
are presented. I then conclude by introducing the therapy of interest in this thesis; 
that is, Adherence Therapy (AT) and by discussing its evidence base from the 
existing literature. 
 
Chapter 6 outlines the justification and methodology for a randomised controlled 
trial investigating whether AT is beneficial for improving medication adherence 
and quality of life. The analyses undertaken and the ethical considerations relating 
to the conduct of the trial are then discussed. Part 3 starts with Chapter 7 where I 
present the quantitative findings of the RCT. In Chapter 8 I provide a detailed 
discussion of the findings. 
 
In Chapter 9 I investigate the acceptability of, and proposed mechanism for, the AT 
intervention using a qualitative methodological approach. In Chapter 10 a detailed 
discussion of the findings is provided and the implications for practice and further 
research are considered. 
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This thesis concludes with Chapter 11. The findings of the Cochrane systematic 
review, presented in Chapter 4, are considered when the results of the clinical trial 
are added. The implications of the overall findings within this thesis are considered 
for both clinical practice and future research. The dissemination of the findings is 
also outlined.     
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Part 1 
 
CHAPTER 2 
 
 
Parkinson’s Disease & Pharmacotherapy 
 
 
Introduction 
Parkinson’s Disease & The Nigrostriatal Pathway 
Prevalence and Cost of Parkinson’s Disease 
Symptoms of Parkinson’s Disease 
Pharmacotherapy for Parkinson’s Disease  
Treatment Regimens and Complexity in Parkinson’s Disease 
Medication Adherence 
Summary: A Greater Understanding 
 
 
 
2.1 Introduction 
This chapter provides an outline of PD. Specifically, I summarise the underlying 
pathophysiology, characteristic symptoms, prevalence and the cost of PD. 
Following this I then highlight the typical anti-parkinsonian medications used to 
treat the symptoms of PD. In the final part of this chapter I discuss medication non-
adherence and the associated consequences for people with PD. 
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2.2 Parkinson’s Disease & The Nigrostriatal Pathway 
The hallmark of PD is the progressive degeneration of the dopamine producing 
neurons within the substantia nigra (Jankovic, 2008). Microscopically, PD is 
characterised by the presence of Lewy bodies found within surviving nigral 
neurons. The protein alpha-synuclein, found in Lewy bodies, characterises PD 
aside from other forms of Parkinsonism (Ahlskog, 2009). 
 
The nigrostriatal pathway is positioned centrally in the extrapyramidal (basal 
ganglia) motor control circuits (Ahlskog, 2009). Identifying that the nigrostriatal 
pathway is dopaminergic resulted in the discovery that replenishing dopamine with 
levodopa is a very effective treatment for PD (Ahlskog, 2009). Today levodopa 
remains the foundation of PD treatment and has been recognised as the most 
effective pharmacological intervention for symptom management (Schapira et al., 
2009b).  
 
2.3 Prevalence and Cost of Parkinson’s Disease 
2.3.1 Prevalence 
Parkinson’s disease is the second most prevalent neurodegenerative disorder after 
Alzheimer’s disease (Mayeux et al., 1995, Bower et al., 1999, Nussbaum and Ellis, 
2003) and is anticipated to impose an increasing social and economic burden on 
society as populations continue to age (De Lau and Breteler, 2006). A report by the 
National Parkinson Foundation (NPF) in the United States (US) suggested that PD 
affects an estimated four to six million worldwide (Oberdorf and Schmidt, 2010). 
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In the UK, PD is estimated to affect 100–180 people per 100,000 of the population 
and has an annual incidence of 4-20 per 100,000 (NICE, 2006). The incidence of 
the disease rises with increasing age (Findley, 2007, Findley et al., 2003). One in 
seven are diagnosed before 50 years of age, with a fivefold increase in diagnosis in 
those aged over 65 (Schrag et al., 2000a). 
 
2.3.2 Cost of Parkinson’s Disease  
Due to an ageing population the prevalence of PD is forecast to increase 
substantially in the long term (De Lau and Breteler, 2006). This will result in 
immense financial dependency on healthcare organisations globally. Current costs 
are estimated to be $23 billion annually in the US alone and are projected to 
increase to $50 billion by 2040 (Oberdorf and Schmidt, 2010).  
 
A cross-sectional study of the economic impact of PD on healthcare providers in 
the UK showed an estimated cost for care of approximately £450 million (Findley 
et al., 2003). However, this calculation was thought to be the most conservative 
scenario. Using current and future predicted prevalence rates, cost for healthcare 
analysis suggests expenditure will reach as high as £3.3 billion annually (Findley, 
2007). Furthermore, the fiscal dependency for increased care in patients with PD 
rises exponentially with the progression of the disease. This is because people 
become increasingly medicated due to incapacitating motor and non-motor 
dysfunction.  
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Personalised one-to-one care may also be required for those who develop 
significant cognitive dysfunction, adding substantial costs for care (Oberdorf and 
Schmidt, 2010); researchers have shown cognitive impairment and dementia in PD 
greatly reduce QoL and can be more debilitating to patients and burdensome for 
carers than motor symptoms (Leroi et al., 2012). It is also well acknowledged that 
poor cognitive function is a key predictor of nursing home placement and mortality 
in people with PD (Hou and Lai, 2007, Liepelt et al., 2007).  
 
In light of the reported prevalence’s and findings from cost for healthcare analyses, 
it is essential that PD medication is closely managed to ensure that treatments are 
appropriate for each individual suffering from PD. 
 
2.4 Symptoms of Parkinson’s Disease 
Parkinsonism implies the appearance of PD characteristics and is a broad term used 
to include other disorders like progressive supranuclear palsy (PSP), multiple 
systems atrophy (MSA), PD dementia (PDD) and dementia with Lewy bodies 
(DLB) (Albanese, 2003, Jankovic, 2008, Ahlskog, 2009). Prior to the diagnosis of 
PD patients may report non-specific symptoms: feelings of depression and/or 
anxiety, REM (rapid eye movement) sleep disorder, fibromyalgia and olfactory 
dysfunctions. It is not until PD progresses further that parkinsonian associated 
symptoms present (Albanese, 2003).  
 
12 
 
For many the onset of PD is insidious and people classically present with the 
cardinal signs and symptoms associated with the overarching phenomenon of 
Parkinsonism (Table 2.1). Additionally, a dysfunctional presence of thoracic 
flexion and freezing during gait have been proposed as characteristically prominent 
features in advanced Parkinsonism (Albanese, 2003, Jankovic, 2008). 
 
Table 2. 1 - Symptoms of Parkinsonism 
Symptom Description 
  Bradykinesia 
   
  Rigidity 
   
  Gait 
   
  Resting tremor 
   
  Loss of  automatic 
  movements 
 
   
  Poor balance 
Slowed movements 
 
Resistance as the examiner moves a relaxed limb 
 
Shortened stride, reduced heel strike, shuffling 
 
Limbs, chin 
 
Reduced animation; for example, facial masking, 
dampened arm swing when walking, gesturing when 
talking 
 
Often not prominent in early PD 
 
(Ahlskog, 2009) 
 
Diagnostically the motor symptoms of PD characterise the disorder. However, non-
motor symptoms are also significantly debilitating (Chaudhuri et al., 2004, 
Chaudhuri et al., 2006, Hou and Lai, 2007, Poewe, 2008, Chaudhuri and Martinez-
Martin, 2008, Löhle et al., 2009, Park and Stacy, 2009). As many as 90% of people 
with PD are reported to experience non-motor manifestations throughout the 
disease course (Shulman et al., 2001).  
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Table 2.2 provides an outline of the non-motor symptoms of PD. As PD progresses 
non-motor symptoms start to become increasingly troublesome and multiple 
medications can be added (Hou and Lai, 2007). These can be in addition to drugs 
aimed at treating motor symptoms. For many people with PD this leads to 
increasing medication complexity and polypharmacy. 
 
Table 2. 2 - Non-motor Symptoms of Parkinson's disease 
Category of Non-
motor symptom 
Specific complaint 
Neuropsychiatric 
 
 
 Depression, apathy, anxiety, anhedonia, attention 
deficit, hallucinations. 
 Delusions, dementia, obsessive behaviour. 
Sleep Disorders 
 
 Restless legs, periodic limb movements, REM 
behaviour disorder. 
 Excessive daytime sleepiness, vivid dreaming, non-
REM sleep movement disorder, insomnia. 
Autonomic  Bladder disturbance: urgency, nocturia and frequency, 
sweating, Orthostatic Hypotension (OH), falls related 
to OH, coat-hanger pain, sexual dysfunction, 
hypersexuality, erectile impotence. 
Gastrointestinal   Dribbling of saliva, ageusia, dysphagia/choking, 
reflux, vomiting, nausea, constipation, unsatisfactory 
voiding of bowl, bowl incontinence. 
Sensory  Pain, paraesthesia, olfactory disturbance 
Other  Fatigue, diplopia, blurred vision, seborrhoea, weight 
loss 
 
 
Cognitive impairment is estimated to affect up to 85% of patients with PD if 
executive dysfunction is included (Aarsland and Kurz, 2010). Deficits include 
dysfunctional planning and organisation, visuospatial difficulties and impaired 
memory recall, amongst others (Dubois and Pillon, 1997, Hou and Lai, 2007). 
Even in early PD, subtle decline in cognitive function may be evident (Park and 
Stacy, 2009). As the disease progresses cognitive decline persists and PD patients 
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may develop dementia (PD dementia (PDD)) (Leroi et al., 2012). Aarsland & 
colleagues (2005) conducted a meta-analysis including a total of 1767 PD patients 
with a mean age of 73 years (range 70-76) and found the prevalence of dementia to 
be 30%. However, estimates suggest dementia affects 50% of PD patients who 
have had the disease for 15 years or more. It is likely therefore that in advanced PD 
treatment may be aimed at managing the consequences of dementing illness as 
opposed to treating motor symptoms which may have been the focus in earlier 
stages of PD (Dubois and Pillon, 1997, Bosboom et al., 2004, Ahlskog, 2009, 
Montine, 2010).  
 
The remainder of this chapter focuses on two topics. First I outline the various 
pharmacological treatments used for the management of PD. I then discuss the 
issue of medication adherence and the consequences of non-adherence specifically 
in PD. Finally, I summarise the chapter by placing it within the context of the 
overall thesis.  
 
2.5 Pharmacotherapy for Parkinson’s Disease 
Despite much research into strategies to inhibit PD progression, no treatment has 
yet been shown to offer promising neuroprotective properties (Suchowersky et al., 
2006). Currently there is no encouraging evidence that any drug truly modifies the 
underlying pathophysiology of PD. Therefore, managing and controlling the 
symptoms of PD is the chief therapeutic goal of current treatment strategies; the 
aims of which are to keep patients engaged in society, remain ambulatory and 
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maximise QoL (Chaudhuri et al., 2006). Despite medications appearing to lack 
neuroprotective efficacy, drugs aimed at controlling the symptoms of PD can be 
substantially beneficial. Table 2.3 outlines the most common orally administered 
PD preparations. 
 
Table 2. 3 - Oral Drug Preparations for Parkinson’s disease 
Classification Drug Names Preparations 
 Generic Brand  
Levodopa Co-careldopa 
(carbidopa)* 
 
Sinemet 
(tablet) 
50mg/12.5mg   Half Sinemet 100mg/25mg     
100mg/10mg    Sinemet CR 200mg/50mg 
200mg/25mg 
           
 Co-beneldopa 
(benserazide)* 
Madopar 
(capsule) 
50mg/12.5mg                      
100mg/25mg                      (dispersible tbl) 
200mg/50mg                      100mg/25mg 
CR** 100mg/25mg            (dispersible tbl) 
 Co-careldopa 
+ Entacapone 
 
Stalevo 50mg    70mg    100mg 
125mg  150mg  200mg  
Catechol-O-Methyl 
Transferase Inhibitors 
Entacapone Comtess 200mg 
 Tolcapone Tasmar 100mg 
 
Monoamine Oxidase 
B Inhibitors 
Rasagiline Azilect 1mg 
 Selegiline Elderpryl 
(tbl or syrup) 
5mg   10mg                         10mg/5ml 
 Selegiline 
 
Zelapar 1.25mg 
Dopamine Receptor 
Agonists 
(Non-ergot derived) 
Pramipexole Mirapexin 0.088 mg base/0.125 mg salt 
0.18   mg base/0.25   mg salt 
0.35   mg base/0.5     mg salt 
0.7     mg base/1        mg salt 
 
 Pramipexole  Mirapexin 
PR** 
0.25  mg base/0.375  mg salt 
0.52  mg base/0.75    mg salt 
1.05  mg base/1.5      mg salt 
1.57  mg base/2.25    mg salt 
2.1    mg base/3.0      mg salt 
2.62  mg base/3.75    mg salt 
0.7    mg base/1         mg salt 
 
 Ropinirole Requip 0.25 mg   0.5mg   1mg   2mg   5mg 
 Ropinirole Requip 
XL** 
2mg         4mg      8mg 
Glutamate Antagonist Amantadine Symmetrel 100mg 
 
* Dopa-decarboxylase inhibitor added to Levodopa in a ratio of 1:4 i.e. 4 parts Levodopa to one part 
inhibitor **CR (continuous release) drugs are complete doses that are released over a prolonged 
period. Often prescribed for overnight delivery of levodopa 
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2.5.1 Levodopa Therapy 
Since its discovery more than fifty years ago, levodopa has been by far the most 
efficacious drug for managing the symptoms of PD (Schapira et al., 2009b). 
Levodopa is the amino acid precursor of dopamine and its administration has been 
shown to promptly raise dopamine concentrations in the nigrostriatal pathways, 
leading to increased QoL and overall life expectancy (Karlsen et al., 2000, Rajput, 
2001, Schapira, 2007, Schapira et al., 2009b). 
 
Following the diagnosis of PD careful consideration is required to establish the 
optimal dose of medication. Traditionally this has awaited the manifestation of 
significant motor symptoms and reduced QoL (Schapira and Obeso, 2006, Schapira 
et al., 2009b). However, evidence now suggests that early dopamine replacement 
therapy (DRT) offers long-term benefit to patients (Schapira and Obeso, 2006). It 
has been reported that the rate of clinical deterioration can be rapid within the first 
year post diagnosis of PD, with a significant decline of 8-10 points in the Unified 
Parkinson’s Disease Rating Scale (typically considered large) observed in this short 
duration (Fahn et al., 2004). This suggests that early intervention with anti-
parkinsonian therapies may offer worthwhile benefit for controlling PD symptoms 
in the long term. 
 
2.5.2 Levodopa Response 
Early in the course of PD the therapeutic response to levodopa is typically constant; 
that is, patients are not usually susceptible to response fluctuations (Ahlskog and 
Muenter, 2001). Some patients can take doses later than the prescribed time or even 
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completely miss doses without noticing a substantial decline in symptom control. 
This phenomenon has been referred to as the long-duration levodopa response and 
may partly explain medication underuse in early PD (Lopez et al., 2001).  
 
After a few years some of the benefit offered by levodopa starts to become time 
locked. Patients may note 20-60 minutes post drug administration that their 
symptoms improve. However, the therapeutic response often declines after a few 
hours and people with PD may start to feel their symptoms return sooner than they 
once did. For example, patients commonly report slowing-up during gait and 
feeling progressively more rigid. This is referred to as the short-duration response 
which is reported to represent the underpinning for the ‘wearing-off’ phenomenon 
in PD (Lopez et al., 2001, Sesar et al., 2011). Once this starts to occur levodopa 
regimens almost certainly require modification. Doses can be increased or more 
doses can be added so that the time between each dose is reduced. Adjunctive 
medications can also be used, however this further complicates the medication 
regimen (Ahlskog, 2009). 
 
2.5.3 Dopamine Receptor Agonists 
Dopamine receptor agonists imitate the action of the neurotransmitter dopamine by 
stimulating dopamine receptors at the post synaptic membrane (Lim et al., 2009). 
Drugs from this classification do not require enzymatic conversion or a specific 
transport system to cross the blood-brain barrier, making their successful uptake 
simpler than levodopa preparations (Gerlach et al., 2003). The main orally 
18 
 
administered dopamine agonists are pramipexole (Mirapexin) and ropinirole 
(Requip). 
 
In contrast to levodopa, the principal benefit of dopamine receptor agonists is that 
they have a longer duration of action. The half-life of levodopa is only around 
ninety minutes (Yeh et al., 1989). In contrast, the half-life of pramipexole is 
substantially longer (8-12 hours) and is around 6 hours for ropinirole (Kvernmo et 
al., 2006). The prolonged-release formulation of ropinirole, pramipexole MR and 
the rotigotine transdermal patch each deliver a reasonably constant 24-hour supply 
which aims to keep dopaminergic tone stable (Pfeiffer, 2005). 
 
In advanced PD levodopa conversion and storage is limited, as is the regulation of 
synaptic dopamine concentrations. Often in later disease stages functioning nigral 
cells (i.e. cells still able to convert levodopa to dopamine) are lacking. What’s 
more, loss of receptor cells at the post synaptic membrane can also be substantial. 
Consequentially, what dopamine is readily available may become redundant. Due 
to this the motor response to levodopa can be erratic and pulsatile and in time some 
patients will experience significant response fluctuations and dyskinesias (Péchevis 
et al., 2005, Grosset, 2008). In this scenario, longer acting dopamine receptor 
agonists may be of benefit (Ahlskog, 2009). 
 
There are however limitations to the use of dopamine agonists, such as incomplete 
receptor agonism. Dopamine receptors are divided into five types: D1-D5. The 
main motor effects of dopamine have been primarily attributed to D1 and D2 
receptor stimulation (Ahlskog, 2009) which are greatly expressed in striatal 
19 
 
regions. However, all three dopamine agonists mentioned have specific affinity to 
D3 receptor cells. Ropinirole and pramipexole for example have a 100-fold affinity 
to D3 than D2 receptors (Gerlach et al., 2003). Rotigotine has around a 20-fold 
greater predilection to D3 than D2 (Jenner, 2005). Neither pramipexole nor 
ropinirole have however demonstrated affinity to D1 receptors (Gerlach et al., 
2003) and the affinity of the transdermal patch to D1 receptor site stimulation is 
100-fold less than it is for D3 (Jenner, 2005). This continuum of receptor cell 
stimulation offers two clinically relevant implications when comparing dopamine 
agonist efficacy to that of levodopa: 
 
(1) Agonists offer reduced capacity for improving motor control than dopamine 
generated from levodopa because of the specificity and affinity to certain receptors;  
 
(2) There is greater potential for patients developing behavioural problems as a 
result of D3 receptor stimulation (Joyce, 2001). 
 
2.5.4 Monoamine Oxidase-B Inhibitors 
Monoamine oxidase (MAO) enzymatically degrades monoamines such as 
dopamine within the brain tissue. Inhibiting the activity of MAO type-B thus 
increases brain dopamine concentrations, potentially improving PD symptoms 
(Henchcliffe et al., 2005, Fernandez and Chen, 2007a, Fernandez and Chen, 
2007b). The therapeutic indication for the use of MAO-B inhibitors (selegiline and 
rasagiline) is still a source of debate. Whilst evidence shows that they do improve 
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the clinical symptoms of PD, they appear to do so only moderately (Ives et al., 
2004). 
 
2.5.5 Catechol-O-Methyltransferase Inhibitors 
As highlighted earlier in Table 2.3, levodopa is mostly prescribed in a ratio of one 
to four. For example, one part dopa-decarboxylase inhibitor (25mg carbidopa) may 
be prescribed with four parts levodopa (100mg) to produce Sinemet (125mg). The 
added carbidopa aims to prevent conversion of levodopa to dopamine outside of 
the central nervous system in an attempt to optimise brain dopamine 
concentrations. However, despite the addition of the dopa-decarboxylase inhibitor, 
levodopa can still be metabolised in the periphery by the enzymatic activity of 
Catechol-O-Methyltransferase (COMT) (Bonifati and Meco, 1999, Männistö and 
Kaakkola, 1999). As COMT can reduce the availability of levodopa, one of two 
COMT inhibitors may also be prescribed: entacopone (Comtess) and tolcapone 
(Tasmar). Inhibiting COMT helps to reduce the quantity of levodopa metabolised 
peripherally and thus helps to lengthen the therapeutic effect of levodopa. 
 
2.5.6 N-Methyl-D-Aspartate (NMDA) Glutamate Antagonist 
Amantadine has been used to treat PD for almost as long as levodopa. Originally 
the therapeutic indication was for the treatment of early parkinsonism. However, 
when prescribed today it is mainly used to combat levodopa induced dyskinesias 
(Metman et al., 1998, Metman et al., 1999). Although amantadine is proposed to 
attenuate levodopa induced dyskinesias without worsening PD symptoms (Metman 
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et al., 1999), findings from a Cochrane systematic review did not support this claim 
(Crosby et al., 2003). 
 
2.5.7 Anticholinergics 
Anticholinergics drugs were the first medications to be routinely prescribed to treat 
PD. One of the most commonly administered anticholinergics is trihexyphenidyl 
(Broflex). Drugs from this classification can reduce resting tremor in some PD 
patients but do little to combat bradykinesia, gait problems or other motor and non-
motor symptoms of PD. Given their vast side effect profile and limited therapeutic 
benefits, most often a more efficacious anti-parkinsonian agent is prescribed in 
place of an anticholinergic drug (Ahlskog, 2009). 
 
2.6 Treatment Complexity in Parkinson’s Disease 
2.6.1 Early Treatment 
Optimum medication management typically allows people who are newly 
diagnosed with PD to remain active in all aspects of their lives. When symptoms 
impede on working commitments, reduce social interaction, or result in sedentary 
lifestyles initiating treatment is necessary. The natural progression of PD confers 
less drug efficacy and more disability later in the disease course (Apaydin et al., 
2002). There is no evidence that the best drug response can be saved for later years. 
By deferring treatment and accepting early disability, the patient may be sacrificing 
good years of life for no therapeutic gain (Ahlskog, 2009). 
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The pharmacological management of PD is complex. Dopaminergic drugs like 
levodopa, MAO-B inhibitors and dopamine receptor agonists are the main 
therapeutic options and represent usual first line treatment strategies (NICE, 2006, 
Schapira and Obeso, 2006, Schapira, 2007). All of these drugs have supporting 
clinical data to justify their therapeutic use (Goetz et al., 2005, Pahwa et al., 2006). 
Typically younger individuals are treated with an MAO-B inhibitor (once daily), 
especially if symptoms are mild, or a dopamine receptor agonist (three daily doses) 
as first line intervention. Older individuals (≥75 years), especially those with or at 
risk of cognitive impairment, may be treated with levodopa as first line therapy 
(Schapira et al., 2009b, Schapira, 2007). Figure 2.1 shows a decision pathway for 
initiating PD treatment. 
 
Two studies showed that although the use of levodopa improved the Unified PD 
Rating Scale by 3-5 points more than a corresponding agonist, motor control was 
still considered satisfactory by patients and clinicians when treated with the agonist 
alone (Rascol et al., 2000). Additionally, researchers have shown MAO-B 
inhibitors are useful as monotherapy in early disease or as adjuvant therapy in later 
stages of PD (Fernandez and Chen, 2007a, Fernandez and Chen, 2007b). It is well 
acknowledged, however, that MAO-B inhibitors are not as effective as levodopa or 
dopamine agonists for the management of PD and thus their therapeutic indications 
are limited (Ives et al., 2004). 
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(Schapira, 2007) 
 
 
 
 
 
 
 
 
Diagnosis 
Decision to 
treat 
No 
Yes Review 
Evaluate patient 
characteristics and 
degree of disability 
Moderate to severe 
disability and age 70+ 
years or with significant 
comorbidity including 
cognitive impairment 
Mild to moderate motor 
disability and no 
cognitive impairment 
 
Mild motor disability and 
no cognitive impairment 
Begin levodopa 
 
Begin dopamine agonist 
 
Begin MAO-B inhibitor 
 
Figure 2. 1 - Decision Pathway for Initiating Parkinson's disease Treatment 
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2.6.2 Advancing Treatment 
As PD progresses, controlling symptoms becomes considerably more challenging.   
Researchers have shown that more than half of people with PD take two to four 
anti-parkinsonian medications three to four times daily (Leoni et al., 2002, Tan et 
al., 2005). This is because multiple drug classes are required as PD progresses 
(Rascol et al., 2000, Holloway et al., 2004, Bainbridge and Ruscin, 2009, Schapira 
et al., 2009a). Long-term follow-up studies indicate that of the PD patients who 
began receiving a dopamine agonist, approximately half at three years and two-
thirds at five years required levodopa supplementation (Rascol et al., 2000, 
Holloway et al., 2004).  
 
As levodopa is added, treatment regimens become more complex. The transition 
from MAO-B inhibitor or dopamine agonist to levodopa marks a significant 
juncture in PD treatment when considering the specificity of dose timing. A patient 
previously managed with an MAO-B inhibitor is likely to have only taken one 
tablet daily. Although a dopamine agonist may have been prescribed in three daily 
doses to manage symptoms, comparable to levodopa when initiated, the 
considerably longer half-life of agonists affords the patient a greater time window 
in which medication needs to be taken. A patient can be more flexible with the time 
of dosing with little or no ill effect. This phenomenon also stands true for levodopa 
in the initial years of treatment when the long-duration response predominates. As 
some patients may be able to omit doses without detrimental consequences to 
function, this may partly explain medication non-adherence in early PD.  
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However, as the half-life of levodopa is only around 90-120 minutes (Yeh et al., 
1989), patients with advanced PD will require a more stringent dosing schedule to 
maintain steady plasma concentrations and desired therapeutic benefit (Ahlskog, 
2009, Schapira et al., 2009b). 
 
Occasionally people with long standing PD will experience responses to therapy 
lasting only 1-2 hours, reflecting the plasma half-life of levodopa (Yeh et al., 
1989). By five years of active levodopa treatment, approximately 40 per cent with 
PD report experiencing the short-duration response and this becomes increasingly 
more likely and debilitating over subsequent years (Ahlskog and Muenter, 2001, 
Rascol et al., 2000). At this juncture, one strategy is to add a further dose to shorten 
the time interval between each pill taken (Ahlskog, 2009). This however starts to 
add significant regimen complexity. Around this time, and as PD continues to 
progress, some patients also begin to experience debilitating motor fluctuations and 
dyskinesias resulting from long-term use of dopaminergic therapy. 
 
In addition to adding further doses, each drug prescribed may have different dosing 
schedules, which can complicate treatment regimens (Leoni et al., 2002). COMT 
inhibitors can supplement levodopa but this approach adds further complexity if 
given as a separate tablet.  
 
With advancing disease the therapeutic window narrows and becomes dependent 
on more frequent dosing to maintain the treatment effect (Grosset et al., 2005b, 
Schapira et al., 2009b). Some people with advanced PD can take as many as ten 
doses a day in attempt to control symptom fluctuation (Schapira, 2007, 
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Valldeoriola et al., 2010). Dyskinesias (involuntary movements) associated with 
long-term levodopa use may also require remediation in later PD. This adds even 
greater treatment complexity to a population already potentially highly medicated 
(Schapira et al., 2009b, Valldeoriola et al., 2010). Additionally, specific non-motor 
complications may necessitate further drug use which adds to the polypharmacy in 
PD (Chaudhuri et al., 2006, Bainbridge and Ruscin, 2009). 
 
Whilst medication use may be consistent in many chronic illnesses, it is evident 
that in PD treatment strategies can change in order to address a patient’s 
progressive symptom manifestation. Such amendments to treatment can add 
considerable complexity and this may make accurate pill taking challenging for 
even the most cognitively able individuals. 
 
2.7 Medication Adherence 
The effectiveness of prescribed drugs depends not only on the efficacy of the 
medications, but also on adherence to the therapeutic regimen. Adherence is 
defined by the World Health Organisation (WHO, 2003) as: 
 
“the extent to which a person’s behaviour – taking medication, following diet, 
and/or executing lifestyle changes, corresponds with agreed recommendations 
from a health care provider”. 
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Adherence to medication is paramount for achieving optimal therapeutic benefit. 
Using medication appropriately is dependent on two factors: ability and motivation 
(Horne, 2000). Most of the early research on adherence focussed on a patient’s 
ability to take medication. As a result, non-adherence was assumed to be 
unintentional (e.g. forgetfulness and poor understanding), or a physical ailment 
(e.g. poor eyesight or lack of dexterity). These factors are unquestionably 
important. However, it is also being increasingly acknowledged that non-adherence 
to medication may result from a decision to avoid medication or to use it in a 
manner inconsistent with the prescriber’s instructions (Horne and Weinman, 1999, 
Horne, 2000). Previously such behaviour may have been viewed as disobedient. 
However, a new view of health has emerged in which patients are encouraged to 
take a more active role in their healthcare and more specifically in decisions about 
their treatment (Barber, 1995).  
 
In PD pharmacological management is essential for managing symptoms and 
maximising QoL. Sound medication adherence therefore cannot be over 
emphasised (Rigby, 2007). This is especially relevant as motor function becomes 
progressively worse, requiring increasingly intricate medication regimes to manage 
symptoms (Davis et al., 2010). Furthermore, as non-motor symptoms have been 
reported by patients and carers to be more negatively impactful than motor 
complaints in PD (Martinez-Martin et al., 2011), adequately adhering to prescribed 
regimens is likely to be important for maximising health related quality of life 
(HRQoL). However, in spite of the identified importance of medication adherence, 
non-adherence to treatment is a problem in PD as the next part of this chapter 
outlines. 
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2.7.1 Prevalence of Non-adherence in Parkinson’s Disease 
Researchers propose that a third to half of all medicines prescribed to people with 
long-term conditions are not taken as recommended (Haynes et al., 2002b, WHO, 
2003, NICE, 2009). Despite recognising that non-adherence is prevalent in many 
chronic conditions, it has only recently been acknowledged that people with PD do 
not take prescribed medication as intended (Grosset et al., 2005b, Bainbridge and 
Ruscin, 2009, Grosset, 2010).  
 
Dutton et al (1993) were one of the first research groups to identify that elderly 
people with PD were under-medicating. Soon after Copeland and colleagues (1994) 
found that many blood samples taken from PD patients were below the lower 
levodopa concentration limit, indicating poor medication adherence. Additionally, 
five samples were shown to be above the therapeutic range and understandably 
dyskinesia was common in this group of patients. Despite medication having the 
potential to optimise QoL in PD, these early studies suggest that medication non-
adherence is prevalent. 
 
More recently researchers have highlighted the prevalence of medication non-
adherence in PD using a variety of assessment strategies. Leopold and colleagues 
(2004) used Medication Electronic Monitoring caps (MEMS), the reported gold 
standard method, to show that only 10% of PD patients fully adhered to treatment. 
 
A further study identified that 20% of patients with PD were under users of anti-
parkinsonian medication (Grosset et al., 2005a). In addition, patients who 
satisfactorily adhered to medication (average total pill taking > 80%) all showed 
29 
 
substantial problems with dose timing adherence (number of doses taken at the 
correct time interval). Furthermore, findings revealed that 56% of patients were 
more likely to take once-daily drugs on time than drugs that had to be taken more 
frequently, where as few as 3% adhered satisfactorily (Grosset et al., 2005a). 
Kulkarni and colleagues (2008) conducted a retrospective longitudinal cohort study 
in people with PD and found the prevalence of sub-optimal adherence to be 67%.  
 
Collectively these findings indicate that medication non-adherence is a significant 
problem in people with PD. Specifically, findings to date have revealed that dose 
timing is poor, even in PD patients with overall satisfactory adherence (those 
taking greater than 80% of their prescribed dose). 
 
2.7.2 Consequences of Non-adherence in Parkinson’s Disease 
The consequences of non-adherence to medication in PD can be substantial and 
should be considered from various perspectives. For the patient, medication does 
not work if it is not taken as the prescriber intended. However, assumptions by 
clinicians that non-adherence is a passive process; that is, forgetfulness or resulting 
from impaired cognition, may be too simplistic and it should be recognised that 
medication taking behaviour is more complex (Grosset, 2010). Active 
consideration may in some cases be significant. For example, discontinuing 
treatment due to perceived side effects, either accurate or fallacious; medication 
sparing based on the belief of loss of efficacy over time (i.e. becoming immune or 
unresponsive to treatment); or fear of long-term complications such as peak dose 
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dyskinesias and response fluctuations are all proposed reasons why a patient with 
PD may not adhere to treatment (Bainbridge and Ruscin, 2009, Grosset, 2010). 
 
Patients with PD should take their medication as prescribed for numerous reasons. 
Firstly, sudden withdrawal of dopaminergic drugs can result in suppression of 
central dopamine transmission and thus trigger the neuroleptic malignant 
syndrome, which may lead to fatality (Mizuno et al., 2003). Secondly, one major 
theory for the genesis of motor fluctuations is that erratic, pulsatile dopaminergic 
stimulation is contributory (Juncos et al., 1989, Rascol et al., 2000, Grosset et al., 
2005a). Sporadic dopamine levels in blood plasma, partly from inadequate timing 
of medication taking, correlate with alternating high and low levels in the brain. 
Such erratic stimulation (the so called peak and trough effect) is proposed to result 
in motor fluctuations (Bezard et al., 2001).  
 
Researchers evaluating the effect of reduced pill intake in PD showed that non-
adherence was associated with the ‘wearing off’ of the treatment effect (Kulkarni et 
al., 2008). This was shown to result in motor fluctuations and increased risk of 
worsening symptoms compared to medication adherent individuals. Furthermore, 
poor adherence to treatment was associated with more unplanned hospital 
admissions for PD related problems and an overall poorer prognosis (Kulkarni et 
al., 2008).  
 
Interestingly, and perhaps unique to PD, non-adherence to medication is not 
specific to sub-optimal pill intake. Patients may also non-adhere by over 
medicating. Excessive intake of dopaminergic agents was prevalent in 10% of 
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patients diagnosed with PD at a younger age (Grosset et al., 2005a). The 
consequences of over medicating can be substantial and include severe medication 
induced dyskinesia, behavioural disturbances and potentially even psychosis 
(Merims and Giladi, 2008, O'Sullivan et al., 2009). 
 
Medication non-adherence in PD also has serious consequences for other parties 
involved. From the perspective of family members, their relative’s health is 
deteriorating leading to poor QoL and increasing care requirements. This can place 
significant burden on the spouse/carer which can greatly affect their health and 
QoL. For treating clinicians, future management decisions are based on the premise 
that the patient is correctly taking the intended treatments. Dose escalation, 
adjunctive therapy use and, in some cases, diagnostic reconsideration may all result 
from seeing a patient in clinic who apparently has had a poor response to therapy 
(Bainbridge and Ruscin, 2009, Grosset, 2010).  
 
Poor drug management in PD is not confined to patients living in the community 
but is also an acknowledged problem in secondary care. Parkinson’s UK launched 
a “Get it on time” campaign aiming to ensure people admitted to hospital receive 
medication at their individual time. Such a campaign emphasises the critical 
relationship between medication non-adherence and functional deterioration in PD 
and helps illuminate the importance of ensuring patients adhere to their medication 
dosing as intended. 
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2.8 Summary: A Greater Understanding 
The symptoms of PD can be extremely debilitating in all aspects of life. What is 
considered a small complaint by one individual may be significantly troublesome 
and impactful to another. However, as stated earlier in this thesis, many of the 
symptoms of PD are treatable to varying extents. Healthcare professionals therefore 
have the ability to improve the QoL of many people with PD for several years. 
Unlike decades previous, today’s arsenal of pharmacological agents is more 
substantial with clinicians having many treatment options available that can be 
tailored to the patient’s specific needs.  
 
Despite this, however, it is clear from the evidence that some people with PD are 
not taking their prescribed anti-parkinsonian medication in accordance with 
medical advice. Furthermore, it is evident that non-adherence to medication in PD 
results in many people experiencing a ‘wearing off’ of their treatments therapeutic 
effect. This has been shown to negatively impact on function and QoL. It is 
therefore essential for clinicians to be able to identify non-adherent PD patients. 
With a greater knowledge of who is likely to non-adhere to prescribed medication, 
targeted interventions can be provided in attempt to improve adherence and thus 
maximise the therapeutic effect of prescribed treatment.  
 
In the next section of this thesis I present the rationale, methods, results and 
discussion of two systematic reviews. In Chapter 3 I provide the findings of a 
systematic review identifying what factors are associated with medication non-
adherence specifically in PD. In Chapter 4 I present the findings of a Cochrane 
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systematic review on interventions used to enhance medication adherence in people 
with PD. 
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CHAPTER 3 
 
 
Factors Affecting Medication Non-
adherence in Parkinson’s Disease 
 
 
Background 
Study Design 
Risk of Bias/Internal Validity 
Findings 
Discussion 
 
 
 
3.1 Background 
As highlighted in Chapter 2, to achieve optimum symptom control in chronic 
conditions medication adherence is imperative. Despite this, the World Health 
Organization (2003) report that as much as half of all medications prescribed for 
long-term conditions are not taken as intended. Therefore, it is not surprising that 
medication adherence is poor in PD.  
 
Leopold et al (2004) reported as few as 10% of a PD cohort showed full adherence. 
Kulkarni et al (2008) found the prevalence of poor adherence ranged between 60% 
and 70% when followed over 5-years while Grosset et al (2005a) reported 
complete medication adherence in as few as 3% of PD patients. These findings are 
concerning when placed in a clinical context. Kulkarni and colleagues (2008) 
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showed that poor medication adherence increased the risk of worsening symptoms 
compared to medication adherent people with PD. As PD treatments are self-
administered, there is a need for greater understanding of why people do not take 
their prescribed medications as intended. This theoretical knowledge could help to 
better understand how best to improve medication adherence in people with PD. 
 
Pharmacological based interventions such as simplifying drug regimens and non-
pharmacological approaches such as provision of educational material have been 
advocated to address non-adherence in PD (Bainbridge and Ruscin, 2009, Grosset 
and Grosset, 2007). However, whilst these interventions may be beneficial in other 
chronic conditions, such approaches in a PD population are theoretical because the 
current evidence on why medication non-adherence develops specifically in PD is 
limited. 
 
Regardless of the various theories, it remains unclear which factors are associated 
with non-adherence specifically in PD. The identification of such factors may 
allow healthcare professionals to identify potentially non-adherent individuals. 
With this knowledge, the development of targeted interventions to counteract or 
prevent non-adherence may be possible and could prove beneficial. This is both in 
terms of symptom management and the clinicians’ understanding of a patient’s 
treatment response and disease progression.  
 
In the next part of this chapter I outline the processes used to identify which factors 
are associated with medication non-adherence in people with PD. 
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3.2 Study Design 
I used the systematic review approach to identify literature relating to medication 
non-adherence in PD.  
 
3.2.1 Search Methods 
To ensure that both quantitative and qualitative evidence was identified, I 
performed a systematic search of online databases in April 2011. The five 
databases searched were Medline (Ovid, 1948), EMBASE (Ovid, 1980), AMED 
(Ovid, 1985), PsycINFO (Ovid, 1806) and CINAHL (EbscoH, 1982). In January 
2012 I updated the search to capture more recently published articles. I also 
conducted a supplementary hand search of bibliographies of extracted articles and 
reviews to acquire records not identified electronically. Next I outline the search 
strategy for the systematic review. 
 
3.2.2 Search Terms 
Before conducting the systematic search I reviewed the key words and search 
strings used by the authors of related articles with the aim of developing a 
comprehensive set of search terms. When relevant key words were identified I 
added these to the search string. This practice continued until I was satisfied that I 
had the key words required to conduct a comprehensive search of the topic. The 
terms ‘Parkinson’s disease’ and ‘Parkinsonism’ were combined with keywords 
relating to non-adherence: ‘non-adherence’, ‘non-compliance’, ‘influencing 
37 
 
factors’, ‘caregiver compliance’, ‘sub-optimal’, ‘determinants’, ‘drug adherence’, 
‘therapy adherence’, ‘drug compliance’, ‘denial psychology’ and ‘therapy 
compliance’. To make the search strategy more comprehensive, I mapped key 
terms to database specific subject headings (MeSH). I then ‘exploded’ each MeSH 
term to include all relevant sub-categories. Truncations and Boolean operators (e.g. 
‘and’, ‘or’) were used where necessary to broaden the search window. Exact search 
strings can be seen in Appendix 1. 
 
3.2.3 Selection Criteria 
Once identified records had been imported into the Endnote reference manager and 
duplicated items had been removed, I proceeded by reviewing all relevant titles and 
abstracts for potential study inclusion. Full text articles were obtained either where 
abstracts appeared relevant or when insufficient information was provided from 
which an adequate assessment of relevance could be made from the abstract alone. 
Studies meeting the following criteria were included: 
 
(1)  English language  
(2)  Full-article publication available (accessed directly or requested from the 
study authors) 
(3)  Idiopathic PD population (iPD) (defined by the authors). 
(4) All age ranges and duration of anti-parkinsonian treatments. 
(5)  Presented either quantitative or qualitative data on factors associated with 
medication non-adherence. 
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3.2.4 Data Extraction 
Having identified potentially eligible records, the full text of each article was 
reviewed for potential inclusion in the systematic review. I developed a concise, 
standardised data extraction table (Table 3.1) to acquire information relevant to the 
review from each included study. Extracted data were checked twice for accuracy. 
Relevant study information was tabulated focusing on study design, 
methodological characteristics, included participants and the analytical methods 
used. Extracted data for each included study can be seen in Appendix 2. 
 
Table 3. 1 - Data Extraction Table 
 
 
 
 
 
 
 
 
 
 
 
 
Study Design 
What was the study design? 
What were the aims and objectives? 
  
Participants 
What was the sample size? 
Were participant demographics reported and how were they collected? 
How were participants recruited and from where? 
Was there specific inclusion/exclusion criteria? 
 
Measurement Tools/Outcomes 
What was the primary outcome? 
Was adherence to medication assessed? If so, what method or instruments were 
used? 
How was the instrument administered and by whom? 
 
Statistical Analysis 
What analysis was used to determine factors that influence/are associated with 
medication adherence? 
Were covariates identified and included in the analysis? 
  
Results 
What were the response rates? 
What were the main reported determinants of non-adherence to medication in PD? 
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In the next section of this Chapter I will describe the procedure used to assess the 
risk of bias of the studies included in this systematic review. 
 
3.3 Risk of Bias/Internal Validity 
3.3.1 Terminology 
Bias is defined as the risk of systematic error, or deviation from the truth, when 
interpreting the findings or inferences of a study. The term ‘risk of bias’ is 
interchangeable with internal validity, which is often defined as the extent to which 
the design and conduct of a study are likely to have prevented bias (Higgins and 
Green, 2009). 
 
Despite the risk of bias assessment being a key phase when conducting a 
systematic review, the specific term used varies substantially across review groups 
and specialities. A common alternative term to risk of bias is quality assessment. 
However, the meaning of quality can vary greatly. For example, one source defines 
quality as: 
 
“The extent to which all aspects of a study’s design and conduct can be shown to 
protect against systematic bias, non-systematic bias and inferential error.” 
(Lohr, 2004) 
 
In the US the Preventive Services Task Force (USPSTF), an independent panel that 
systematically reviews evidence of effectiveness, equates quality with internal 
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validity and classifies individual studies first according to a hierarchy of study 
design and then by individual study criteria. In contrast the Cochrane Collaboration 
argues for a wider use of the phrase risk of bias instead of quality, reasoning that: 
 
“An emphasis on risk of bias overcomes ambiguity between the quality of reporting 
and the quality of the underlying study’s methodology.” 
 (Higgins and Green, 2009) 
 
Due to the inconsistency and potential confusion of the term ‘quality’, I will refer 
to validity assessment as ‘risk of bias assessment’ throughout the remainder of this 
thesis. In the next section of this thesis I describe the development of the appraisal 
tool that I used for the current systematic review. 
 
3.3.2 Development of the Risk of Bias Appraisal Tool 
I developed a specific, novel appraisal tool to assess the risk of bias of the studies 
included in this systematic review. To comprehensively assess the studies I sought 
to evaluate the impact of bias, confounding and statistical chance on the study 
findings. Having identified the effect of these risks of bias, I aimed to assess their 
individual and combined impact on the interpretability of each study’s findings. 
 
Prior to developing the appraisal tool I systematically reviewed existing quality 
indicator scales and checklists. Medline (Ovid, 1948), EMBASE (Ovid, 1980), 
AMED (Ovid, 1985), PsycINFO (Ovid, 1806) and CINAHL (EbscoH, 1982) were 
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searched using pre-defined search terms. The following terms/key words were 
exploded and then combined in each respective database:  
 
‘bias’, ‘confounding’, ‘chance’, ‘internal validity’, ‘threats to validity’, ‘validity’, 
‘reliability’, ‘appraisal’ were combined by ‘OR’ during the search. This was then 
combined by ‘AND’ with the results of the following search string:   
 
‘data collection’, ‘epidemiology’, ‘observational study’, ‘questionnaires’, ‘scales’, 
‘checklists’, ‘indexes’, ‘assessments’, ‘tools’, ‘instruments’. 
 
Many of the appraisal tools identified appeared to replicate published reporting 
guidelines such as the STROBE (Strengthening the Reporting of Observational 
Studies in Epidemiology) (Von Elm et al., 2007) and MOOSE statements (Meta-
analysis of Observational Studies in Epidemiology) (Stroup et al., 2000). These 
statements were developed for use by authors to ensure a high standard of 
reporting, not for assessing methodological rigor.  
 
Many tools focused on whether authors clearly reported the methodological steps 
undertaken, instead of providing guidance on how to assess the risk of bias in what 
was reported. For example, many tools asked whether participant recruitment was 
described by study authors without providing guidance on whether the methods 
used to screen and recruit participants were prone to selection bias.  
 
I also reviewed the 47 scales and 51 checklists identified by Shamliyan and 
colleagues (2010) in a systematic review of tools to assess the quality of 
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observational studies. In comparison to the appraisal tools identified in my 
independent search, many tools identified by Shamliyan and colleagues (2010) also 
failed to differentiate between poor reporting and risk of bias.  
 
To this end, I designed a novel, generic use quality indicator tool with the view to 
detect risk of bias (threats to internal validity) in non-interventional studies (Table 
3.2).  
 
Having assessed the methodological performance of each included study using this 
novel appraisal tool, I was able to create a risk of bias (Threats to Validity) table 
highlighting the methodological strengths and limitations of each study included in 
the review.  
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Table 3. 2 - Tool to Appraise Risk of Bias in Non-Interventional Studies 
Quality Criteria Threat to Validity Source of Threats to Validity Identification & Evaluation: 
Representativeness of 
population: cases and 
controls 
 
Selection Bias 
(misclassification bias) 
 
Selection Bias 
 
 
Chance 
 
Confounding 
Diagnosis inaccuracy 
 
 
Source and method for sampling 
 
 
Sample size 
 
Demographics/characteristics of participants 
Were eligibility criteria used?  
Were inclusion/exclusion criteria specified?  
How were these determined and used?  
Was screening adequate or bias?  
Where were participants accessed?  
Is this representative of the population?  
How was the sample size determined?  
Was this sample target reached?  
Comparability of control to cases: disease severity, duration, medication profile, comorbidity? 
 
Quality of 
measurement and 
outcome 
 
Detection Bias 
(misclassification bias) 
 
Detection Bias 
 
Validity/reliability 
 (systematic bias/errors) 
- Instrumentation  
(e.g. calibration) 
Measurement biases: 
- Self-report 
- Recall 
- Observer/ interviewer 
 
Are measurement tools valid?  
Has reliability been determined?   
Does the instrument have cut-offs or do the authors determine this? Is this consistent? 
What efforts have been made to minimise measurement biases?  
Are measurement biases acknowledged and reported? 
 
Appropriate statistical 
methods and result 
interpretation 
 
Detection Bias 
(Information bias) 
 
Detection Bias 
(Unmasked bias) 
 
Chance 
 
 
 
 
Attrition Bias 
 
Follow-up period time  
 
 
Blinded analysis 
 
 
Analysis: 
- Study power & probability value 
- Sub-analysis power 
- Confounders 
- Effect Modification** 
- Missing data 
 
Were follow-up periods the same for cases and controls? 
 
 
Was data collection/analysis masked where necessary?  
 
 
Did authors conduct appropriate analysis? 
Was adjustment performed for identified confounders? 
What was used to control for known effect modifiers and confounders?  
I.e. randomisation, matching, restriction (exclusion), stratification, multivariate analysis. Could 
significance be a result of chance? 
Was missing data discussed and dealt with appropriately?  
 
Conflict of interest Reporting Bias Investigator bias, funding bias Were conflicts of interest disclosed? Who funded the research? Could this explain findings? 
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3.4 Findings 
The five databases searched yielded a total of 1880 records. An additional six 
records were identified through targeted hand searching of reference lists. Figure 
3.1 shows the PRISMA diagram depicting the stages of study identification. After 
discarding duplicates and reviewing abstracts of identified records, 46 articles were 
suitable for full text retrieval. Of them, six articles met the study inclusion criteria: 
Leopold et al. (2004), Grosset et al. (2005a), Evans et al. (2005), Banks and 
Lawrence (2006), Grosset et al. (2009), Valldeoriola et al. (2010). A further study 
by Drey & colleagues (2012) was later added to the list of included papers 
providing a total of seven records. This article had not been published at the time of 
the initial search and therefore it was not originally identified. 
 
3.4.1 Summary of Studies 
The characteristics of the seven included studies are presented in Table 3.3. The 
systematic review included a total of 787 PD patients. Five of the studies were 
observational in design of which four were cross-sectional surveys (Leopold et al., 
2004, Grosset et al., 2005a, Grosset et al., 2009, Valldeoriola et al., 2010) and one 
was a case-controlled study (Evans et al., 2005). Of the remaining two studies one 
was a postal survey which encompassed one-to-one patient interviews (Banks and 
Lawrence, 2006) and the other was an exploratory qualitative study using semi-
structured interviews (Drey et al., 2012). 
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Figure 3. 1 - PRISMA Flow Diagram of Study Identification 
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Total number of records 
included in systematic 
synthesis: 
n = 7 
(n= 6 from database search 
& n=1 later added) 
 
 
Number of full-text articles excluded with reasons: 
n=40 
- Article not in English (n=1)  
 
- Abstract only available (n=1) 
 
- No data provided on factors influencing non-
adherence (n=8)  
  
- No reference to medication non-adherence (n=5)    
 
- No assessment of adherence (n=3) 
 
- Non-adherence to functional activity and 
exercise (n=1) 
 
- Review papers on adherence (n=10)  
  
- Pathogenesis of Dopamine Dysregulation 
Syndrome  review (n=1)  
 
- No reference to PD (n=9)     
 
- Commentary (n=1) 
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Table 3. 3 - Characteristics of Included Studies 
Article Study 
Design 
Study Aims Source of 
Participants 
Participant 
Characteristics 
  Adherence 
Assessment 
Identified Factors for Non-
adherence 
    Intervention/ 
study group 
Control or 
comparison group 
n=   
Evans et al 
(2005) 
Case- 
control 
Identify 
predisposing 
factors to DDS in 
people with PD 
Outpatients 
attending a 
specialist PD 
clinic 
Dopamine 
dysregulation 
syndrome 
n=25 
 
Patients without 
identified DDS 
n=100 
 
125 n/a Novelty Seeking 
Depression 
Alcohol intake 
Age of PD onset   
 
Grosset et al 
(2005a) 
 
Cross-
sectional 
survey  
 
Compare 
medication intake 
and characteristics 
of patients 
according to 
medication intake 
 
 
Outpatient 
movement 
disorder clinics 
 
All participants 
given MEMs 
device. 
 
n/a 
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Electronic 
Event 
Monitoring 
(MEMS) 
 
Younger age 
Depression 
Poor quality of life 
More daily tablets 
 
Valldeoriola 
et al (2010) 
 
Cross-
sectional 
survey 
 
Determine 
demographic, 
social and clinical 
aspects modifying 
therapy adherence  
 
 
Multiple 
academic 
tertiary and 
secondary 
hospitals in 
Spain 
 
All participants 
assessed by  
MMAS-4 
 
n/a 
 
418 
 
Physician 
subject 
assessment & 
Morisky-4 scale 
 
Low knowledge of PD 
Poor clinical control 
No spouse or partner 
low income 
Cognitive Impairment 
Psychiatric symptoms 
 
 
Leopold et al 
(2004) 
Cross-
sectional 
survey 
To report on drug 
use in PD using 
MEMS. 
PD and 
movement 
disorder clinic. 
 
 
 
 
All participants 
given MEMs 
devise. 
n/a 39 MEMS Gender (females less accurate at 
reporting miss-timed doses) 
Level of education 
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Banks and 
Lawrence 
(2006) 
Postal 
survey 
Explore the 
impact of PD on 
employment from 
the perspective of 
the PD patients. 
 
 
Identified 
through the PD 
Society. 
339 returned 
questionnaire. 
n/a 24 n/a Maintaining employment – 
adjustment of dosing 
Grosset et al 
(2009) 
Cross-
sectional 
survey 
To define the 
pattern of therapy 
adherence, to 
assess factors 
associated with 
non-adherence. 
 
Large Multi-
centre (8 centres 
in 5 countries) 
All assessed with 
MEMS for 
adherence. 
n/a 112 MEMS Higher motor impairment assessed 
by UPDRS and PDQ-39 motor sub-
score. 
Timing adherence associated with 
total tablets, disease duration and 
age. 
Complexity of regimens 
 
 
Drey et al 
(2012) 
Exploratory 
qualitative 
study with 
semi-
structured 
interviews 
To identify how 
people with PD 
adhere to 
prescribed 
medication, and 
what are the 
antecedents of 
non-adherence to 
antiparkinsonian 
medication. 
A specialist PD 
clinic in an 
unnamed 
National Health 
Service hospital 
in England.  
All participants (9 
males and 6 
females) 
interviewed  
n/a 15 Self-report All participants demonstrated at 
least one type of non-adherent 
behaviour.  
- Forgetfulness 
- Minor, deliberate 
amendment of doses 
- Major, deliberate non-
adherence - often over-
use of mediation. 
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Four of the seven studies recruited from single-centre clinics (Leopold et al., 2004, 
Grosset et al., 2005a, Evans et al., 2005, Drey et al., 2012). One recruited from 
secondary and tertiary care hospitals across Spain (Valldeoriola et al., 2010), whilst 
one multi-centre study identified PD patients from eight centres across five 
European countries: France, Germany, Italy, Spain and the UK (Grosset et al., 
2009). The seventh study recruited from the PD Society register, nurse specialist 
clinics and the PD Society magazine in the UK (Banks and Lawrence, 2006).  
 
The mean age of the participants in this review was 62 years (range 44 – 74 years) 
with a mean disease duration of 7.4 years (range < 1 year – 17 years) and a mean 
Hoehn & Yahr (H&Y) score of 2.2 (a widely used clinical rating scale which 
defines broad categories of motor function in PD).  
 
Of the studies reporting medication profiles, a mean of two anti-parkinsonian drugs 
were taken (Grosset et al., 2005a, Grosset et al., 2009, Valldeoriola et al., 2010) 
with a mean of five daily PD drug doses (Grosset et al., 2005a, Grosset et al., 
2009). Combined with other medication use, an average of 6 (range 4-11) 
prescriptions were taken daily (Leopold et al., 2004, Grosset et al., 2005a, Grosset 
et al., 2009, Valldeoriola et al., 2010). The mean PD daily tablet intake was eight 
doses (Grosset et al., 2005a, Grosset et al., 2009). The mean complete medication 
intake was 9 doses (range 5-11) (Leopold et al., 2004, Grosset et al., 2005a, 
Grosset et al., 2009).  
 
Four studies assessed cognitive impairment using the Mini-Mental State 
Examination (MMSE) (Leopold et al., 2004, Evans et al., 2005, Grosset et al., 
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2005a, Grosset et al., 2009). The combined mean was 28/30. One study reported 
cognitive impairment in 22% of participants but did not report the method of 
assessment (Valldeoriola et al., 2010). 
 
3.4.2 Risk of Bias (Threats to Internal Validity) 
The reporting quality was reasonable throughout the seven included studies. One 
study was accepted for publication prior to version one of the STROBE statement 
becoming available (Leopold et al., 2004). None of the observational studies 
published after the release of STROBE acknowledged adhering to the reporting 
guidelines. 
 
Each article was evaluated against five potential biases using nine sub-bias items, 
as determined by the novel quality appraisal tool that was specifically developed 
for this review. Table 3.4 shows each study’s specific risk of bias. The nine quality 
markers considered are presented below: 
 
 Selection Bias      - 1. Diagnostic Inaccuracy 
2. Participant Representativeness 
3. Sampling 
 Random variation/chance    - 4. Sampling Size 
 Detection Bias     - 5. Validity of Adherence Assessment 
   - 6. Follow-up 
   - 7. Blinding 
 Attrition Bias     - 8. Loss to Follow-up 
 Reporting Bias     - 9. Appropriateness of Analysis 
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Table 3. 4 - Study Specific Risk of Bias 
Risk of Bias/Threats to Validity Evans et al 
(2005) 
Grosset et al 
(2005a) 
Valldeoriola et 
al (2010) 
Leopold et al 
(2004) 
Banks & 
Lawrence (2006) 
Grosset et al 
(2009) 
Drey et al 
(2012) 
 
1. Selection Bias                                            
(Diagnostic Inaccuracy) 
      
 
 
2. Selection Bias 
(Participant Representativeness)                                                              
      
 
 
3. Selection Bias 
(Sampling)          
      
 
 
4. Random Variation/Chance 
(Sample Size) 
    
 
n/a 
 
 
n/a 
 
5. Detection bias 
(Validity of Adherence Assessment)                     
    
 
n/a 
 
 
 
 
6. Detection Bias 
(Follow-up) 
 
n/a 
 
 
n/a 
 
 
n/a 
 
 
n/a 
 
7. Detection Bias                                                          
(Blinding) 
    
 
n/a 
 
 
n/a 
 
8. Attrition Bias                                                           
(Loss to Follow-up)                 
 
n/a 
 
 
n/a 
 
 
 
n/a 
 
 
n/a 
 
9. Reporting Bias 
(Appropriate Analysis) 
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In the next part of this chapter I outline the performance of each included study in 
respect to the nine risk of bias items described. 
 
Selection Bias (Diagnostic Inaccuracy): 
All authors stated recruiting patients with PD. However, the diagnostic criteria used 
were only reported in three studies (Evans et al., 2005, Grosset et al., 2005a, 
Grosset et al., 2009). The accuracy of the PD diagnosis was uncertain in four of the 
reviewed studies (Leopold et al., 2004, Banks and Lawrence, 2006, Valldeoriola et 
al., 2010, Drey et al., 2012). As the purpose of the review was to identify factors 
associated with medication non-adherence in idiopathic PD, I felt the accuracy of 
PD diagnosis to be imperative. A lack of diagnostic accuracy could have resulted in 
patients with others forms of parkinsonism being included. These types of patients 
can have different medication profiles to people with idiopathic PD and may also 
have different reasons for not adhering to treatment. It is important to note, 
however, that the uncertainty of PD diagnosis in these four studies was a 
consequence of poor reporting. 
 
Selection Bias (Participant Representativeness):  
Five studies showed no evidence of biased participant representation (Leopold et 
al., 2004, Evans et al., 2005, Grosset et al., 2009, Valldeoriola et al., 2010, Drey et 
al., 2012). Grosset et al (2005a) excluded PD patients prescribed selegiline or 
amantadine. I regarded this as selection bias as no justification was given for this 
exclusion criterion. Banks and Lawrence (2006) provided no information 
concerning the representativeness of their sample. 
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Selection Bias (Sampling): 
Only three studies provided sufficient information of sampling methods to discount 
selection bias (Evans et al., 2005, Grosset et al., 2005a, Drey et al., 2012). Two 
studies provided no information concerning participant selection and therefore an 
assessment of bias was not possible due to poor reporting (Leopold et al., 2004, 
Valldeoriola et al., 2010). Valldeoriola and colleagues (2010) described physicians 
enrolling three consecutive out-patients. The authors claimed selection bias was 
avoided in that patients were previously unselected and had to have been attending 
clinic the same day. I felt this description lacked clarity concerning how selection 
bias was actually avoided.  
 
Banks and Lawrence (2006) were vague concerning their sampling method. 
Participants were identified by PD nurses, a PD partners and relatives database and 
eight participants contacted the research team directly. No further details were 
provided from which an adequate assessment of risk of bias could be made. I 
therefore was unable to discount selection bias in this study. Grosset et al (2009) 
reported selecting participants non-sequentially at the investigator’s discretion. I 
believed this to represent substantial selection bias as investigators may possess 
prior knowledge of the patients’ medication taking behaviour. 
 
Chance/random Variation (Sample Size): 
Of the seven studies included only Valldeoriola et al (2010) described a sample 
size calculation, reporting standard values for significance (0.05) and the statistical 
power (0.8) (the probability of finding an effect if one exists). The accuracy of the 
dependent variable (medication adherence) was reported as ± 4.6%. No clear 
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explanation or justification was given for this value; however, the authors state that 
no previous data was available to facilitate a more informed sample size 
calculation.  
 
Evans et al (2005) compared 25 patients with Dopamine Dysregulation Syndrome 
(DDS) (where patients develop a harmful pattern of compulsive drug use) to 100 
PD patients without DDS. Although a sample of 25 is low for observational 
studies, it must be acknowledged that the prevalence of DDS in the PD population 
is small. Therefore, high numbers likely yielded from a sample size calculation 
would likely be problematic from a recruitment perspective. Despite the small 
sample, a statistically significant association between patient characteristics and 
non-adherence was identified. As associations were identified, even with a small 
sample, I felt this substantiated the reliability of the findings.  
 
In support of this, Grimes & Schulz (2005) state that where the prevalence of cases 
is low compared to controls, increasing the number of controls up to a ratio of four 
to one is acceptable. As the ratio of patients in the study by Evans et al (2005) was 
four controls to one DDS case, I felt this sample ratio was acceptable. The lack of 
an appropriate sample size calculation however predisposes the findings to type 1 
error (i.e. rejecting the null hypothesis when it should be accepted). I felt caution 
should therefore be exercised when interpreting the identified associations in this 
study. 
 
The postal survey with interviews conducted by Banks and Lawrence (2006) 
provided no numerical data to warrant a sample size calculation. The same was the 
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case for the exploratory study by Drey et al (2012). As both were qualitative 
studies, sample size calculations do not apply. The remaining three studies were 
cross-sectional designs of which no research group calculated a sample size 
(Leopold et al., 2004, Grosset et al., 2005a, Grosset et al., 2009). As stated earlier, 
this predisposes to type 1 error and therefore I was cautious when interpreting the 
identified associations. As statistical significance was established, despite no 
sample size calculation, type 2 error which relates to statistical power (accepting 
the null hypothesis when it should be rejected) was not relevant. 
 
Detection Bias (Validity of Adherence Assessment): 
Three studies assessed adherence using MEMS devices, the reported gold standard 
method (Leopold et al., 2004, Grosset et al., 2005a, Grosset et al., 2009). Evans et 
al (2005) used the criteria for DDS as a marker for non-adherence (Evans et al., 
2005). As this is clinically diagnosed I felt confident that participants in this study 
were over-medicating. Valldeoriola et al (2010) assessed adherence with the 
Morisky Medication Adherence Scale (MMAS-4). Although the interpretation of 
self-report measures requires caution, the MMAS-4 has been investigated and 
shown to be moderately comparable to pill counts in PD (Elm et al., 2007). 
 
One study did not report any method for determining non-adherence as this was not 
the aim (Banks and Lawrence, 2006). Drey et al (2012) used an experienced 
healthcare interviewer with limited knowledge of PD to question patients on their 
medication taking behaviours. As non-adherence is often not self-confessed, under 
or overuse of drugs may not have been identified in many people. In contrast, this 
method may have encouraged more patients to provide greater insight into their 
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medication taking practices without the worry of disappointing clinical staff. 
However, due to this uncertainty I was unable to discount bias. 
 
Detection Bias (Follow-up): 
Three studies had a follow-up assessment phase: two were one month post baseline 
(Leopold et al., 2004, Grosset et al., 2009) and one was 3 months post baseline 
(Grosset et al., 2005a). Although the studies were cross-sectional in design, follow-
up assessments were required due to the use of MEMS (i.e. an adequate time 
interval is required to assess pill bottle opening). The remaining studies did not 
require a follow-up period. 
 
Detection Bias (Blinding): 
Four studies did not report whether patients or researchers were blinded (Grosset et 
al., 2009, Grosset et al., 2005a, Evans et al., 2005, Valldeoriola et al., 2010). As the 
studies were cross-sectional, I did not feel this represented a suitable risk of bias. 
Leopold et al (2004) withheld the study aim from participants so that medication 
adherence could be accurately determined. 
 
Attrition Bias (Loss to Follow-up): 
Three studies reported numbers lost to follow-up (Grosset et al., 2005a, Grosset et 
al., 2009, Leopold et al., 2004). In one study, 8 withdrew, 2 lost the MEMS device, 
1 died, 1 had a prolonged hospital admission and 3 patients misused MEMS 
(Grosset et al., 2005a). Grosset et al (2009) enrolled 124 PD participants of which 1 
patient died and 10 used MEMS inconsistently. These were therefore withdrawn 
leaving data for 112 participants. Leopold et al (2004) excluded 1 participant due to 
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symptoms of depression. The remaining three studies had no follow-up assessment 
phase (Evans et al., 2005, Banks and Lawrence, 2006, Valldeoriola et al., 2010). 
No researcher group described a method for imputing missing data.  
 
Reporting Bias (Analytical Methods): 
All seven research groups appropriately analysed their data. Authors used logistic 
regression analysis (Grosset et al., 2005a), multivariate linear regression (Grosset et 
al., 2009, Valldeoriola et al., 2010) or Pearson’s correlation coefficients (Leopold 
et al., 2004) to identify associations between non-adherence and other variables. 
Interview transcripts were analysed with thematic analysis (Drey et al., 2012) and 
content analysis (Banks and Lawrence, 2006) techniques, however, in one study no 
method was reported (Banks and Lawrence, 2006). 
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3.4.3 Factors Associated with Medication Non-adherence 
Various factors, both clinical and demographic, were found to be associated with 
medication non-adherence in PD. To transform the findings from a list of factors 
into something clinically useful, I ranked each factor independently according to 
the strength of association with medication non-adherence. My main justification 
for this approach was to aid healthcare professionals in identifying patients at risk 
of medication non-adherence by informing them of the most salient factors 
correlated with non-adherence in PD.  
 
3.4.3.1 Assessing Study Risk of Bias 
For each included article I provided an assessment of overall study quality; that is, 
high, moderate or low. For example, where the risk of bias in a study appeared to 
be low, the study was defined as high quality.  
 
The risk of bias in each study was used to determine overall quality. From the risk 
of bias table presented earlier I divided the number of ‘ticks’ awarded by the total 
number of risk of bias items to produce a percentile for individual study quality. 
Studies scoring ≥70% were deemed high quality, 40-69% moderate, and <40% low 
quality. Table 3.5 shows how each score was determined for the seven individual 
studies. From this I was then able to rank the factors in order of clinical 
importance, as portrayed in Table 3.6, so that clinicians could see which factors 
appear to be most strongly associated with medication non-adherence. The 
importance of each factor was decided by the reported level of significance and by 
the number of participants associated with each factor. 
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Table 3. 5 - Calculating Risk of Bias 
Study N
o
 of relevant threats 
to validity items 
according to 
research method 
N
o
 (√) 
given 
N
o
 (X) 
given 
N
o
 (?) 
given 
Overall % given 
N
o
 √ ÷ (√ + X + ?) x 
100 
Assessment of 
Bias 
Leopold et al. (2004) 9 5 1 3 (5 ÷ 9) x 100 = 55 Moderate 
Evans et al. (2005) 7 6 0 1 (6 ÷ 7) x 100 = 85 High 
Grosset et al. (2005a) 9 6 2 1 (6 ÷ 9) x 100 = 67 Moderate 
Banks and Lawrence (2006) 4 1 0 3 (1 ÷ 4) x 100 = 25 Low 
Grosset et al. (2009) 9 6 2 1 (6 ÷ 9) x 100 = 67 Moderate 
Valldeoriola et al. (2010) 7 4 0 3 (4 ÷ 7) x 100 = 57 Moderate 
Drey et al. (2012) 5 3 0 2 (3 ÷ 5) x 100 = 60 Moderate 
 
 
Risk of Bias: 
≥ 70   % 
 
High 
40-69 %    
 
Moderate 
<40    % 
 
Low 
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Table 3. 6 - Factors Associated with Medication Non-adherence 
Rank Factor for Poor Adherence Authors Non-adherence Study Design Study  
n =  
Total   
n = 
Correlation 
Coefficients 
Level of Significance Quality 
 
1 Mood Disorders (i.e. depression) Grosset et al (2005a) n=11 (20%) Cross-sectional  54 
497 
Not reported P = 0.02 Moderate  
  Evans et al (2005) n=25  (20%) Case-control 25 Not reported P < 0.01 High 
  Valldeoriola et al (2010) n=163  (40%) Cross-sectional 418 Not reported P < 0.001 Moderate  
          
2 Poor symptom control/poor reported QoL Grosset et al (2005a) n=11  (20%) Cross-sectional 54 
599 
Not reported P = 0.002 (PDQ-39)  Moderate  
  Grosset et al (2009) n=14  (13%) Cross-sectional 112 R2 = 0.13 P < 0.001 (PDQ-39 & UPDRS) Moderate 
  Valldeoriola et al (2010) n=163  (40%) Cross-sectional 418 Not reported P < 0.001 Moderate 
  Drey et al (2012) n=15 (100%) Qualitative study 15  n/a n/a Moderate 
          
3 Regimen complexity/polypharmacy Grosset et al (2005a) n=11  (20%) Cross-sectional 54 
166 
Not reported P = 0.007, P = 0.01 Moderate 
  Grosset et al (2009) n=14  (13%) Cross-sectional 112 Not reported P = 0.0001 Moderate 
          
4 Younger age/longer disease duration Grosset et al (2005a)  n=11  (20%) Cross-sectional 54 
206 
Not reported P = 0.007 Moderate  
  Grosset et al (2009) n=14  (13%) Cross-sectional 112 Not reported NS Moderate 
  Evans et al (2005) n=25 (20%) Case-control 25 Not reported P = 0.016 High 
  Drey et al (2012) n=15 (100%) Qualitative study 15  n/a n/a Moderate 
           
5 Impaired cognition Valldeoriola et al (2010) n=163 (40%) Cross-sectional 418 
432 
Not reported CI 95%: 1.24 – 3.61 Moderate  
  Drey et al (2012) n=15 (100%) Qualitative study 15 n/a n/a Moderate 
          
6 Poor knowledge of PD/ Valldeoriola et al (2010) n=163  (40%) Cross-sectional 418 
472 
Not reported P = 0.04 Moderate 
  Drey et al (2012) n=15 (100%) Qualitative study 15 n/a n/a Moderate 
 More years in education (>16 yrs) Leopold et al (2004) n=35 (90%) Cross-sectional 39 Not reported P = 0.04 Moderate 
          
7 Risk behaviours 
(alcohol, novelty seeking) 
Evans et al (2005) n=25 (20%) Case-control 25 25 Not reported 
Not reported 
P < 0.001 (novelty seeking) 
P = 0.006 (alcohol intake) 
High 
          
8 Not living with a spouse/life partner Valldeoriola et al (2010) n=163  (40%) Cross-sectional 418 418 Not reported P = 0.037 Moderate 
          
9 Lower income Valldeoriola et al (2010) n=163  (40%) Cross-sectional 418 418 Not reported P = 0.05 Moderate 
          
10 Gender Leopold et al (2004) n=35  (90%) Cross-sectional 39 39 Not reported P < 0.05 Moderate  
          
11 Maintaining employment Banks & Lawrence (2006) n/a Survey/interviews 24 
39 
n/a 25% self-reported  Low 
  Drey et al (2012) n=15         (100%) Qualitative study 15 n/a n/a Moderate 
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3.4.3.2 Clinical Factors 
Mood Disorders  
Grosset et al (2005a) showed adherence was inversely associated with more severe 
depression. Evans et al (2005) reported individuals with DDS showed more 
depressive symptoms than PD patients without DDS. Valldeoriola et al (2010) 
reported a highly negative correlation between adherence to medication and 
depressive symptoms.  
 
Cognition 
Valldeoriola & colleagues (2010) identified a strong negative correlation between 
adherence to therapy and the presence of psychiatric symptoms. Such patients were 
almost twice as likely to take medication incorrectly. Specifically, the presence of 
hallucinations and psychosis were both negatively correlated with medication 
adherence. Patients with cognitive deterioration were also twice as likely to be non-
adherent to prescribed regimens as non-cognitively impaired PD patients.  
 
Drey et al (2012) found all of their respondents inadvertently non-adhered to 
medication doses, admitting to occasionally forgetting or becoming confused about 
which medications were due. Despite no objective measure being used to quantify 
cognitive capacity, the authors reported considerable variation in mental capacity. 
For example, 3 participants were heavily dependent on carers to manage their 
medications due to cognitive impairment.  
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Poor Symptom Control & Poor QoL 
Due to the relationship between motor/non-motor symptom control and reported 
QoL in PD, I felt it necessary to combine these two factors. Banks & Lawrence 
(2006) found patients had difficulty maintaining a balance between medication 
taking and QoL, drawing particular attention to the burden of side effects which 
often outweighed symptom control. Grosset et al (2005a) showed poor QoL 
correlated with medication non-adherence, with the strongest association for low 
social support. Valldeoriola et al (2010) reported greater adherence in patients with 
good clinical control. Similarly, Grosset et al (2009) showed non-adherence was 
associated with a poorer clinical state. Drey et al (2012) found a perceived lack of 
efficacy of prescribed medication to control symptoms was associated with 
deliberate non-adherence: 
 
“It’s very obvious now (the tremors). I’m concerned that the medication is not 
doing what it’s supposed to be doing so I don’t bother with it sometimes.” 
(Respondent 7, Drey et al (2012)) 
 
Alternatively, some respondents reported taking extra doses to accommodate what 
they anticipated to be demanding activities, especially those which involved 
outings or work commitments: 
 
“I always carry extra tablets when I go out to cover the sudden return of my 
symptoms. I panic if I realise I have forgotten to take extra with me, just in case I 
need them.” 
(Respondent 15, Drey et al (2012)) 
62 
 
Deliberate over-use of medication was also reported in relation to dose timing. One 
respondent moved all doses forward by 30 minutes to create a large enough time 
gap later in the day for an additional dose to be added. Across many respondents 
medication was manipulated to mask the symptoms of PD from other people: 
 
“I often take my first dose very early so that my long walk coincides with the time 
when I feel the medication is most effective. This helps me to look normal should I 
strike up a conversation with somebody whilst out walking.” 
 (Respondent 3, Drey et al (2012))  
 
Most respondents believed that manipulating dose timing or taking extra doses 
reflected good symptom control and this approach was often adopted by many. One 
respondent reported taking the day’s entire quota of tablets at once in order that he 
would be able to dance at a party. For others, such amendments had become more 
routine: 
 
“I’m an early person. I kick off at six in the morning. They say it should be taken 
before or after eating but I don’t eat then. I don’t eat at six in the morning but I’m 
in need of them (tablets). So I take two at six, two more at ten and then two at two 
in the afternoon. That sorts me out. It often is around those times depending on 
what I’m doing that morning you see. Sometimes on a bad day I might take an 
extra two at some point.” 
(Respondent 14, Drey et al (2012)) 
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Age/disease Duration 
Whilst older age is not always associated with the later stages of PD, I felt it was 
reasonable to combine both age and disease duration when reporting them in the 
context of medication non-adherence. Evans et al (2005) reported patients with 
DDS were significantly younger at PD symptom onset (median 43 years, range 17-
57) than people without DDS (median 56 years, range 21-76). Younger age of PD 
onset was also an independent predictor for developing DDS. Whilst non-DDS 
patients were older at PD onset, it is important to note that due to the small DDS 
sample (n=25) caution is required when interpreting the reliability of age of onset 
as a prognostic factor for developing DDS.     
 
Grosset et al (2005a) showed older age was associated with better overall 
adherence (total dose taken, expressed as a percentage of the total dose prescribed), 
better daily adherence (percentage of days when correct number of doses were 
taken) and better timing adherence (percentage of doses taken at the correct time 
interval).  
 
Grosset et al (2009) reported that poor timing adherence was associated with longer 
disease duration and younger age. However, only small differences in age and 
disease duration were reported (mean age for adherers 65, versus 63 for suboptimal 
adherers and mean PD duration for adherers 7 years versus 10 years for suboptimal 
adherers) of which the differences were non-significant. I therefore decided that 
insufficient explanation was provided to substantiate this claim. Similarly, Drey et 
al (2012) showed deliberate non-adherence was more prevalent in PD patients with 
longer disease duration. 
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Regimen Complexity & Polypharmacy  
Grosset et al (2009) reported 12.5% of participants were medication underusers, 
defined as taking <80% of prescribed drugs. The prescribed dosage of levodopa in 
patients non-adhering to treatment was significantly higher than the dosage in those 
who adhered satisfactorily. Adherent individuals took a median of 8mg per day 
(Inter Quartile Range (IQR) 0-33) less than their prescribed dose of levodopa (a 
non-significant difference), whilst non-adherent patients took a median of 481 mg 
per day (IQR 205-670) less than the prescribed dose (P = 0.0006). Overall 
adherence and timing-adherence were all significantly higher for once-daily 
medications than drugs prescribed more frequently. This was true for once-daily 
versus three times daily dopamine agonists.  
 
Grosset & colleagues (2009) showed 21% (n=23) of participants omitted one or 
more anti-parkinsonian drugs on at least one day during the month of monitoring. 
Longer periods of omission were also apparent: 12% (n=13) had 2-days with 
missed doses and 5% (n=6) had 3-days with missed doses. Most only reduced the 
number of doses taken, while some omitted all drugs. Exact numbers of missed 
doses were not provided. One patient overused anti-parkinsonian medication, 
reporting a personal total adherence of 134%. 
 
Grosset et al (2005a) found that patients taking more medication on a daily basis 
adhered poorly to drugs. This was true for both PD and non-PD prescribed 
medications. Median overall adherence was 98% in adherent individuals compared 
to only 65% in the non-adherers. Median daily adherence was 84% in adherent 
individuals compared to only 27% in the under users. This suggests that those 
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taking less than 80% of their medications (under users) had many more days of 
sub-optimal dosing. Median timing adherence was 25% for satisfactory adherers 
compared to 11% in the underusers. As both are very low this may signify that 
even those categorised as satisfactorily adhering to treatment (i.e. taking > 80% of 
drugs prescribed), many PD patients can still struggle to take doses on time. This 
suggests that erratic drug-taking is likely to be common in PD.  
 
Evans et al (2005) showed patients with DDS (n=25) had significantly higher 
Levodopa Equivalent Daily Doses (LEDD) (median 2000mg, range 700-3200mg) 
compared to PD controls (n=100) without DDS (median 700mg, range 0-1600mg). 
Valldeoriola et al (2010) found levodopa plus dopa-decarboxylase inhibitor 
benserazide (Madopar) was the only treatment showing a difference in the level of 
drug adherence. However, the authors did not specify what other treatments this 
was compared to or whether Madopar was associated with better or worse 
adherence. 
 
Risk Taking Behaviours 
Evans et al (2005) reported that patients with DDS had higher alcohol intake 
compared to PD controls. However, no level of statistical significance was 
provided. DDS patients showed greater past experimental drug use compared to 
non-DDS patients. Furthermore, patients with DDS had higher novelty seeking 
scores, characterised by increased impulsivity, addiction, an inability to delay 
gratification, recklessness and aggressive behaviour (Djamshidian et al., 2011). 
Higher current alcohol intake was also an independent predictor for developing 
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DDS. As stated above, these claims should be carefully considered due to the small 
sample of DDS patients in this study. 
 
3.4.3.3 Demographic Factors 
Education and Knowledge 
Leopold et al (2004) showed participants with more than 16 years of education 
over reported their number of timing errors compared to MEMS data. This finding 
is inconsistent with the idea of greater education predicting better adherence 
behaviour. Although the actual number of participants with more than 16 years of 
education was not reported, the small study sample (n=39) led me to question the 
reliability of this finding.  
 
Furthermore, this finding only suggests that individuals with more education may 
over estimate their errors. Therefore, the true prevalence of incorrectly timed doses 
may in fact be insignificant when the more objective MEMS data is used. As 
MEMS adherence rates for people with more than 16 years of education was not 
reported, I felt there was little evidence to substantiate this claim. 
 
Contrary to Leopold et al (2004), Valldeoriola et al (2010) showed medication 
adherence was significantly worse in patients with limited knowledge of PD. In 
spite of this finding only just reaching significance (P=0.04), I felt the larger 
sample (n=418) to be more representative of PD patients to support the findings. 
However, it should be recognised that poor knowledge of PD is not the same as 
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years in education, which may partly explain the inconsistency between the two 
studies. 
 
Drey et al (2012) found some respondents regarded afternoon sleep to be an 
effective method for symptom control. Whilst this strategy may provide some 
benefit for patients suffering with fatigue, this behaviour frequently resulted in 
missed doses. Despite this, respondents felt afternoon sleeping was a positive 
approach for managing PD fluctuations and often failed to understand or 
acknowledge the consequences of missing medication on their overall symptom 
management. This suggests that poor knowledge of anti-parkinsonian 
pharmacodynamics and insufficient understanding of the need for consistent 
medication dosing may be common in PD.   
 
Spouse/life Partner 
Valldeoriola et al (2010) reported marriage to be positively correlated with greater 
adherence behaviours compared to other relationship status. However, this 
association was non-significant following multivariate logistic regression 
modelling. 
 
Income & Maintaining Employment 
Valldeoriola et al (2010) reported low income was positively correlated with non-
adherence in PD. However, as with the spouse/life partner association, this was 
also non-significant following multivariate logistic regression modelling.  
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Banks & Lawrence (2006) showed 25% (n=6) of participants (mean age, 51 years) 
reported that decisions relating to drug treatment had been influenced by how they 
thought it would affect their ability to work. One patient stated: 
 
“My drug treatment is specifically geared to enable me to continue to work.” 
 
Findings showed that drug regimens were modified to facilitate work 
commitments. Participants reported taking higher doses than they would if not 
working, and/or adjusting medication timing in attempt to maximise the treatment 
effect during working hours. One participant said:  
 
“I probably am taking more than I would want to take if I wasn’t working. I need 
them to get through the working day more than when I am home.” 
 
Findings further revealed that more PD patients diagnosed in their 30’s (50%) 
modified their treatment regimens to facilitate working commitments compared to 
people diagnosed in their 40’s (42%) and 50’s (36%). However, this trend was not 
statistically significant. Many respondents reported delaying the start of 
medication. Others were unwilling to dose escalate due to fear of potential side 
effects and a perceived lack of long-term efficacy, as exemplified by one 
participant: 
 
“I was not prepared to medicate heavily and sooner than necessary in order to 
continue to work in view of the prospect of side effects from long-term drug use.” 
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Drey et al (2012) further revealed how respondents concealed their diagnosis of PD 
from their employers through a regular strategy of extra dosing and rescheduled 
medication timings, especially in manual jobs where people feared loss of 
employment on the grounds of health and safety at work: 
 
“I drive to work before the tablets kick in, so that hopefully they will be optimally 
effective ready for when my shift starts.” If they start to run out, or I feel it’s been 
some time since the last dose, I’ll have another to try and prevent symptoms 
returning whilst I’m there.” 
 
Gender 
Leopold et al (2004) showed females were more likely than males to accurately 
estimate the frequency of missed doses; however, males were more likely to report 
miss-timed doses. Despite significance, I felt the sample size (21 males, 18 
females) was insufficient to provide firm evidence of this association. 
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3.5 Discussion 
In this chapter I systematically reviewed the evidence to identify factors associated 
with medication non-adherence in PD. I assessed each included paper for their 
respective risk of bias and gave each study an arbitrary score for overall quality 
based on the nine risk of bias items described. The findings of the review were 
separated into demographic and clinical factors. Clinical factors included mood 
disorders (depression) impaired cognition, poor symptom control/QoL, younger 
age/longer disease duration, regimen complexity/polypharmacy and risk taking 
behaviours. Demographic factors included higher education and poor knowledge of 
PD, lack of spouse/partner, low income, gender and desire to maintain 
employment.  
 
Medication non-adherence in chronic conditions is high (WHO, 2003), with 
reviews identifying non-adherence in 93% of people with diabetes and 60% of 
people with affective disorders respectively (Lingam and Scott, 2002, Cramer, 
2004). Despite medication providing a degree of symptom relief for many people 
with PD, findings from studies described earlier in this thesis show non-adherence 
is prevalent. Due to the relationship between adherence and symptom control in 
PD, motivation to adhere is often assumed by clinicians (Setter, 2008, Bainbridge 
and Ruscin, 2009, Grosset, 2010). However, in many cases non-adherence is not 
accidental. Medication taking is a complex phenomenon which is affected by 
various factors and patient beliefs.  
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Despite proposed explanations for non-adherence in PD, few studies have reported 
data to substantiate such claims. Therefore, by undertaking this systematic review it 
was my intention to collate the evidence for factors associated with medication 
non-adherence in PD. Through this approach I envisaged the findings being 
directly applicable to healthcare professionals managing PD patients in both 
primary and secondary care environments.    
 
Depression 
Depression was associated with medication non-adherence in three studies. This 
replicates findings from other chronic conditions such as ischaemic heart disease, 
cancer, renal disease and rheumatoid arthritis (DiMatteo et al., 2000, Katon and 
Ciechanowski, 2002). As depressed patients are three times more likely to non-
adhere to prescribed medication than their non-depressed counterparts (DiMatteo et 
al., 2000), this finding in a PD population was not unexpected.  
 
Depression caused by the burden of living with a chronic condition may result in 
medication non-adherence. Patients can struggle to adapt to the limitations imposed 
upon them by their illness and many perceive treatments to lack worthwhile future 
benefit due to the progressive nature of their condition (DiMatteo et al., 2000, 
Katon and Ciechanowski, 2002). Specifically in PD, however, medication non-
adherence may actually lead to the development of depressive symptoms. For 
instance, sub-optimal pill taking in PD can lead to reduced motor/non-motor 
function. Subsequently, this may result in poor QoL which could then lead to 
symptoms of depression.  
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Alternatively, Shiba and colleagues (2000) proposed that the pathogenesis of 
depression in PD may result, at least in part, from the degeneration of 
neurotransmitter systems. Supporting this theory are the findings of preliminary 
studies indicating that optimising dopaminergic therapy may provide anti-
depressant properties (Poewe and Seppi, 2001, Rektorová et al., 2003, Antonini et 
al., 2010, Barone et al., 2010).  
 
Whilst the association between depression and non-adherence is recognised, it is 
important to note that the overall relationship between PD severity and the 
incidence of depression remains poor (Schrag, 2006). This may suggest that disease 
severity may not be sufficient to explain depressive symptoms alone. Other factors 
are therefore likely to contribute to the development and severity of depression in 
PD, either due to extrastriatal pathology or psychological and environmental 
factors which may lead to reactive depression (Schrag, 2006). 
 
As depression affects up to 40% in PD, often presenting early in the disease course 
(Shiba et al., 2000), one useful approach for clinicians is to be mindful of the 
potential emergence of depressive symptoms and consider the use of targeted anti-
depressant interventions early, which may prevent non-adherence from developing. 
Regular surveillance of psychological wellbeing is therefore required throughout 
the entirety of the disease process. It is important to note however that the findings 
from this review provide no indication that management of depression would 
improve medication adherence. This subsequently requires specific investigation.  
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Quality of Life 
Poor QoL/symptom control was associated with non-adherence in four studies. As 
with any association, causation cannot be inferred. However, it is more likely that 
non-adherence to anti-parkinsonian medications in PD causes poor QoL/symptom 
control, especially when considering that bradykinesia and rigidity respond well to 
therapy. 
 
Alternative scenarios however must not be disregarded. Poor QoL may be 
associated with medication non-adherence in PD because of underlying symptoms 
of depression which may impact negatively on QoL. Furthermore, poor QoL and 
symptoms of depression may have a combined negative impact on medication 
adherence in PD; it is known that the presence and severity of depression in PD is 
strongly correlated with poor QoL and both have been reported to be associated 
with medication non-adherence (Grosset et al., 2005a, Bainbridge and Ruscin, 
2009, Valldeoriola et al., 2010). Therefore, where PD patients report experiencing 
poor QoL in clinical settings, underlying symptoms of depression should be 
investigated and the overall impact on medication adherence should be considered. 
 
There is an additional explanation for why poor QoL and poor symptom control are 
associated with non-adherence. In advanced PD patients will have been taking 
levodopa preparations for a considerable time. It is known that long-term levodopa 
use can result in dyskinesia & motor fluctuations in some patients and that these 
consequences of long-term treatment may be more negatively impactful on QoL 
than the symptoms of PD itself; the risk of motor fluctuations and dyskinesia is 
about 40% after 4-6 years of treatment (Ahlskog and Muenter, 2001) and 
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dyskinesia is reported to develop in 100% of young onset PD patients (diagnosed 
before 40 years) after six years of levodopa use (Clarke, 2002). Therefore, some 
patients may attempt to off-set or minimise these debilitating consequences of 
dopaminergic therapy by intentionally non-adhering to prescribed regimens. 
 
From the articles included in this review, one study reported dyskinesia in 26% of 
patients (Grosset et al., 2005a), whilst two studies reported motor complications in 
76%  and 71%, respectively (Grosset et al., 2009, Valldeoriola et al., 2010). Two 
thirds or more were taking levodopa and had had PD for 5 years or more. Although 
it may be more likely that poor QoL/symptom control results from medication non-
adherence, the prevalence of motor complications within the reviewed studies and 
the known impact of these complications on QoL may provide an alternative 
explanation for non-adherent behaviours. This is particularly the case in advanced 
PD where such complications of treatment may be more prevalent. 
 
Dose Manipulation 
The findings of this review also suggest that people with PD manipulate drug doses 
for many other reasons. For example, symptom severity, treatment efficacy, 
perceived need for medication and the understanding of the indication for treatment 
have all been proposed as being contributory to non-adherence in PD (Setter, 2008, 
Bainbridge and Ruscin, 2009, Grosset, 2010, Drey et al., 2012). The following 
paragraph provides evidence for these factors. 
 
Drey & colleagues (2012) showed that in addition to minor inadvertent non-
adherence (occasionally forgetting medication), patients reported episodes of over-
75 
 
medicating to accommodate situations anticipated to be especially demanding 
(deliberate non-adherence). Others described scenarios in which dose timings were 
purposely adjusted to facilitate participation in recreational activities, whilst some 
reported their desire/financial necessity to remain in employment resulted in them 
continuously altering doses in attempt to remain ‘on’ whilst at work. Moreover, 
dosing times were manipulated to mask the symptoms of PD from other people in 
the workforce, suggesting an underlying social stigma may be perceived by some 
with PD.  
 
Whilst some appreciated that sporadic taking of medication satisfies criteria for 
non-adherence, many believed that taking additional doses or adjusting dose 
timings to accommodate planned events reflected good symptom management 
(Drey et al., 2012). This provides evidence of the disparity between patients and 
healthcare professionals views regarding the correct use of anti-parkinsonian drugs.  
 
Alternatively, manipulating doses may be indicative of inadequate symptom 
management due to being under-medicated. Drey et al (2012) found patients 
carried extra medication to cover sudden exacerbations or re-emergence of 
symptoms. Grosset and colleagues (2009) reported that one PD patient had a 
personal total adherence of 134% of the prescribed dose. Whilst demographical 
information was not reported for this patient, the overuse of anti-parkinsonian 
agents in these studies may be indicative of sub-optimal symptom management.  
 
Non-adherence also has consequences for the prescriber. Management decisions 
are based on the premise that patients are correctly taking their medication. Dose 
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escalation, adjunctive therapy use and in some scenarios diagnostic reconsideration 
may all result from seeing a patient in clinic who apparently has had a poor 
response to treatment (Grosset, 2010). These findings suggest that more regular 
reviews of PD medication may be required for ensuring patients are medicated 
optimally and to their individual need. Optimised adherence may also help 
clinicians monitor disease progression more reliably.  
 
Furthermore, collaboration between patients and healthcare professionals is 
imperative for facilitating adherence (Grosset, 2010). Findings show that where 
patients and healthcare professionals make treatment choices together, adherence 
will be enhanced (Gray et al., 2006, Gray, 2011). It is likely to be beneficial 
therefore for clinicians to discuss treatment strategies with patients. Additionally, it 
may be useful to specifically train PD nurse specialists to help patients incorporate 
medication into their daily routines.  
 
The consequences of non-adherence in PD must also be considered in the short-
term. Adverse events associated with intermittent or sub-optimal medication use 
can be life-threatening. Sudden withdrawal of dopaminergic agents can cause 
suppression of central dopamine transmission and thus trigger the neuroleptic 
malignant syndrome, which may lead to fatality (Mizuno et al., 2003). Typically 
symptoms develop between 18 hours and 7 days following anti-parkinsonian 
treatment cessation (Newman et al., 2009). Patients develop pyrexia, increased 
muscle rigidity, reduced conscious levels (potentially leading to a coma), 
autonomic instability and a raised creatine kinase (Newman et al., 2009). Although 
the neuroleptic malignant syndrome is relatively rare, the potential for fatality 
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following acute withdrawal of dopaminergic treatments in PD makes the 
identification of medication non-adherence essential. 
 
Age & Risk Behaviours 
Grosset et al (2005a) showed younger age was associated with medication non-
adherence. During early PD levodopa typically confers a long-duration response. 
Patients may miss doses while experiencing no functional decline and this may 
partly explain medication underuse in younger, more asymptomatic patients. 
However, the long duration response is not age dependent but is more likely related 
to disease severity. Therefore, in younger but more severely affected patients, the 
long duration response may not apply. In early PD healthcare professionals should 
monitor medication taking as non-adherence may not be recognised in 
asymptomatic/mild individuals. In younger, symptomatic patients medication 
adherence should be thoroughly investigated prior to consideration of dose 
escalation. 
 
Evans et al (2005) reported medication overuse in patients with DDS. Whilst this 
represents an exceptional PD group, I felt it was essential to include this study as 
medication overuse is recognised as a modified drug adherence behaviour in DDS. 
Although DDS occurs more in younger PD patients, it is unlikely that age 
independently explains overuse in these individuals and therefore non-adherence 
should be considered in a wider context.  
 
While Evans et al (2005) made no reference to Impulse Control Disorder (ICD), 
defined as a failure to resist temptation, urge or impulse that may result in harm 
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(Ceravolo et al., 2009), associations between non-adherence and increased alcohol 
intake, past experimental drug use and novelty seeking tendencies were identified. 
Epidemiological studies reveal substance addiction and impulsive sensation 
seeking primarily develop in young adulthood (Chambers et al., 2003). As DDS 
patients are younger but also experience novelty and impulsive sensation seeking, 
characteristic of ICD (Ceravolo et al., 2009), it seems more likely that over-
medicating in patients with DDS results from a combination of 
behavioural/personality traits, with younger age related but not independently 
casually linked.  
 
Although ICD characteristics were not directly reported by the authors in the 
reviewed studies, these traits may contribute to the non-adherence observed in 
patients with DDS. In a clinical context when treating a PD patient diagnosed at a 
young age, professionals should acknowledge personality phenotypes and consider 
screening for novelty seeking/compulsive behaviours which may help to prevent 
medication overuse. Moreover, treating susceptible individuals with dopamine 
agonists should be cautiously considered in light of their widely reported 
propensity to induce compulsive behaviours in some PD patients (Evans et al., 
2005).  
 
In contrast to findings reporting non-adherence in younger PD patients, Drey et al 
(2012) identified deliberate non-adherence was prevalent amongst patients with 
longer disease duration. This led the authors to propose that the expert patient 
concept (often associated with people who have managed a chronic illness for 
many years) may not be helpful in the management of PD. However, it is more 
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likely that other factors associated with older age are responsible for the non-
adherence observed in this sample, especially considering that the notion of the 
expert patient is reported to benefit medication adherence (Badcott, 2005).  
 
These findings may also propose the importance of patient-centred education in 
PD. Drey and colleagues (2012) showed that whilst patients appeared familiar with 
treatment goals, patients understanding of PD medication was not sophisticated 
enough to sufficiently manage their condition. In particular, patients did not 
appreciate that to achieve symptom control strict timing of doses can be imperative, 
especially in later stages of disease. A possible strategy may be therefore to 
develop an intervention that promotes patient awareness of the relationship 
between adherence and symptom control. 
 
Regimen Complexity, Polypharmacy & Cognitive Impairment 
Regimen complexity/polypharmacy was associated with non-adherence in PD 
(Grosset et al., 2005a, Grosset et al., 2009). This replicates findings in the elderly 
and other chronic disease areas where non-adherence is prevalent in patients taking 
a considerable number of daily doses (Cramer, 2004, Saini et al., 2009). A review 
by Saini & colleagues (2009) of medication use and polypharmacy in chronic 
conditions showed patients were as much as 44% more adherent to prescribed 
drugs taken once-daily compared to drugs requiring multiple daily doses. 
Furthermore, findings showed that once daily treatment regimens resulted in up to 
twice as many adherent days than in patients where more frequent dosing 
scheduled were prescribed. 
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Schnitzler et al. (2010) reported that patients with PD showed 98% adherence to 
the daily applied rotigotine patch. Similarly, the once-daily tablet rasagiline has 
been associated with greater adherence rates than PD medications requiring 
multiple daily doses (Tarrants et al., 2010). Furthermore, Fargel et al (2007) 
revealed that patients with PD found a high tablet load difficult to manage. These 
combined findings therefore emphasise the importance of prescribing simpler 
treatment regimens in PD (Fargel et al., 2007). Valldeoriola and colleagues (2010) 
found Madopar was the only drug associated with non-adherence. The reasons for 
this are unclear but may result from Madopar preparations being mostly dispensed 
in capsules which can be more difficult to swallow than pills, particularly in 
patients with dysphagia.  
 
This review identified cognitive impairment as being associated with medication 
non-adherence in PD. As deficits in cognition are estimated to affect 20-40% of PD 
patients (Aarsland and Kurz, 2010), this finding was not surprising. Dysfunctional 
planning, attention/mental flexibility and working memory, cognitive domains 
commonly affected in PD, have also been associated with medication non-
adherence in other chronic conditions such as diabetes, cancer and hypertension 
(Stilley et al., 2010). Non-adherence in elderly patients with cognitive decline is 
also widely acknowledged (Arlt et al., 2008).  
 
As cognitive impairment can be substantial in PD, and as studies show simpler 
drug regimens reduce non-adherence in many chronic conditions, it is sensible to 
focus on the early detection of cognitive dysfunction and where indicated prescribe 
simpler drug regimens to reduce pill intake. This may include prescribing longer 
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acting agents where possible or favouring, where tolerated, combined preparations 
which eradicate the need for further tablets. Additionally, assisting cognitively 
challenged individuals with problem solving strategies might help patients to find 
ways to adhere to prescribed drugs, particularly if treatment is placed within their 
own personal context. 
 
Drey & colleagues (2012) found patients regularly missed doses due to episodes of 
sleeping during the afternoon or insomnia at night. This is often reported in patients 
suffering with fatigue or PD related sleep disruption such as restless legs syndrome 
or being ‘off’ during the night (Ferreira et al., 2006). Despite recognising that 
missing doses would go against the prescriber’s intentions, some patients appeared 
unable to instigate plans to prevent such episodes from recurring. This may suggest 
that daytime somnolence, combined with an inability to problem solve, could 
account for some of the non-adherent behaviours observed.  
 
What’s more, the capacity to anticipate the onset of fluctuating symptoms did not 
necessarily increase patients’ ability to time medication successfully in order to try 
and prevent fluctuations from occurring. This may suggest that for some 
individuals with PD planning and problem solving may be problematic, resulting in 
sub-optimal medication taking. Alternatively, these findings may suggest that 
patients may not appreciate the importance of specific dose timing in PD. 
 
Education & Knowledge of PD 
Greater knowledge of PD was associated with better adherence. This is consistent 
with findings reporting improved timing adherence in PD patients after receiving 
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educational material (Grosset and Grosset, 2007). Drey & colleagues (2012) found 
that for some people with PD a lack of understanding concerning the necessity for 
timed medication resulted in frequently missed or miss timed-doses. This suggests 
that a greater emphasis on education may be beneficial for improving medication 
adherence in PD. Furthermore, educational material that is personally relevant may 
be more likely to have a positive impact on adherence behaviours. 
 
Alternatively, however, higher levels of general education may in some cases 
hinder medication adherence. Leopold et al (2004) showed higher educational 
attainment was associated with sub-optimal adherence. This association was 
surprising and may be a result of more educated and better informed individuals 
having greater capacity to challenge medical opinion.  
 
Gender and Spouse/carers 
Males were less accurate at estimating the frequency of miss-timed doses. 
However, I believed that the small sample involved in this association reduced the 
reliability of this claim. Living with a spouse/life partner was associated with 
greater adherence. This is not surprising; in chronic illness caregivers are critical in 
helping to manage the disease. Specifically in PD, cognitive impairment can leave 
caregivers inheriting the responsibility of medication management. Therefore, it is 
paramount that spouse/caregivers are involved and supported throughout the 
entirety of the disease process, and that they themselves possess the appropriate 
knowledge of the importance of accurate dose timing. 
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Maintaining Employment 
The desire to maintain employment was associated with non-adherence. Drey and 
colleagues (2012) found that some PD patients escalated doses to maximise 
working capacity whilst others withheld treatment fearing future motor 
complications which may inhibit working performance. Many patients also failed 
to accept that doses must be timed evenly to maintain consistent plasma dopamine 
levels.  
 
Traditionally, deviation from prescribed medication regimens satisfies healthcare 
professionals’ criteria for non-adherence. However, whilst dose timings are 
important in PD, professionals should recognise that the ultimate goal of treatment 
is to maintain Health Related QoL (HRQoL). For many the workplace affords self-
fulfilment, helping to optimise QoL. Although findings seem to suggest that 
patients require greater knowledge of the effect of manipulating doses, it is evident 
that patients require their regimens to be specific to their need. Prescribers should 
acknowledge that medication may be focused around functioning optimally at work 
and therefore working collaboratively with patients through shared decision-
making may help to maximise adherence in PD. It is worth noting however that 
although physical and cognitive demands may be considerably less in the elderly, 
their dysfunctions may be no less impactful on QoL and so this must also be 
considered. 
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3.5.1 Strengths and Limitations 
When interpreting this review, some limitations require consideration. Statistical 
synthesis was not undertaken due to the heterogeneity of the seven included 
studies. As most studies were observational, causation between factors and non-
adherence cannot be inferred. However, it is more likely that many of the identified 
factors cause non-adherence as opposed to being a product of non-adherent 
behaviour. The definitions and assessment methods for adherence also require 
consideration as these vary widely across studies. Nevertheless, irrespective of the 
definition, it is important to emphasise that adherence is a moving target which is 
likely to become increasingly more difficult to achieve with advancing disease.  
 
Although the findings of the review did not identify financial or healthcare system 
constraints as factors for non-adherence, it is important to note that once daily 
drugs such as dopamine agonists which help reduce regimen complexity may not 
be readily available on prescription in some countries, such as the US. There are 
also financial barriers to prescribing expensive drugs for the sole purpose of 
reducing the number of daily doses. 
 
The summation of the nine risk of bias items to produce an overall risk of bias 
score in this review should also be acknowledged. Although the described method 
allowed for ease of presentation and is advocated by organisations such as the 
Cochrane Collaboration, it is important to note that not all risk of bias items should 
be given the same weighting. For example, in a RCT the method of randomisation 
and concealment of allocation are risk of bias items that should be given the most 
importance.  
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Although I acknowledged that some risk of bias items for different studies were 
more important and thus should be given more weighting, this was not reflected in 
the overall risk of bias score. This may be deemed a limitation of the review. 
Furthermore, the cut-off scores for low, moderate and high risk of bias were 
arbitrary.         
 
The major strength of this review is the critical appraisal of the literature against a 
novel risk of bias tool which I developed following a thorough systematic search of 
existing quality instruments. This risk of bias assessment tool was purposely 
designed for generic use and therefore is applicable to other disease areas and non-
interventional studies. Another strength of this review is that identified factors were 
ranked by weight of supporting evidence. This novel approach allows clinicians to 
understand the most salient factors likely to be associated with medication non-
adherence in PD. With such knowledge, healthcare professionals should be able to 
identify who is more likely to be non-adherent to anti-parkinsonian drugs.  
 
It must be emphasised however that this ranking was based on the quality of each 
study, the number of patients associated with each factor, and the level of 
significance for each factor. As a result, factors such as the desire to maintain 
employment were ranked lower down in the list. Whilst this may not be as 
common as others ranked much higher (due to most people with PD being retired 
for example), it must be recognised that to individuals for whom this is relevant, 
such a factor may be no less impactful on their medication taking behaviour than 
some of the more highly ranked factors. 
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3.5.2 Summary 
The symptoms of PD can be extremely debilitating and often result in poor QoL. 
Medication can be an effective treatment for controlling some of the reported 
symptoms in people with PD. However, findings show that many people with PD 
do not adequately adhere to treatment. Non-adherence is associated with a variety 
of both clinical and demographic factors, as described in this chapter. Moreover, 
contrary to existing belief, much of the non-adherent behaviours identified are not 
accidental. Healthcare professionals should acknowledge these factors when 
consulting patients which could prove beneficial for identifying patients at risk of 
medication non-adherence.  
 
In light of the identified factors, targeted, patient-centred interventions that 
acknowledge factors associated with non-adherence should be investigated in an 
attempt to improve medication adherence in PD. Therefore, with a greater 
knowledge of adherence issues in PD, I decided to investigate what interventions 
have been used in PD for improving medication adherence. This work is presented 
in Chapter 4.  
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CHAPTER 4 
 
 
Interventions to Improve Medication 
Adherence in Parkinson’s disease 
 
 
Background 
Methods 
Results 
Discussion 
 
 
 
4.1 Background 
The investigation of the effectiveness of strategies aimed at improving medication 
adherence in PD has received little attention. This is in contrast to other chronic 
conditions where evidence from numerous systematic reviews has shown a number 
of interventions have been investigated in attempt to enhance adherence behaviour 
(Kripalani et al., 2007, Haynes et al., 2008, Nunes et al., 2009). 
 
The aim of adherence interventions is to increase acceptance of, and persistence 
with, prescribed treatments (WHO, 2003, Nunes et al., 2009). Once factors 
associated with poor adherence have been identified and their mechanisms of 
action are understood, interventions aimed at enhancing adherence behaviours can 
be developed and investigated.  
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The National Institute for Health and Care Excellence in the UK recommend 
focusing on exploring patient beliefs and attitudes towards disease and drug 
treatments (NICE, 2009). Whilst some findings are equivocal, evidence mainly 
suggests that such an approach is beneficial for enhancing medication adherence in 
people with chronic illness (Horne and Weinman, 1999, Maneesakorn et al., 2007, 
Haynes et al., 2008, Alhalaiqa et al., 2011).  
 
A recent review of medication adherence in the US showed a variety of 
interventions (e.g. educational and behavioural approaches) were beneficial for 
improving adherence rates in several chronic conditions (Viswanathan et al., 2012). 
However, despite various research groups reporting the efficacy of such 
interventions (Peterson et al., 2003, Kripalani et al., 2007, Haynes et al., 2008, 
Viswanathan et al., 2012), there is a paucity of evidence specifically investigating 
the effectiveness of adherence promoting interventions in a PD population.  
 
Therefore, it is reasonable to suggest that an intervention aimed specifically at 
improving medication adherence, and that recognises factors associated with non-
adherence, could be beneficial for improving adherence behaviours in PD. 
However, before a novel treatment can be developed I decided to investigate which 
interventions have been evaluated previously in PD. To answer this research 
question I conducted a Cochrane systematic review. Cochrane reviews mostly 
evaluate evidence relating to the efficacy of healthcare interventions. As I aimed to 
investigate adherence enhancing interventions in PD, I believed a Cochrane 
systematic review methodology was most appropriate.   
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4.2 Methods 
The methods described in the next section of this chapter outline the process used 
when searching for and evaluating the relevant literature. The protocol, including 
the search strings used for each online database, was approved by expert systematic 
review and meta-analysis methodologists from the Movement Disorder Group at 
the Cochrane Collaboration. Appendix 3 shows the search strings used in this 
systematic review. 
  
4.2.1 Criteria for Considering Studies for this Review (Inclusion Criteria) 
4.2.1.1 Types of Studies: 
 Published Randomised Controlled Trials aiming to increase adherence to 
anti-parkinsonian medications. 
 
4.2.1.2 Types of Participants: 
 Adults with a clinical diagnosis of idiopathic PD (as defined by the authors 
of the included studies) in a primary care, outpatient or community setting. 
 
4.2.1.3 Types of Interventions: 
For the purpose of this review I grouped studies by intervention type and proposed 
mechanism of action. The interventions were categorised into one of the following 
groups: 
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1. Simplification of Dose Regimen 
These studies enhance adherence by amending dosage schedules in order to 
simplify the regimen. This can be by reducing the number of pills taken daily 
and/or the number of doses required daily for adequate symptom control to be 
achieved. Through this approach the burden associated with pill taking is reduced. 
 
2. Patient Education 
Studies designed primarily to educate patients through prescriptive/didactic means 
(i.e. educational material). This method is based on the premise that patients who 
possess greater knowledge of their illness and its respective treatment will be more 
informed and therefore more likely to adhere to prescribed therapies. 
 
3. Behavioural Interventions 
Studies using interventions designed to influence adherence behaviours. Such 
interventions are likely to have two proposed mechanisms of actions: 
 
(i) Positive adherence behaviours are assumed; that is, it is expected that the patient 
wishes to adhere to drug regimens. By enhancing/maximising motivation the 
patient’s ability to take medication as intended will be optimised. This may then 
benefit clinical outcomes (Haynes et al., 2008).  
 
Interventions to facilitate this largely consist of problem solving, reminders 
(diaries), regular follow up appointments, social/community and professional 
support such as involvement of allied health professionals (e.g. nurse specialists, 
pharmacists). 
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(ii) Positive adherence behaviours are not assumed; that is, the patient may not 
wish to adhere to prescribed medication regimens. This type of intervention aims to 
modify beliefs/attitudes, which subsequently changes adherence behaviours leading 
to improved clinical outcomes (Nunes et al., 2009). 
 
4. Combined or Complex Interventions 
These interventions include two or more of the preceding categories and may have 
multiple phases for introducing the different types of interventions. 
 
Control/treatment as usual groups either received no intervention or received usual 
care, as defined by the study authors. 
 
4.2.1.4 Exclusion Criteria 
1. Interventions that did not aim to enhance adherence to anti-parkinsonian 
medication, 
2. Interventions that were not directed at patients with PD (e.g. education of 
healthcare professionals about the importance of adherence), 
3. Studies that did not report the results in full (e.g. conference abstracts) and 
where further information (sufficient to make a fair appraisal of the 
methodological quality of the study) was not available from the authors, 
4. Studies that did not report a measure of adherence. 
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4.2.1.5 Types of Outcome Measures: 
As I was interested in interventions aimed specifically at improving medication 
adherence in PD, I felt that adherence should be the primary outcome. 
  
Primary Outcome:  
1. Adherence to medication (including any definition of adherence and noting 
how this was defined and measured in each study). 
 
Secondary Outcomes:   
1.   Change in global clinical scale e.g. Unified PD Rating Scale, 
2. Change in other clinical indicators e.g. off-time and dyskinesia, 
3. Change in attitudes and beliefs towards medication, 
4. Reporting of major clinical events associated with the consequences of poor 
medication adherence (e.g. increased dyskinesia, motor fluctuations, 
worsening of PD symptoms and on rare occasions psychosis), 
5. Cost analysis of the intervention, 
6. Potential adverse events of the intervention, 
7. Acceptability of the provided intervention, 
8. Carer load e.g. carer strain index. 
 
In the next section of this chapter I outline the procedure used for identifying 
articles for consideration in this review. Furthermore, I discuss the process used for 
assessing risk of bias and I outline the method for conducting a meta-analysis if 
that was possible. Finally, I end this chapter by reporting and discussing the main 
findings. 
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4.2.2 Electronic Search Methods for Identification of Studies 
I used a comprehensive sampling strategy to retrieve all relevant RCTs relating to 
medication adherence in PD. The following sources were searched: 
 
 The Cochrane Central Register of Controlled Trials (CENTRAL)  
 The Movement Disorder Society Specialised Register 
 MEDLINE (Ovid, 1946 to February 2013) 
 EMBASE (Ovid, 1974 to February 2013) 
 AMED (Ovid 1985 to February 2013) 
 PsycINFO (Ovid 1806 to February 2013) 
 CINAHL (EbscoH, 1981 to February 2013) 
 
I also searched the WHO International Clinical Trials Registry Platform (ICTRP) 
Search Portal, Current Controlled Trials, the International Standard Randomised 
Controlled Trial Number (ISRCTN) register and the UK National Research 
Register (NRR) archive (all to February 2013) for on-going and recently completed 
trials. There was no restriction on language or publication status. 
 
Appendix 3 shows the search strings used when searching the five online 
databases. When conducting the search I mapped key terms to database speciﬁc 
subject headings (MeSH terms) and exploded each to include all sub-categories. 
Truncations (*after search term) and Boolean operators (AND, OR, NOT) were 
also used to broaden the search window. Finally, I screened reference lists of all 
retrieved articles to identify additional records. Where necessary, I contacted the 
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authors of relevant studies to acquire additional information relating to an 
identified study/abstract. 
 
4.2.3 Selection of Studies  
All studies and abstracts were evaluated according to the methods highlighted in 
the Cochrane Handbook (Higgins and Green, 2009). Specifically, full paper copies 
of potentially relevant citations were sought and two reviewers (I and KHOD, one 
of my supervisors) independently assessed each full text against the review 
inclusion criteria. Disagreements were resolved by formal discussion. 
 
4.2.4 Data Extraction and Management 
The standardised data extraction form provided in the Cochrane Collaboration 
Handbook was used for data extraction (Higgins and Green, 2009). This acted as a 
template for data entry. 
 
4.2.5 Assessment of Risk of Bias 
Two reviewers (I and KHOD) independently assessed studies for risk of bias using 
the Cochrane Collaboration quality assessment tool (Higgins and Green, 2009). 
The assessment of overall risk of bias was based on the following bias items: (1) 
random sequence generation, (2) allocation concealment, (3) blinding, (4) selective 
reporting and (5) the potential effect of incomplete outcome data.  
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Other risk of bias items that I decided were appropriate for this review included 
idiopathic PD diagnostic accuracy (e.g. UK Brain Bank Criteria or other 
appropriately defined criteria) and the reliability/validity of reported outcome 
measures; that is, whether adherence assessment methods were standardised/valid 
and whether clinical outcomes used were standardised measures. 
 
4.2.6 Dealing with Missing Data 
Where data was insufficient or missing, additional information was sought from 
study authors. If there was no response, I planned to analyse the data that was 
available. 
 
4.2.7 Measurement of Treatment Effect 
I planned to perform all statistical analyses using the RevMan software provided by 
the Cochrane Collaboration. Before conducting the search I recognised that 
sufficient heterogeneity may exist between identified studies which could prohibit 
a meta-analysis of the results. Under such circumstances I planned to perform a 
descriptive ‘narrative’ review.  
 
4.2.8 Data Synthesis 
If a meta-analysis was possible I planned to use standardised statistical techniques 
to calculate and report the results as odds ratios (and 95% confidence intervals) for 
dichotomous outcomes and mean differences (MD) for continuous outcomes. The 
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significance of any differences between the odds ratios or MD would then be 
calculated using a standard method (Altman and Matthews, 1996).  
 
As I anticipated that the true effect size of the intervention would vary considerably 
between studies, I planned to adopt a random-effects model where data synthesis 
was possible. Possible factors that I believed may vary substantially included: age 
of the participants, level of education, baseline level of adherence, disease severity 
and the intensity/type of the adherence intervention. 
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4.3 Results 
The five databases searched yielded a total of 3615 records as shown in Table 4.1.  
 
Table 4. 1 - Records Identified by Database 
Database Number of Records 
 
MEDLINE (Ovid) 105 
EMBASE (Ovid) 3332 
AMED (Ovid) 0 
PsychINFO (Ovid) 69 
CINAHL (EbscoH) 109 
  
Total: 3615 
 
 
A further three records were identified from the Cochrane Central Register of 
Controlled Trials (CENTRAL). After combining the search results into one library 
and then removing duplicated records (n=230), a total of 3388 records remained. 
Figure 4.1 shows the PRISMA diagram depicting the stages of study identification.  
 
After reviewing titles and abstracts of all 3388 identified records, 38 articles were 
suitable for full text retrieval. Five of these records were in fact conference 
abstracts (Bhidayasiri et al., 2009, Aguiar et al., 2010, Aljanati et al., 2010, Guo et 
al., 2010, Al-Din et al., 2012). All the authors’ for each abstract were contacted to 
ensure that the study had not been published. Of the three authors who responded, 
all confirmed that the results had only been presented at a conference. These five 
abstracts were thus excluded as insufficient data was provided in the abstract from 
which an adequate assessment of risk of bias could be made. 
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Three records were not published in English language (German n=2, Dutch n=1). 
Email correspondence with the author of the Dutch study (Aerts et al., 2011) 
confirmed the paper had not been published in English in another journal. Also, as 
the paper was a literature review of adherence in PD it was not relevant. The two 
articles published in German language (Unknown, 1994, Ameri, 2009) were 
reviewed by a German speaking colleague who confirmed that they were 
commentary reports. These were therefore also not relevant to the systematic 
review. 
 
I excluded a further five records as they were review papers (Antonini et al., 2010, 
Agyapong et al., 2011, Farlow and Somogyi, 2011, Hametner et al., 2011, Allen et 
al., 2012). An additional five records were excluded as they were not concerned 
with medication adherence (Hutton et al., 1996, Allain et al., 2000, Clarke et al., 
2009, Pretzer-Aboff et al., 2011, Manning et al., 2012).  
 
Fifteen studies were not RCTs and thus I excluded them on this basis (Al-Zakwani 
et al., 2003, Nausieda et al., 2005, Myllyla et al., 2006, Arbouw et al., 2009, Sethi 
et al., 2009, Davis et al., 2010, Delea et al., 2010, Schnitzler et al., 2010, Tarrants 
et al., 2010, Wood et al., 2010, Delea et al., 2011, Hamlen and MacGregor, 2011, 
Schlesinger and Rabinowitz, 2011, Sesar et al., 2011, Santos-Garcia et al., 2012).  
 
Two studies were further excluded because they did not provide an assessment of 
medication adherence (Hinson et al., 2009, Pickering et al., 2013). An additional 
study by Stocchi and colleagues (2008) was excluded because the intervention 
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described did not constitute a reduction in the number of daily pills, as was 
portrayed in the abstract.  
 
One final study by Montgomery and colleagues (1994) was excluded because the 
described adherence assessment did not constitute a valid method; drug usage was 
tabulated per patient per day but the actual doses prescribed and the timing of the 
doses was not documented. 
 
Therefore, the evaluation of the 38 full texts yielded only 1 study by Grosset and 
Grosset (2007) that met the inclusion criteria for the Cochrane systematic review. 
The characteristics of this study are presented in Table 4.2. 
 
In the final part of this chapter I provide a summary of the results and include an 
outline of the risk of bias assessment used. Following this I discuss the findings 
within the context of adherence enhancing interventions used in other chronic 
conditions. 
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Figure 4. 1 - PRISMA Flow Diagram of Study Identification 
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Potentially relevant 
records identified 
through electronic 
database search: 
n = 3615 
 
 
Additional records identified 
through CENTRAL: 
n = 3 
 
 
Number of duplicates 
removed: 
n = 230 
 
 
Number of records 
screened: 
n = 3388 
 
Number of full-text records 
retrieved for detailed 
evaluation: 
n = 38 
 
 
Number of records excluded 
by review of title/abstract:  
n = 3350 
 
 
Total number of records 
included in systematic 
synthesis: 
n = 1 
 
 
Number of records excluded with reasons: 
n=37 
 
- Conference abstract only  (n=5) 
 
- Article not in English (n=3)  
 
- Review paper  (n=5) 
 
- Not concerned with medication adherence 
(n=5)  
  
- Not a randomised controlled trial (n=15)    
 
- No assessment of adherence (n=2) 
 
- Intervention not a true dose reduction (n=1) 
 
- Not a valid assessment of medication 
adherence (n=1)  
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Table 4. 2 - Characteristics of Included Study 
Grosset & 
Grosset 
(2007) 
      Description 
 
Methods - Parallel RCT, 3 month follow-up. Analysis employed intention 
to treat. A sample size calculation was carried out. 
- Adherence determined using MEMS. Monitored drug intake 
during two 3 month periods (before and after the intervention).  
 
Recruitment - Recruited from a regional movement disorder clinic. All were 
prescribed at least one anti-parkinsonian medication. 
 
Participants - 89 patients with PD (diagnosed by UK Brain Bank criteria) 
were asked to participate. 6 (7%) declined. 
- 43 were randomised to the active group and 40 to the control 
group using computer generated opaque envelopes. 
Randomisation preceded baseline assessment. 
- 14 dropped out during the first 3-month monitoring, 10 from 
the active group. Baseline adherence data were therefore 
available for 69 patients (33 active group and 36 control group). 
- In the post intervention period, 17 patients dropped out (10 
active group). Post intervention adherence data were evaluable 
for 52 patients (23 active group).   
 
Intervention - After the first 3 months of monitoring using MEMS, patients in 
the active group were given verbal and written information 
about the dopaminergic theory and tailored written guidance on 
optimal medicine timing for their regimen. 
- Control patients received standard care, but also had medication 
intake monitored using MEMS. 
 
Outcomes - Unified Parkinson’s Disease Rating Scale (UPDRS),  
- Hoehn & Yahr assessment of disease severity, 
- Schwab and England Scale (ADL assessment) 
- Mini-Mental State Examination (MMSE), 
- Geriatric Depression Score, 
- Parkinson’s disease Quality of Life Questionnaire (PDQ-39). 
- All were assessed at baseline. The PDQ-39 was also repeated at 
the final visit. All clinical recordings were blind to patient 
group. 
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4.3.1 Assessment of Risk of Bias 
The reporting quality of the included study was sufficient to adequately assess the 
potential risk of bias. Two reviewers (I and KHOD) independently assessed the 
included article for various aspects of bias using the risk of bias assessment tool 
from within the Cochrane Handbook (Higgins and Green, 2009). Specifically, we 
independently assessed the overall risk of bias based on the classification scheme 
for types of bias outlined in Table 4.3.  
 
 
Table 4. 3 - Classification Scheme for Bias 
Type of Bias Description Relevant domain in 
Cochrane’s ‘Risk of Bias’ tool 
Selection bias Systematic differences 
between baseline 
characteristics of the groups 
that are compared.  
 
 Sequence generation. 
 Allocation concealment. 
Performance bias Systematic differences 
between groups in the care 
that is provided, or in 
exposure to factors other 
than the interventions of 
interest. 
 
 Blinding of participants 
and personnel. 
Detection Bias Systematic differences 
between groups in how 
outcomes are determined. 
 
 
 Blinding of outcome 
assessment. 
Attrition Bias Systematic differences 
between groups in 
withdrawal from the study. 
 
 Incomplete outcome data. 
Reporting Bias Systematic differences 
between reported and 
unreported findings 
 Selective outcome 
reporting. 
 
(Source: Higgins and Green (2009)) 
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4.3.2 Judging Risk of Bias in Included Studies 
When reviewing the included study, judgements regarding the risk of bias were 
categorised as: ‘Low risk of bias’, ‘High risk of bias’ or ‘Unclear risk of bias’ 
(Higgins and Green, 2009). Appendix 4 shows the specific criteria used when 
making a judgement of risk of bias. Table 4.4 shows the judgement for each risk of 
bias item in the included study. 
 
Table 4. 4 - Risk of Bias 
Grosset & Grosset (2007)  
 
 
Bias Item 
 
Judgement Comment &/or support for 
judgement 
Random sequence generation  Low risk Computer generated 
 
Allocation concealment Low risk Placed in opaque envelopes 
 
Blinding - participants  
Blinding - clinicians 
High risk 
High risk 
Unavoidable with this intervention  
Unavoidable with this intervention 
Blinding - analyst 
 
Unclear No mention of statistician. 
 
Blinding - outcome assessor Low risk Clinical recordings blinded to group 
allocation 
 
Incomplete/missing data Low risk Intention to treat using last 
observation carried forward 
 
Selective reporting Unclear Study protocol reported 
(NCT00361205). Although 
medication timing compliance and 
motor scores are mentioned, PDQ-39 
and adverse events are not. 
 
Diagnostic accuracy 
 
Adherence assessment 
Low risk 
 
Low risk 
UK Brain Bank criteria used 
 
MEMS caps used. 
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4.3.3 Description of Adherence Intervention 
As only one study met the inclusion criteria for this systematic review, it was not 
possible to pool the results and conduct a meta-analysis. 
 
Of the different types of intervention described earlier in this chapter for improving 
medication adherence, Grosset and Grosset (2007) satisfied the criteria for patient 
education. Patients in the treatment group were given verbal and written 
information relating to the continuous dopaminergic theory 3 months after starting 
to use MEMS bottles. After receiving the intervention, MEMS monitoring 
continued for a further 3 months. Participants in the control group used MEMS for 
the entirety of the trial duration. 
 
4.3.4 Baseline Measurements and Observations 
At baseline, timing adherence was a median of 17% (IQ 9-51) in the active group 
versus 21% (IQ 10-59) in the control group. This difference was not significant. All 
other outcome measures did not differ significantly between the active and control 
groups. These measurements included: UPDRS, Hoehn & Yahr (measure of 
disease severity), Schwab and England scale (assesses activity of daily living) and 
the Mini-Mental State Examination (a non-disease specific assessment of cognitive 
impairment). 
 
Timing adherence was significantly better at baseline for once daily drugs (median 
82%, IQ 70-93) than drugs prescribed twice daily (33%, IQ 4-47) or more 
frequently (p < 0.0001). 
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4.3.5 Efficacy of the Intervention 
4.3.5.1 Primary Outcomes 
Adherence 
After receiving the educational intervention, timing adherence significantly 
improved in the active treatment group (n=23) (median 39%, Inter Quartile Range 
(IQR) 22–58) compared to the control group (n=29) (median 20%, IQR 10–47, p = 
0.007). The intervention effect (difference in timing adherence pre to post 
intervention between the groups) was 13.4% (95% Confidence Interval (CI): 5.1, 
21.7; p = 0.002). After excluding drugs taken once daily from the analysis, the 
intervention effect was 23.1% (95% CI: 11.7, 34.5, p = 0.0001).  
 
4.3.5.2 Secondary Outcomes Reported 
Change in Global Clinical Scales 
The Parkinson’s Disease Questionniare-39 total score increased by a mean of 6.0 
(95% CI: 2.3, 9.7) in the active treatment group, versus a mean increase of 3.5 
(95% CI: -1.6, 8.6) in the control group (p = 0.4). The mean change in UPDRS 
motor scores was 0.1 (95% CI: -3.4, 3.7) in the active treatment group versus 4.5 
(95% CI: 1.6, 7.1) in the control group (p = 0.06). Both outcomes showed no 
statistically significant difference between the groups. 
 
Potential Adverse Events of the Intervention 
Grosset and Grosset (2007) reported there were no significant differences in 
frequency or type of adverse events between the two groups (active treatment 
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group 1.5 adverse events per patient, versus 1.1 in the control group). The authors 
report that the most common adverse effects (i.e. insomnia, sleepiness, dyskinesia 
and nausea) were in declining frequency. No further information was provided and 
so it was unclear whether this was anticipated to result from a changed pattern of 
medication taking.  
 
4.3.5.3 Secondary Outcomes Not Reported 
Change in Global Clinical Scale 
The difference in the remaining measurements taken (i.e. Schwab and England, 
Hoehn and Yahr and the Mini-Mental State Examination) from baseline to follow-
up between the two groups was not reported. Although these scales were completed 
at baseline and follow-up, Grosset and Grosset (2007) did not report that they were 
secondary outcomes. 
 
Change in Other Clinical Indicators (e.g. off-time and dyskinesia) 
Grosset and Grosset (2007) did not report off-time in study participants both before 
and after the intervention. Dyskinesia was acknowledged to be in declining 
frequency as described above. However, no data was provided to substantiate this 
claim. 
 
Other Secondary Outcomes Not Reported 
A change in attitudes and beliefs towards medication, carer load/burden, 
acceptability of the intervention provided and cost analysis of the intervention were 
not reported by Grosset and Grosset (2007). 
107 
 
4.4 Discussion 
In this chapter I outlined the methods and results of a Cochrane systematic review. 
My aim was to identify randomised controlled trials that investigated the efficacy 
of interventions for improving medication adherence in PD. The search was 
performed using five online databases and a list of clinical registers to identify all 
possible trials of adherence interventions in PD. Furthermore, I endeavoured to 
identify unpublished RCTs through correspondence with all authors named within 
identified abstracts. Search strings for each of the five databases were extensive 
and were peer-reviewed by Cochrane methodology specialists. Despite the 
methodological rigour used to search for relevant RCTs, only one study was 
identified that met the inclusion criteria. This indicates the paucity of high quality 
research in this area. 
 
4.4.1 Summary of Main Results 
The intervention investigated in the included study consisted of didactic 
educational material relating to the continuous dopaminergic theory. Of the 83 
participants randomised (n=43, active treatment group), only 52 completed the trial 
(n=23, active treatment group). Grosset and Grosset (2007) showed a statistically 
significant difference in timing adherence between the two groups, favouring the 
intervention group. However, clinical outcomes worsened in both groups over the 
trial period and showed no statistically significant difference between the groups. 
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4.4.2 Quality of Evidence 
The overall risk of bias in the included study was low. The methods for both 
random sequence generation and allocation concealment were adequately reported 
and appropriate. The diagnosis of PD was determined using the UK Brain Bank 
Criteria and MEMS bottles were used to assess medication adherence. Both are 
reported gold standard methods and therefore the risk of bias regarding these items 
was low. Only blinding of participants and clinicians to group allocation resulted in 
a high risk of bias. However, as the intervention was in the form of educational 
material, blinding of participants and the clinicians providing the intervention was 
not possible. Therefore, I was not concerned by this risk of bias. Moreover, all 
clinical assessments at baseline and follow-up were completed by raters masked to 
group allocation, resulting in a low risk of bias. Therefore, using the method 
described earlier in table 3.5, this study had a moderate overall risk of bias. 
 
4.4.3 Discussion of Findings 
The evidence from this review suggests that providing simple, didactic information 
relating to the continuous dopaminergic theory is an effective strategy for 
improving timing adherence in patients with PD. In Chapter 2 I outlined the 
consequences of medication non-adherence in PD. Good timing adherence is 
encouraged to promote continuous drug delivery, which may theoretically help to 
prevent fluctuating motor symptoms and the development of sudden ‘off’ episodes 
(Grosset et al., 2005b). However, despite reporting improvements in medication 
adherence, Grosset and Grosset (2007) were not able to show improvements in 
either motor symptoms or QoL. Several factors may offer explanation for this. 
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Firstly, in PD it may be that there is a minimum adherence threshold that must be 
exceeded before clinical benefit is detected. This has been proposed by researchers 
investigating adherence in patients with hypertension to explain findings showing 
improvement in medication adherence but with an absence of clinical improvement 
(Alhalaiqa et al., 2013b). As the level at which sub-optimal adherence becomes 
clinically relevant in PD is not known, this may explain, at least in part, why 
improved medication adherence did not lead to improved symptoms in the study by 
Grosset and Grosset (2007). For example, at baseline timing adherence was 17% 
for the active treatment group. This increased to 39% post intervention. Despite the 
significant improvement observed, this percentage of correct timing of doses may 
not be sufficient to impact in a clinical context.  
 
Secondly, the findings by Grosset and Grosset (2007) only refer to the effects of 
improved timing adherence. Although it is more likely that improving timing 
adherence in PD leads to optimal symptom control, whether improving total daily 
adherence leads to a greater benefit remains unknown.  
 
Furthermore, unlike many chronic conditions that may require a sustained period of 
adherence prior to detecting clinical improvement, symptoms of PD can respond 
quickly to treatment. Therefore, it is surprising that improved timing adherence did 
not result in improved clinical outcomes. Once again, this may suggest that timing 
adherence is not as important as overall daily adherence for managing symptoms in 
PD. This particularly may be the case in less severely affected patients where the 
specificity for timely pill taking may not always be essential. This may also be 
relevant in patients who are prescribed a long acting dopamine receptor agonist. 
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A counter argument could however also be made as the short half-life of levodopa 
requires regularity in dosing to maintain steady plasma dopamine concentrations. 
Only in early stages of disease where neuronal degeneration is less severe can 
doses be missed without significant consequence to symptom control. As the 
patients in the active treatment group had been diagnosed with PD for over seven 
years and had moderate disease severity, it is probable that missed dose timings 
would result in a degree of poor symptom control in some of these patients. 
 
The variability in PD symptoms may also explain the lack of clinical benefit 
observed by Grosset and Grosset (2007). Even when medication is optimised, 
patients with PD can experience episodes of poor symptom control. Whilst 
symptoms may have improved from baseline to 3 month follow-up, the known 
variability in symptom control in some patients may mask any overall 
improvements.  
 
This, however, does not explain lower reported QoL, which can improve in PD 
even when motor symptoms do not change. This is because various non-motor 
symptoms such as mood are reported to have a greater impact on QoL than motor 
problems (Martinez-Martin et al., 2011) and have been shown to improve 
following the use of dopaminergic therapies (Kulisevsky et al., 2000, Poewe and 
Seppi, 2001, Antonini et al., 2009, Barone et al., 2010). 
 
Another alternative explanation for the lack of clinical improvement shown by 
Grosset and Grosset (2007) may relate to the adherence assessment employed. 
Although MEMS caps are the reported gold-standard, there is no guarantee that 
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patients were taking all of their prescribed medication. It is known that PD patients 
may omit or increase/decrease drug doses based on perceived illness severity, 
treatment efficacy and the understanding of the indication for treatment, either 
accurate or fallacious (Bainbridge and Ruscin, 2009, Grosset, 2010, Drey et al., 
2012). Therefore, it is possible that patients could have taken out the pills from the 
bottle (thus activating the MEMS cap) but then not ingested the medications.  
 
It should be remembered that all participants were aware of the MEMS cap 
monitoring system, and so such deceitful behaviours may have been induced if 
participants wished to please the investigators but did not wish to take their 
medications. This could explain apparent improved adherence rates (according to 
MEMS readings) but lack of symptom benefit.  
 
A further methodological limitation that may explain the non-significant findings 
for improvement in symptoms/QoL relates to the small sample. Whilst Grosset and 
Grosset (2007) conducted a sample size calculation, only 52 participants from the 
83 participants randomised completed the trial. This can lead to analyses being 
underpowered to detect an effect on clinical outcomes (UPDRS & PDQ-39), even 
if an effect exists. Thus, being underpowered in this manner can result in a type 2 
systematic error (i.e. the null hypothesis is accepted when it should be rejected). 
 
4.4.4 Type of Intervention 
The intervention investigated by Grosset and Grosset (2007) for improving 
adherence to medication in PD came under the category of patient education. The 
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findings reported replicate those from other chronic disease areas. A review by 
Dunbar-Jacob et al. (1991) reported the benefits of education based interventions 
for improving medication adherence in patients with hypertension. More recently, 
however, a large scale Cochrane review in patients with hypertension found that 
medication adherence did not improve overall after providing educational material 
relating to correct medication use, hypertensive disease and the potential effects of 
not medicating (Alhalaiqa et al., 2013b). This finding is consistent with Haynes et 
al. (2008) who found that even when assuming the largest magnitude of effect of 
education based interventions in a range of chronic conditions, this did not lead to 
significant improvements in adherence behaviour.  
 
Despite the positive findings relating to adherence reported by Grosset and Grosset 
(2007), the large scale systematic reviews in other chronic disease areas propose 
that education may not be an effective intervention for improving adherence 
behaviours. However, as information regarding the importance of correct dose 
timing might be more relevant to patients with PD because of the greater potential 
for symptom fluctuation, it may be that education is perceived as being more 
important than in other chronic conditions. This could explain the inconsistency 
between the review findings and those identified by Grosset and Grosset (2007). 
Therefore, although the wider evidence suggests that patient education may lack 
therapeutic effectiveness in chronic conditions, interventions aimed specifically at 
PD may however be enhanced by the inclusion of educational material.   
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4.4.5 Alternative Strategies for Enhancing Adherence 
Due to the lack of trials identified in the current Cochrane systematic review, it is 
not possible to determine whether other adherence enhancing interventions would 
show benefit in PD equal to, or above, the effect detected by Grosset and Grosset 
(2007) using educational material. Evidence from a review investigating adherence 
interventions in hypertension showed that behaviourally targeted treatments 
provide the greatest magnitude of effect for improving adherence behaviour 
(Alhalaiqa et al., 2013b). Moreover, reviews by Haynes et al. (2008) and Kripalani 
et al. (2007) showed that complex/combined interventions that explored patient 
beliefs about treatment were effective for increasing adherence rates across a 
variety of chronic disease areas. 
 
Simplification of dose regimens is an alternate approach to improving medication 
adherence that has been shown to be effective in a range of chronic conditions. 
Connor et al. (2004) showed a positive trend towards enhanced medication 
adherence and improved clinical outcomes in hypertension, diabetes and 
medication management in the elderly when fixed-dose and single unit packaging 
were used. Bangalore et al. (2007) in a meta-analysis revealed that fixed dose 
combinations decreased the risk of medication non-adherence in patients with 
either diabetes, HIV, tuberculosis or hypertension.  
 
Furthermore, Dezii et al. (2002) showed that initiation of once-daily medication 
resulted in better adherence and persistence to treatment compared with twice-daily 
regimens in patients with diabetes. When considering this evidence and the fact 
that Grosset and Grosset (2007) found baseline timing adherence to be significantly 
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better for once-daily drugs than more frequent regimens, it may be that 
interventions aimed at simplifying dose regimens are also effective in PD. 
However, as this review did not identify any interventions other than patient 
education, this remains unknown and thus is worthy of investigation.   
 
The wide variety of factors associated with medication non-adherence in PD 
presented in Chapter 3 suggests that for some patients education may not be 
effective as a standalone intervention. Symptoms of depression, complex treatment 
regimens and poor cognition were factors most highly ranked as being associated 
with non-adherence in PD. Although educational material was shown to be 
effective by Grosset and Grosset (2007), it is unlikely that this type of intervention 
alone will impact positively on adherence in PD patients who have poor problem 
solving abilities or negative attitudes and beliefs surrounding medication use. It 
may be, as shown by reviews in other chronic disease areas, that patient centred 
interventions that explore beliefs and concerns about treatment and that assist in 
problem solving strategies are also effective in PD patients, especially if 
supplemented by educational material. 
   
4.4.6 Implications for Research 
The paucity of trials identified in this review suggests that studies investigating 
interventions for improving medication adherence in PD are in need of 
investigation. Although Grosset and Grosset (2007) showed a significant 
improvement in adherence after providing simple didactic material, it seems 
reasonable to suggest that future studies should adopt a tailored approach that 
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targets individual needs. NICE (2009) and WHO (2003) advocate in their 
respective guidelines that interventions for improving adherence in chronic 
conditions should adopt a patient centred, shared decision-making consultation 
style. These recommendations, coupled with the lack of trials identified in this 
review, emphasise the need for further RCTs in a PD population. 
 
Furthermore, many of the secondary outcome measures stated earlier in this 
chapter (i.e. beliefs and attitudes towards medication, carer burden, patient 
acceptability of interventions and cost analysis) were not investigated by Grosset 
and Grosset (2007). Although patient education was found to be effective in PD, 
suggesting that poor knowledge of treatment may be an important factor for non-
adherence, negative attitudes and beliefs towards treatment may also be an 
important reason for non-adherent behaviour. Therefore, it is essential that attitudes 
and beliefs towards medication are investigated when determining the effectiveness 
of adherence enhancing interventions in future RCTs. 
 
The findings presented in Chapter 3 showed that living with a spouse/life partner 
was associated with greater adherence behaviour. As spouse/caregivers can inherit 
the responsibility of managing a loved one’s medication, it is crucial that they are 
involved when designing interventions aimed at improving medication adherence 
in PD. 
 
Despite the variety of interventions investigated for improving adherence in other 
chronic conditions, few researchers have evaluated their interventions. This is 
important for two reasons. Firstly, it is useful to establish the acceptability of the 
116 
 
treatment from the perspective of the patient. Secondly, by exploring patients’ 
experiences of the treatment, it may be possible to determine the interventions 
mechanism of action. Identifying which components of a treatment are effective, 
especially in complex therapies, would represent a valuable insight into both the 
reasons for non-adherence and how such interventions can address these issues. 
 
Finally, as with all interventions in healthcare, it is paramount that cost 
effectiveness is considered. This is especially important when developing novel 
interventions. Although the educational material provided by Grosset and Grosset 
(2007) is likely to be of minimal cost to healthcare services, it is important that the 
anticipated cost of more complex and time intensive interventions are also 
explored.       
 
 
 
 
   
 
 
 
 
 
 
 
 
117 
 
Part 2 
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Behaviour Change & Adherence Therapy 
 
 
Introduction 
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A Need for Adherence Therapy 
Adherence Therapy 
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5.1 Introduction 
In Chapter 3 I presented the findings of a systematic review showing there are a 
number of demographic and clinical factors associated with medication non-
adherence in PD. The results I presented in Chapter 4 revealed that despite non-
adherence being prevalent in PD, there are few published studies investigating the 
efficacy of adherence enhancing interventions. With a greater understanding of 
factors associated with non-adherence, it therefore seemed essential to develop and 
test the effectiveness of a novel intervention for improving adherence specifically 
in a PD population.  
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In this chapter I discuss the development of Adherence Therapy (AT). First I 
provide an overview of, and briefly discuss the evidence for, a range of widely 
reported behaviour change theories applicable to long-term medication adherence. 
Following this I briefly discuss evidence for the disciplines of Motivational 
Interviewing (MI) and Cognitive Behavioural Therapy (CBT). Finally, I show how 
these two disciplines and the described theories of behaviour change led to the 
development of the PD specific AT intervention. 
 
5.2 Behaviour Change 
Adhering to medication in order to manage a chronic condition can represent a 
considerable behaviour change for many people (Konkle-Parker, 2001). An 
individual may suddenly be required to take several pills a day for a newly 
diagnosed condition. Patients who previously took medication infrequently may 
have to adopt a stricter, more regular pattern of usage as a condition progresses. 
This is the reality for people with PD. What may have been a simple, relatively 
burden free course of treatment in early disease stages can develop into a more 
substantial medication load.  
 
However, despite many people becoming dependent on their medication to remain 
functional and ambulatory, changing behaviour in order to incorporate medication 
into daily life is a complex phenomenon that represents a considerable challenge to 
health initiatives (Prochaska et al., 1993, Haynes et al., 2002b, Munro et al., 2007). 
 
119 
 
A fundamental principle of learning a new behaviour is that behaviour is 
determined by the perceived value of the outcome (Bandura, 1977). Therefore, 
understanding a patient’s readiness to change, appreciating barriers to change and 
helping patients anticipate relapse are likely to be key to facilitating sound 
medication adherence.     
 
For this reason, repeatedly educating the patient is not always successful (Willey et 
al., 2000). Promising patients improved health outcomes, particularly in conditions 
known to be progressive, also does not guarantee motivation for long-term change 
(Zimmerman et al., 2000). This is even more apparent when the improved outcome 
(e.g. reduction in dyskinesia) is not considered a priority by the patient. 
 
Relapse during any treatment programme requiring a change in behaviour is 
essential to acknowledge. However, relapse is sometimes viewed by clinicians as a 
failure on the part of the patient. Classifying a patient in this manner does not 
promote self-efficacy and ignores the complexity of the behaviour change process 
(Zimmerman et al., 2000). Such an approach is therefore not likely to lead to 
improved rates of adherence. 
 
5.3 Theories of Behaviour Change 
Many interventions have been developed to improve medication adherence in 
chronic conditions. However, the underlying process of many treatment strategies 
is often not proposed. Currently more than 30 psychological theories of behaviour 
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change exist, making it difficult to select the most suitable approach when 
designing interventions for enhancing adherence behaviours (Michie et al., 2005). 
 
Leventhal and Cameron (1987) identified five main theoretical perspectives related 
to adherence: biomedical, behavioural, communication, cognitive and self-
regulatory. However, more recently a stage perspective of adherence has emerged 
with the Transtheoretical model of behaviour change being most widely reported 
(Brawley and Culos-Reed, 2000, Redding et al., 2000).  
 
I will now briefly describe the main characteristics of the common theories of 
behaviour change and provide evidence for their use in interventions to promote 
long-term medication adherence. 
 
5.3.1 The Biomedical Perspective 
In the biomedical theory patients are assumed to be passive recipients of treatment. 
It is suggested therefore that non-adherence is a result of patient characteristics 
such as gender and age (Blackwell, 1992). Psycho-social influences and a patient’s 
perspective of their illness or treatment are known to be contributory to poor 
adherence in chronic conditions (Blackwell, 1992, WHO, 2003). As the biomedical 
model ignores such factors, for this reason it is infrequently used as a theoretical 
basis when designing interventions for improving medication adherence. 
 
The review presented in Chapter 3 showed there are a range of factors associated 
with non-adherence in PD, not just patient demographics. Therefore, due to the 
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passive assumptions of the biomedical model, it is unlikely to be of use when 
considering adherence issues in PD. 
 
5.3.2 Behavioural (learning) Theory 
This perspective focuses on the environment and the teaching of skills (strategies) 
to manage adherence (WHO, 2003). The theory is characterised by the use of 
internal and external antecedents (thoughts and environmental cues) and the 
consequences of their influence on adherence behaviour (punishment or reward). 
Figure 5.1 outlines the behavioural perspective diagrammatically. 
 
 
 
 
 
 
 
 
 
 
(Source: Munro et al. (2007)) 
Figure 5. 1 - Behavioural Learning Theory 
 
 
Internal antecedents: 
I should take my 
medication 
Consequences: 
Side effects 
Wellbeing 
Behaviour 
Medicine taking 
External antecedents: 
My phone reminded 
me to take my pills 
122 
 
Interventions incorporating elements of this theory have been shown to be effective 
for improving medication adherence in chronic conditions (Haynes et al., 2002a). 
In contrast, however, a meta-analysis by Simoni et al. (2006) found that many 
approaches derived from the behavioural learning theory, such as dose cueing, 
were no more effective than interventions not based on this theoretical perspective.  
 
As the findings appear to be inconsistent between studies, it is reasonable to 
suggest that this model should not be recommended for use as a standalone theory 
when developing an adherence enhancing intervention. Furthermore, the theories 
emphasis on immediate reward and its lack of an individualised approach means it 
is unlikely to be beneficial if used as a foundation for an intervention to promote 
adherence in PD. This is because PD patients can have unique reasons for non-
adhering to treatment which may require a patient centred approach to promoting 
adherence behaviour.  
 
5.3.3 Communication Perspective 
This perspective suggests that improved patient-professional communication will 
enhance medication adherence and implies that this can be achieved through 
patient education (WHO, 2003). Interventions aiming to improve patient-
professional interaction are often grounded by this perspective. 
 
A number of Cochrane reviews have examined the effects of interventions that 
include communication focused elements (Lewin et al., 2001, Murray et al., 2005, 
McKinstry et al., 2006). However, few studies have examined the effects of 
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communication styles on health behaviours. Reviews that have focused on patient-
professional interaction have shown that such interventions can improve both 
communication in consultations and patient satisfaction (Lewin et al., 2001, 
McKinstry et al., 2006). However, these reviews also show limited and mixed 
evidence for the effects of communication based interventions on health 
behaviours, such as adherence. Furthermore, communication based interventions 
are unlikely to improve adherence to medication when used in isolation because of 
the impact of other possible factors such as attitudes towards treatment (Munro et 
al., 2007).  
 
5.3.4 Cognitive Perspective 
The cognitive perspective includes theories such as the health belief model (HBM), 
social-cognitive theory (SCT), the theories of reasoned action (TRA) and planned 
behaviour (TPB) and the protection motivation theory (PMT). These theories focus 
on cognitive variables as part of behaviour change and share the assumption that 
attitudes and beliefs (Stroebe, 2011) as well as expectations of future outcomes 
(Gebhardt and Maes, 2001) are major determinants of health behaviours such as 
adherence. Collectively, these theories suggest that patients will choose the action 
that will most likely lead to positive outcomes. 
 
These theories have however been criticised because non-voluntary factors such as 
forgetfulness are not acknowledged to impact on adherence behaviour (Gebhardt 
and Maes, 2001). Also, researchers have suggested that these theories give little 
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attention to the origin of negative beliefs and how such beliefs influence health 
behaviours (Blackwell, 1992). 
 
5.3.4.1 Health Belief Model 
The HBM (Figure 5.2) views behaviour change as being based on a balance 
between the barriers to, and benefits of, a given action (Blackwell, 1992). In this 
model, perceived benefits and barriers of a given health behaviour (e.g. adherence) 
influence a patients perception of the effectiveness of the behaviour change. 
 
 
 
 
 
 
 
 
 
 
 
(Source: adapted from Stroebe and De Wit (1996)) 
Figure 5. 2 - The Health Belief Model 
 
Generally, all of the model’s components are seen as independent predictors of 
health behaviour (Armitage and Conner, 2000). Bandura (1997), however, suggests 
Perceived 
susceptibility: 
No disease in my 
family 
Perceived severity: 
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health threat: 
I’ll get over it 
Belief in the 
effectiveness of 
health behaviour: 
I’m not sure if it will 
work 
 
Health Behaviour 
(adherence): 
If it gets worse I will 
take the medication 
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that perceived threats, especially perceived severity, have a weak correlation with 
health action. Recently self-efficacy was added into the theory. This incorporates 
the need to feel competent to engage in health behaviours for long-term change to 
be successful (Strecher and Rosenstock, 1997). 
 
As with the previously described models, the HBM also has received criticism. 
Firstly, it is assumed that the variables do not moderate each other to produce an 
added effect. For example, if perceived seriousness is high but susceptibility is low, 
it is assumed that the likelihood of engaging in a particular health behaviour 
remains high. However, if both are high, it is unclear how this would affect the 
uptake of a new health behaviour (Stroebe and De Wit, 1996). In addition, some 
behaviour is based on habit rather than an active decision which this model fails to 
account for.  
 
When applying this model to adherence interventions, it is suggested that the 
influence of social-psychological factors are considered. For example, beliefs and 
stigma regarding disease or its associated treatment may reduce an adherence 
intervention’s effectiveness if psychological factors are not acknowledged 
(Harrison et al., 1992). 
 
5.3.4.2 The Protection-Motivation Theory 
According to the PMT theory, behaviour change may be achieved by focusing on 
an individual’s fears. The magnitude of harm, the probability of the perceived harm 
occurring and the efficacy of the protective mechanism (e.g. medication) against 
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harm are all factors inherent in this model (Figure 5.3) (Rogers, 1975). These three 
factors are proposed to combine to determine the motivation to engage in 
preventative behaviour (e.g. medication adherence). 
 
 
 
 
 
 
 
 
 
 
 
 (Source: adapted from Rogers (1975)) 
Figure 5. 3 - Protection Motivation Theory 
 
A meta-analysis examining interventions based on this theory found only moderate 
effects on behaviour (Floyd et al., 2000). This may relate to the fact that this model 
does not recognise environmental and cognitive factors as impacting significantly 
on adherence behaviour. Despite this, the model may be appropriate for adherence 
enhancing interventions in some patients with PD. For example, it is unlikely that 
patients routinely and consciously evaluate their medication taking practices 
(Munro et al., 2007). Therefore, acknowledging that improved adherence may lead 
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to improved symptoms could result in greater motivation to engage in optimal 
adherence behaviours. 
 
5.3.4.3 Social-Cognitive Theory 
This theory evolved from social learning theory and has been suggested to be the 
most comprehensive theory of behavioural change (Figure 5.4) (Redding et al., 
2000). The theory proposes a causal relationship between motivation, action and 
wellbeing and provides possible predictors of adherence and guidelines for 
adherence promotion (Bandura, 1997, Bandura, 1998). 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Source: adapted from Munro et al. (2007)) 
Figure 5. 4 - Social-Cognitive Theory 
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Social-cognitive theory suggests that while knowledge of health risks and benefits 
are a requirement for change, additional self-influences are also necessary for 
change to occur (Bandura, 1998). Self-efficacy is one such influence. 
 
Keller and colleagues (1999) reported that improved self-efficacy could explain 
between 4% and 26% of the variance in health behaviour. However, this was 
limited to studies of exercise behaviour and did not consider adherence to 
medication. Despite this, due to the models focus on self-efficacy, 
acknowledgement of the barriers and facilitators to change and knowledge of the 
benefits to change, it is possible that elements of this model will be effective as part 
of an adherence enhancing treatment.   
 
5.3.4.4 Theory of Reasoned Action and Planned Behaviour 
The TRA suggests behaviour change relates predominantly to intentions (Figure 
5.5). In this theory intention to act is reported to be the single best predictor of 
performing a particular health behaviour (Sutton, 1997). Advocates further propose 
that intention to change behaviour is influenced significantly by attitudes towards 
the action. This includes beliefs about the value of the health outcome (e.g. 
improved adherence). Performing the health behaviour is also allegedly influenced 
by the perceived expectations of significant others (e.g. family members) (Fishbein 
and Ajzen, 1975). 
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(Source: adapted from Stroebe and De Wit (1996)) 
Figure 5. 5 - Theory of Reasoned Action 
 
A limitation of the TRA was that it failed to acknowledge behaviour as being 
unintentional. The authors therefore extended the model to include behavioural 
control (shown in Figure 5.5), and re-named the model as the theory of planned 
behaviour (TPB). According to the authors, behavioural control represents the 
perceived ease or difficulty of performing the health behaviour, and that this 
behavioural decision relates to beliefs (Sutton, 1997). Conceptually, this theory is 
similar to self-efficacy. 
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Meta-analyses examining the efficacy of various components of the theory have 
found inconsistent results (Godin and Kok, 1996, Armitage and Conner, 2001, 
Hardeman et al., 2002). Although not conclusive, the results of the separate 
analyses do show some positive effects on adherence behaviours. This suggests 
that the theory may be of benefit when designing interventions to improve 
adherence to medication. However, a limitation of this perspective is that it is based 
largely on rational processes and does not allow for alternative factors such as 
emotions/mood (Mullen et al., 1987). As mood disorders are known to be 
associated with non-adherence in chronic illness, particularly in PD as reported in 
Chapter 3, it is likely that this model requires some flexibility if adherence 
promoting treatments are to be successful. 
 
5.3.4.5 Information-Motivation-Behavioural Skills (IMB) Theory 
The IMB theory focuses on three components that result in behaviour change: 
information, motivation and behaviour skills. Information relates to basic 
knowledge about an illness and is an essential prerequisite for behaviour change in 
this theory (Fisher and Fisher, 1992). An intervention based on this approach 
would therefore target a patient’s gap in knowledge. The second component, 
motivation, results from personal attitude towards adherence. Finally, behavioural 
skills include factors such as ensuring patients have the strategies and tools 
necessary to perform the health behaviour (Fisher and Fisher, 1992). As with 
previously described models, self-efficacy is also a key component of this theory 
(Figure 5.6).  
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(Source: adapted from Fisher et al. (2006)) 
 
Figure 5. 6 - Information-Motivation-Behavioural Skills Model 
 
In this model, information and motivation are thought to activate behavioural skills, 
which in turn result in behavioural change (Fisher et al., 2006). Although this 
theory has not been evaluated as part of a meta-analysis, researchers have shown 
the model to be effective in promoting behaviour change in chronic illness (Amico 
et al., 2005). As this simple, generalisable model has been shown to be effective in 
changing adherence behaviour, it may also be effective if used in an intervention 
aimed at non-adherent patients with PD. 
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5.3.5 The Transtheoretical Model (TTM)   
This theory, established by Prochaska and DiClemente (1992), is the most 
prominent amongst the stage perspectives of health change (Figure 5.7). The 
authors propose a number of discrete stages of change and reasons that people 
move through these stages, typically relapsing before achieving success (Prochaska 
and DiClemente, 1992, Prochaska et al., 1993). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Source: adapted from Munro et al. (2007)) 
 
Figure 5. 7 - The Transtheoretical Model (Stages of Change)
Precontemplation: 
I am not seriously thinking of changing – I don’t 
think I should adhere to medication 
Contemplation: 
Seriously, I think I should adhere to my medication 
regiment 
Preparation: 
I am ready to change – I am making a reminder in 
my diary 
Action: 
I am trying to remember my medications so I’m 
marking them off in my diary 
Maintenance: 
I have been able to take my pills correctly every 
day for a month 
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Crucially, healthcare professionals may be able to encourage change by identifying 
where a patient is in relation to the model (Zimmerman et al., 2000). With such 
knowledge, specifically targeted, stage dependent interventions may be useful for 
facilitating progression through the various stages of change. 
 
Criticisms of the TTM include the stages postulated and their coverage and 
definitions. Specifically, Bandura (1998) argues that behaviour change is too 
multifaceted to fit into discrete stages and that to do so would constrain adherence 
promoting treatments. Additionally, the TTM provides little information 
concerning the mechanism of change or why some individuals relapse (Armitage 
and Conner, 2000). 
 
A meta-analysis did not show support for this theory (Marshall and Biddle, 2001). 
However, this was used to promote adherence to exercise and not medication 
specifically. Whilst little evidence exists to support this theory for promoting 
medication adherence specifically, the model does allow interventions to be 
tailored to individual needs by identifying which stage of change a patient is in.   
 
5.3.5.1 Related Constructs to the TTM 
Decision-making and self-efficacy are constructs closely related to the TTM. Both 
have been proposed to be central to the process of behaviour change (Bandura, 
1977, Rosenstock et al., 1988, Buchmann, 1997). Decision-making involves 
consideration of the potential benefits and losses before arriving at and maintaining 
a decision. 
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Theoretically, as people progress through the stages, the gap between perceived 
pros and cons reduces. Therefore, by identifying the positives and negatives to 
taking medication, therapists may be able to assist in decision-making which may 
lead to improved adherence (Konkle-Parker, 2001). 
 
A second concept closely related to the TTM is that of self-efficacy. Once a patient 
decides to take medication, doubt about their ability to adhere may represent an 
underlying barrier to change (Willey et al., 2000). Therefore, enhancing self-
efficacy may facilitate transition through the stages of behaviour change. Prochaska 
and DiClemente (1992) showed self-efficacy to be a positive predictor of 
successful progression into the action and maintenance stage in patients with 
affective disorders. As self-efficacy was not found to be a predictor of progression 
in early TTM stages, this may suggest that decision-making is more important in 
patients identified in these stages. 
 
5.4 Summary of Behaviour Change Theories 
Although there are many theories that can be used when developing interventions 
to improve medication adherence, there is limited evidence that facilitates a direct 
comparison of the perspectives. Researchers developing interventions may 
therefore be overwhelmed by the multiplicity of theories for which there is often 
limited evidence. There are also questions regarding the applicability of the 
theories outside of the context from which they were developed. 
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For example, health behaviour change theories have tended to encompass a wide 
range of health behaviours. Reviews have included papers ranging from smoking 
cessation to dietary adherence. It may therefore be the case that certain theories are 
more applicable to specific health behaviours. Furthermore, few studies have 
examined health behaviour theories in relation to long-term medication adherence. 
Therefore, it is unclear whether such theories may actually be useful when 
developing treatments aimed specifically at medication adherence in chronic 
conditions.   
 
The application of theories to the design of adherence promoting interventions 
remains a challenge. Moreover, there is considerable debate regarding whether 
such theories are likely to be effective in informing intervention development 
(Eccles et al., 2005, Oxman et al., 2005). Despite the various theories, there is no 
clear evidence in favour of either perspective within the field of medication 
adherence. However, this does not mean that behaviour change theories are not 
useful. It may be possible to acknowledge the benefits of a variety of theories and 
incorporate them into a more flexible, pragmatic intervention. 
 
In the next part of this chapter I focus on interventions as opposed to basic 
psychological theory. Specifically, I briefly outline the characteristics and evidence 
for the Motivational Interviewing (MI) approach and the discipline of Cognitive 
Behavioural Therapy (CBT) in relation to treatment adherence. 
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5.5 The Motivational Interviewing Technique 
Motivational interviewing is tool for facilitating behaviour change. The approach 
places power in the hands of the patient by encouraging a patient focused 
consultation style. The technique aims to assist in resolving ambivalence by 
changing beliefs about medication (Miller and Rollnick, 1991). Since medication 
adherence is a complex behaviour, this patient-centred approach may be useful for 
facilitating improved medication adherence (Konkle-Parker, 2001). Five basic 
principles central to the therapist-patient interaction in MI are outlined in Table 5.1. 
 
Table 5. 1 - Key Principles in Motivational Interviewing 
Fundamental Principle Description 
 
1. Expressing empathy Demonstrating an understanding of ambivalence 
towards medication adherence. It must be made 
apparent that ambivalence is entirely justified. 
 
2. Developing 
discrepancy  
Eliciting the patient’s goals for medication use 
and encouraging the individual to recognise that 
non-adherence is not contributing towards 
meeting the goals. 
 
3. Avoiding argument The therapist must not be confrontational or the 
individual will be in a position to defend their 
non-adherence, which can strengthen the 
behaviour. 
 
4. Rolling with 
resistance 
Allow patients to take personal responsibility for 
change and help patients develop a number of 
alternative change options in order to allow them 
to begin solving their own problems. 
 
5. Supporting self-
efficacy 
Supporting patients in the successes that they have 
experienced, no matter how small, and providing 
encouragement for further success. This assists 
individuals in believing that they can successfully 
perform the behaviour in question. 
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Practitioners of MI attempt to motivate patients rather than attempting to persuade 
them that change is necessary. One important differentiating factor is maintaining 
the focus of the interview on the individual and their expressed needs, not on the 
health problems or the clinical symptoms that most trouble the professional 
(Rollnick et al., 1992, Konkle-Parker, 2001). 
 
Firstly, the therapist accepts and explores a patient’s ambivalence to adhering to 
treatment, understanding that acknowledgement of the diagnosis or the debilitating 
symptoms associated with the condition are not sufficient for some individuals to 
be motivated to change.  
 
The therapist and the patient then work collaboratively to arrive at a shared goal 
and work to resolve barriers that may inhibit progression. For this to occur, open-
ended questions and reflective listening are critical. This allows a patient to see the 
benefits of change while avoiding commanding dialogue.  
 
A strength of the approach is that it can be used alongside behaviour change 
theories. For example, for patients in the precontemplation stage of the TTM a 
decision balance sheet may be an effective strategy by listing the ‘good things’ and 
the ‘not so good things’ to taking medication (Armer and Miller, 2000).  
 
For contemplators within the TTM who are ambivalent to change, identifying 
discrepancies between the patient’s goals and the non-adherent behaviour may be 
an effective strategy for promoting adherence. For example, if a PD patient’s goal 
is to remain ambulatory throughout a child’s infancy, medication non-adherence 
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may not facilitate this goal. Problem solving strategies may also be crucial when 
discussing ways in which the patient can adhere to their treatment regimen. 
 
5.5.1 Evidence for Motivational Interviewing 
Unlike the psychological theories described earlier in this chapter, MI has been 
shown to be effective for achieving behaviour change (Dunn et al., 2001). A 
systematic review by Knight et al. (2006) showed MI improved psychological, 
physiological and life-style change outcomes in patients with diabetes, asthma, 
hypertension and heart disease. A meta-analysis by Rubak et al. (2005) showed a 
significant effect of MI in 75% of studies targeting treatment for patients with 
alcohol abuse, psychiatric problems and substance addiction. Furthermore, a 
positive effect in 72% of studies using MI to target weight loss, hyperlipidaemia, 
physical activity and smoking cessation was also observed. These findings provide 
evidence of the effectiveness of MI for achieving successful change in a wide 
variety of behaviours. 
 
Despite the positive effects of MI in the general adherence literature, limited 
published information is available evaluating the use of MI for improving 
adherence to medication. A RCT in patients with asthma found those who received 
MI were significantly more likely to show an increased level of readiness to adhere 
to medication over time (Schmaling et al., 2001). Furthermore, in patients with 
psychiatric illness, MI significantly improved adherence to outpatient appointments 
(Swanson et al., 1999). 
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A small RCT of 21 patients with schizophrenia found that patients who received 
MI improved more in their attitudes towards medication than a control group 
(Hayward, 1995). Moreover, Ogedegbe et al. (2008) showed that the use of MI in 
patients with hypertension resulted in the maintenance of medication adherence 
over time compared to a significant decline in adherence for people in a control 
group. This difference in adherence was reported to have led to a modest, but non-
significant, reduction of blood pressure in favour of the active treatment group. 
 
Although many of the psychological theories do not show consistent effects on 
behaviour change, MI does have supporting evidence for improving adherence 
behaviour. Furthermore, although there is limited evidence, studies do show that 
MI may be beneficial if used as the basis for interventions to improve adherence to 
medication. 
 
I will now briefly outline the fundamental characteristics of cognitive-behavioural 
therapy and provide evidence for its use in promoting adherence to medication. 
 
5.6 Cognitive-Behavioural Therapy 
Cognitive Behavioural Therapy (CBT) is a psychotherapeutic approach that aims to 
address dysfunctional emotions and cognitive processes. This technique 
acknowledges that there may be behaviours that cannot be controlled through 
rational thought. CBT therefore is problem focused (undertaken for specific 
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problems) and action oriented (a therapist tries to assist the patient in selecting 
specific strategies to help address those problems) (Schacter et al., 2010).  
 
The cognitive model that CBT therapists use describes how perceptions of, or 
spontaneous thoughts about, situations influence emotional and behavioural 
reactions (Hayes et al., 2011). Individuals’ perceptions are often distorted when 
subjected to distress. CBT therapists therefore attempt to identify and evaluate a 
patient’s dysfunctional thinking so that it more closely resembles reality. 
Theoretically, when successful, distress decreases and individuals are able to 
function optimally (Hofmann, 2011). 
 
The goal of CBT is to help individuals achieve a remission of their disorder and to 
prevent relapse. Much of the work in sessions involves aiding individuals to solve 
their own problems by teaching them to modify their distorted thinking and 
dysfunctional behaviour (Driessen and Hollon, 2010). 
 
5.6.1 Evidence for Cognitive Behavioural Therapy 
Cognitive behavioural therapy has demonstrated efficacy in the treatment of a wide 
variety of psychiatric disorders such as mood, anxiety, personality, eating, 
substance abuse and psychotic disorders. Furthermore, CBT has also been shown 
to be effective as an adjunctive treatment to medication in many conditions such as 
irritable bowel syndrome, hypertension, fibromyalgia, cancer, diabetes, migraine 
and other chronic pain disorders. 
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In spite of its proven effectiveness, little attention has focused on the use of CBT 
specifically for improving adherence to medication. Parsons et al. (2005) evaluated 
the combined effect of CBT and MI in patients’ non-adherent to antiretroviral 
medication. Findings showed there was a significant reduction in substance use 
from pre-treatment to post-treatment with the combined therapy. However, despite 
positive trends, no statistically significant differences were found for changes in 
medication adherence. 
 
Safren et al. (2009)  showed that patients with Human Immunodeficiency Virus 
(HIV) who received CBT significantly improved in medication adherence and 
depression compared to a control group. Furthermore, those originally in the 
control group who chose to cross over to CBT showed similar improvements in 
both depression and adherence outcomes. 
 
Due to the paucity of research investigating the efficacy of CBT for improving 
adherence to medication, it is difficult to appropriately evaluate the intervention. 
Despite the lack of evidence however, it is reasonable to suggest that CBT 
techniques may be effective for improving medication adherence in a PD sample.  
 
The findings reported in Chapter 3 showed that both cognitive impairment and 
treatment regimen complexity are associated with poor medication adherence in 
PD. Problem solving is a cognitive domain that is known to be affected in many 
patients with PD (Cronin-Golomb et al., 1994). As CBT has been shown to be 
effective for assisting patients to problem solve, applying the approach to problem 
solving medication use in PD may be an effective strategy.    
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5.7 A Need for Adherence Therapy 
The World Health Organization (2003) and the National Institute for Health and 
Care Excellence (2009) in their respective guidelines on adherence encourage the 
use of an individualised consultation style that recognises patient involvement in 
treatment decisions as an integral process for facilitating improved adherence. A 
focus on exploring beliefs about illness and disease management, in addition to the 
transference of specific information from professional to patient, are also strongly 
advocated. 
 
As outlined earlier in this chapter, many authors propose that the efficacy of 
adherence enhancing interventions may be optimised by using theory from 
behaviour change models (Lyons, 1997). However, as the evidence suggests, no 
single approach has been able to show consistent improvements in adherence 
behaviour. Many theories also have not been tested specifically in relation to 
medication non-adherence. However, as self-efficacy is a component of many 
behavioural change theories, this may suggest it is fundamental to improving 
adherence behaviour.  
 
Motivational interviewing and CBT have been shown to provide benefit for 
improving adherence to medication. It is therefore likely that an intervention that 
conforms to the principles of these disciplines may be beneficial for improving 
adherence to medication in PD.   
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Factors associated with medication non-adherence in PD can be extensive and 
patient specific, as identified in Chapter 3. Therefore, administering an adherence 
promoting intervention that fails to acknowledge the factors associated with 
suboptimal adherence is unlikely to be effective. By recognising the factors that 
may lead to poor adherence, it is possible to target appropriate interventions to help 
enhance adherence behaviour in PD.  
 
In summary, a therapy that uses MI and CBT techniques as a framework, 
recognises the importance of self-efficacy and acknowledges disease specific 
factors for non-adherence may likely lead to improvement in medication 
adherence. Adherence Therapy (AT) is one such intervention. I therefore used the 
core concepts of AT to develop a novel, patient-centred therapy specifically 
tailored to addressing medication non-adherence in people with PD.  
 
In the remaining part of this chapter I will outline the characteristics of AT and 
report the findings of various RCTs evaluating the intervention in other disease 
areas. 
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5.8 Adherence Therapy 
Adherence Therapy is a brief, person centred cognitive–behavioural approach 
aimed at facilitating a process of shared decision making where both therapist and 
patient work towards agreed goals (Gray, 2011). The fundamental principle is that 
when patients make shared choices with a professional they are more likely to 
continue with those choices because they are personally owned and meaningful 
(Gray et al., 2010). 
 
5.8.1 Cornerstones of Adherence Therapy 
Adherence Therapy utilises four key foundation skills that therapists employ 
throughout the patient-therapist encounter: 
 
1. Engagement - focusing on the personally relevant benefit to treatment 
The aim is to keep the patient engaged in talking about medication use. Focusing 
on the personally relevant benefit to medication and using a Socratic questioning 
style are essential for engagement in order to encourage patient reflection and an 
open dialogue. 
 
2. Dealing with Resistance  
Patients will not consider different perspectives or change their behaviour if there 
is tension in the relationship between the therapist and the patient. The aim 
therefore is to keep resistance low by working alongside the patient. 
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3. Exchanging Information 
Exchanging information by using an elicit–provide–elicit model affords the 
provision of individually tailored information; that is, what does the patient want to 
know - provide the factual information the patient seeks - ask how the information 
has affected the patient’s thought process. 
 
4. Developing Discrepancies 
The aim is to gently draw the patient’s attention to inconsistencies (discrepancies) 
in their beliefs and attitudes about medication and illness. For example, asking the 
patient to consider and reflect on how they justify their position on medication use 
can facilitate this process without being challenging and confrontational to their 
perspective. 
 
5.8.2 Adherence Assessment 
The aim of the adherence assessment is to understand illness and treatment from 
the patient’s perspective. Vital to the assessment is the exploration of the patient’s 
perceived ‘importance’ of taking, ‘confidence’ in sticking to, and overall 
‘satisfaction’ with their medication. Each of these domains is rated on a 1–10 (low–
high) scale.  
 
The ratings on these scores guide the rest of the therapy process. For example, if a 
patient thinks that medication is very important and is willing to take it, but is not 
confident because of forgetfulness, then AT exercises such as problem solving are 
likely to be indicated. Alternatively, if a patient has confidence in taking 
146 
 
medication, but does not think it is important, therapy can be directed at exercises 
that might increase perceived importance (such as exploring ambivalence). Re-
rating these three items (allowing patients to recognise small but meaningful 
improvements) occurs throughout the therapy process as a tool to encourage 
Socratic dialogue and promote self-efficacy. 
 
5.8.3 Key Adherence Therapy Exercises 
The intervention is delivered using a combination of five key exercises that form 
the core of the therapy:   
 
1. Structured Medication Problem Solving 
The aim is to develop the patient’s ability to sort out practical problems with 
medication for themselves by following a structured template. Problems may 
include strategies to cope with medication side-effects or approaches to facilitate 
improved memory regarding pill taking. 
 
2. Looking Back  
This helps the patient to review past experiences of illness and treatment and reflect 
on the effects of medication (both good and not so good). The aim is to help the 
patient learn from the past to plan for the future. 
 
3. Exploring Ambivalence 
By considering the ‘good and not so good’ aspects of not taking and the ‘good and 
not so good’ aspects of taking medication, the aim of this exercise is to help 
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patients explore, reflect and consider their natural ambivalence (uncertainty) 
toward taking medication. 
 
4. Talking About Beliefs and Concerns  
The aim is to ‘test out’ commonly held beliefs about medication (e.g. ‘I can fight 
this without medication’ and ‘it is unnatural to take medicines’). One at a time, 
beliefs are rated on a conviction scale (0–100%). The evidence for and against the 
belief is then considered and discussed. The belief is then re-rated using the 
conviction scale. 
 
5. Looking Forward  
This exercise seeks to help the patient consider their future goals (short or long-
term) and the role that medication might play in facilitating such goals. 
 
This phased and layered package of foundation skills and key interventions, 
developed on the underlying principles of MI and CBT, form the AT intervention 
under investigation in this thesis. The therapy can be represented diagrammatically, 
as shown in Figure 5.8. The adaptability of the approach has resulted in a 
comprehensive programme capable of being tailored according to individual need, 
in conjunction with NICE guidelines (2009). The Adherence Therapy manual from 
which the intervention was developed can be requested from Professor Richard 
Gray (Richard.gray@uwe.ac.uk).   
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Figure 5. 8 - Adherence Therapy Model 
 
5.9 Evidence for Adherence Therapy 
To date, a number of RCTs have been conducted to evaluate the efficacy of AT for 
improving medication adherence and illness specific symptoms (Table 5.2). Of 
these trials, eight demonstrated that AT approaches were effective for improving 
medication adherence (Kemp et al., 1996, Kemp et al., 1998, Gray et al., 2004, 
Wong et al., 2005, Maneesakorn et al., 2007, Staring et al., 2010, Alhalaiqa et al., 
2011, Cavezza et al., 2013). Despite the statistically significant improvements in 
medication adherence reported in these trials, five studies were unable to replicate 
the positive findings (O'Donnell et al., 2003, Byerly et al., 2005, Gray et al., 2006, 
Anderson et al., 2010, Schulz et al., 2013). 
Adherence Assessment 
Five Key Exercises: 
(Assessment) 
 
Problem Solving 
Looking Back 
Exploring Ambivalence 
Discussing beliefs/concerns 
Looking forward 
Key Cornerstones: 
 
 
Engagement 
Reduce resistance 
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 Adherence Assessment 
  
1
4
9
 
 
 
Table 5. 2 - Adherence Therapy Trials 
Author n Patient population Treatments Primary Outcome Follow-up 
(months) 
Statistically 
Significant 
effect on 
adherence 
Effect Size or 
mean difference 
reported 
Kemp et al. (1996) 47 Psychosis NSC CT Compliance 6 Yes OR = 5.2 
Kemp et al. (1998) 74 Psychotic disorders NSC  CT Compliance 18 Yes 19%* 
Cavezza et al. (2013) 48 Psychotic illness HE   AT Psychopathology & adherence End of therapy Yes not reported 
Gray et al. (2004) 72 Schizophrenia TAU  MM Psychotic symptoms 6 Yes 17.79* 
O'Donnell et al. (2003) 56 Schizophrenia NSC CT Compliance 12  No - 
Byerly et al. (2005) 30 Schizophrenia NR  CT Compliance 6 No - 
Gray et al. (2006) 409 Schizophrenia HE   AT Quality of life 12 No - 
Maneesakorn et al. (2007) 32 Schizophrenia TAU AT Psychotic symptoms 2 Yes 14.00, RR 2.29 
Anderson et al. (2010) 26 Schizophrenia TAU  AT Psychotic symptoms End of therapy No - 
Staring et al. (2010) 109 Schizophrenia TAU  AT Service engagement & adherence 12  Yes 0.43† 
Schulz et al. (2013) 137 Schizophrenia TAU AT Adherence 3  No - 
Wong et al. (2005) 78 Diabetes TAU  AT Blood monitoring adherence 6  Yes 1.8* 
Alhalaiqa et al. (2011) 136 Hypertension TAU  AT Systolic blood pressure 3 Yes 21.6* 
 
RCT: Randomised Controlled Trial; AT: Adherence Therapy; CT: Compliance Therapy; TAU: Treatment as Usual; MM: Medication 
Management Training; HE: Health Education; NSC: Non-specific Counselling; NR: Not Reported 
 
*= mean between group difference post intervention; RR= risk ratio; †= Cohen’s effect size 
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Although some trials have not been successful in improving medication adherence 
after providing a form of AT, the positive findings do outweigh the negatives. This 
suggests that adherence enhancing interventions of this type may be beneficial for 
improving medication adherence in a range of chronic conditions. 
 
Of the 13 RCTs evaluating the efficacy of AT interventions, 11 investigated its use 
in patients with psychiatric conditions. Most of these trials were based specifically 
in patients with schizophrenia. Interestingly, all five studies that failed to improve 
adherence to medication had evaluated the effectiveness of AT in patients with 
schizophrenia. In both trials where study participants were not diagnosed with a 
psychiatric illness (i.e. patients with diabetes or hypertension), adherence to 
medication improved significantly.  
 
Although some studies report improvements in medication adherence following AT 
in patients with schizophrenia (Maneesakorn et al., 2007, Staring et al., 2010), the 
negative findings of most RCTs in this population suggests that brief interventions 
like AT may not be beneficial for such patients. This is not surprising considering 
that the characteristic symptoms of schizophrenia (e.g. paranoia) are known to be 
associated with poor medication adherence (Fenton et al., 1997).  
 
Gray et al. (2006) conducted the largest trial of AT in which 409 patients with 
schizophrenia were randomised. As this trial recruited the most patients of all AT 
studies but did not identify significant improvements in medication adherence, this 
may suggest that AT lacks efficacy in patients with schizophrenia. However, an 
alternative explanation may explain the non-significant results. In this study non-
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adherence to medication was not assessed prior to patients being recruited and 
subsequently randomised. Therefore, the inclusion of potentially medication 
adherent patients would act to dilute the therapeutic effect of the AT intervention. 
Had non-adherence to medication been part of the inclusion criteria in this large 
scale RCT, the true effect of AT may have resulted in a significant improvement in 
medication adherence.  
 
Despite the inconclusive findings in patients with schizophrenia, it is encouraging 
that medication adherence improved significantly in patients with diabetes and 
hypertension. It is likely that the reasons for non-adherence in these populations 
differ greatly from patients with psychiatric conditions and this may explain the 
positive findings identified in these studies. 
 
The findings presented in Chapter 3 showed the main factors that are associated 
with non-adherence in PD. With this knowledge, and considering that AT has been 
shown to be effective in chronic conditions, it is possible that the intervention may 
also be beneficial in PD. 
 
To establish the efficacy of AT for improving medication adherence in PD, a well-
designed RCT is required. In the next chapter of this thesis I outline the design and 
methods of a RCT to test whether PD patients who receive a programme of AT 
significantly improve in medication adherence and QoL compared to PD patients 
who receive only usual care. 
    
 
152 
 
 
CHAPTER 6 
 
 
Methodology 
 
 
Introduction 
The Randomised Controlled Trial 
Hypothesis and Study Aims 
Selecting the Outcome Measures 
Methods 
Determination of Sample Size 
Analysis 
Ethical Considerations 
Protocol Amendments 
Chapter Summary 
 
 
 
6.1 Introduction 
In Chapter 5 I outlined the development of, and evidence for, the AT intervention. 
In this chapter I describe the methods used for evaluating the effectiveness of AT 
in PD. Specifically, I outline the study design adopted; that is, a randomised 
controlled trial and provide justification for using this methodological approach. I 
then provide a detailed description of the study methods and analytical processes. 
Finally, ethical considerations are discussed in relation to the clinical trial. 
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6.2 The Randomised Controlled Trial 
Randomised controlled trials (RCTs) are a quantitative methodology in which 
study participants are randomly assigned to one of two or more clinical 
interventions (Borenstein et al., 2009). The RCT is the most scientifically rigorous 
method of hypothesis testing available and is regarded as the gold standard design 
for evaluating treatment effectiveness (Akobeng, 2005). The basic structure of a 
RCT is presented in Figure 6.1. 
 
  
 
 
 
 
 
 
Figure 6. 1 - The Basic Structure of a RCT 
 
A representative sample of the target population is randomly assigned to the active 
treatment/experimental group (participants receiving the intervention of interest) or 
a control group (participants receiving usual best practice care). Apart from one 
group receiving the experimental treatment, the two groups are treated and 
observed in an identical manner. All participants’ complete measurements or 
observations at the start of the trial (baseline) before being randomised. At the end 
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of interest 
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population 
 
Treatment A 
 
Treatment B 
Randomisation 
Outcomes 
Outcomes 
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of the study (a pre-defined time point), the measurements of interest are completed 
again by each group and are analysed. In most RCTs the analysis compares 
outcomes between groups from baseline to follow-up to establish whether a 
statistically significant difference exists. All outcomes and analytical methods are 
also pre-defined at the study outset (Akobeng, 2005). 
 
6.2.1 Advantages of the Randomised Controlled Trial 
There are many advantages to the RCT research design. The main benefit that 
randomisation provides is to prevent selection bias and the effect of confounding. 
These are prevented by evenly distributing the characteristics of patients at baseline 
that may influence the study outcome. By this means, any difference in the 
outcomes at study follow-up should be a consequence of the intervention only 
(Borenstein et al., 2009). Randomisation therefore makes it more likely that there 
will be an even balance of characteristics between groups with regards to both 
known and unknown factors (e.g. age, disease severity and duration, medication 
load). 
 
6.2.2 Randomisation 
Randomisation refers to the practice of assigning participants to experimental or 
control groups at random, such that each participant has an equal chance of being 
placed in either condition (Evans, 2003, Akobeng, 2005). As previously stated, the 
main purpose to randomisation is to eliminate selection bias and balance both the 
known and unknown confounding factors. 
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6.2.3 Block Randomisation 
Block randomisation is often used to ensure a balance in the numbers of 
participants assigned to each group in a RCT (Chia, 2000). For example, 
participants may be considered in blocks of four at a time. Using this block size for 
two treatment groups (A and B) leads to six possible arrangements of two A’s and 
two B’s (blocks): 
 
AABB, BBAA, ABAB, BABA, BAAB, ABBA 
 
A random allocation sequence is then used to select a particular block out of the six 
available, which determines the allocation order for the first four participants who 
are randomised. The treatment group is then allocated in the order specified by 
another of the six blocks for the next four participants who enter the trial.  
 
Despite this process, it may still be possible for researchers to anticipate what 
group a participant will be allocated to. As each block contains two A’s and two 
B’s, theoretically, researchers could track the block allocations in order to identify 
the next group allocation. For example, if two A’s and one B have come up, the 
researcher would know the next allocation is going to be group B. Therefore, to 
ensure assignment is unknown, I will use block randomisation of four and six as 
detailed later in the procedure. This makes it impossible to determine the next 
allocation as researchers do not know whether a block of four or six is being used. 
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6.2.4 Allocation Concealment 
Allocation concealment is the technique of ensuring that implementation of the 
random allocation sequence occurs without knowledge of which patient will 
receive which treatment. This is essential in RCTs because prior knowledge of the 
next group assignment could influence whether a patient is included or excluded 
based on an investigator’s understanding of the patient’s likelihood of success 
(Dettori, 2010). 
 
6.2.5 Stratification 
While randomisation may help remove selection bias and the influence of 
confounding, it may not always ensure that groups will be similar with regards to 
important patient characteristics or predictor variables (Chia, 2000). One way of 
ensuring groups are balanced is to generate separate block randomisation lists for 
combinations of factors that are known, or believed, to exert an effect on the 
outcome of interest. Randomising in this manner is known as stratification, with 
each possible category representing a specific stratum. 
 
For example, it is known that the presence of a carer (often a spouse or family 
member) is associated with better medication adherence in people living with a 
chronic condition. Supporting this are the findings presented in Chapter 3 which 
identified that the lack of a spouse/carer is associated with medication non-
adherence in people with PD. Therefore, with this knowledge, I felt it was essential 
to identify whether the presence of a spouse/carer had a significant impact on the 
effectiveness of AT in this study.  
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As the presence of a spouse/carer may be associated with better medication 
adherence in people with PD, to determine this I stratified study participants into 
two strata: spouse/carer present or no spouse/carer present. This meant that where a 
PD patient’s spouse/carer was also randomised with the patient, they too received 
the experimental treatment as outlined later in the study procedure. Stratifying in 
this manner gave four possible categories as shown in table 6.1. 
 
Table 6. 1 - Randomisation by Strata 
Strata Randomisation group 
 
Numbers randomised 
Treatment alone Control 14 
Treatment alone Intervention 13 
Treatment with a carer Control 24 
Treatment with a carer Intervention 25 
 
 
This method of stratification therefore allowed me at the analysis stage to test for a 
possible interaction (effect modification) between the presence of a spouse/carer 
and the outcome of interest (i.e. does having a carer present during AT result in a 
greater therapeutic effect than receiving AT without a carer present). It is worth 
noting however that despite this planned analysis, all sub-group analyses are 
subject to low statistical power which can result in a type 2 systematic error (i.e. 
accepting the null hypothesis when it should be rejected). Therefore, although a 
statistically significant interaction may exist between the treatment effect of AT 
and the presence of a spouse/carer, this planned sub-group analysis may not be 
sufficiently powered to detect it.   
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6.2.6 Other Advantages of the RCT 
A further advantage of RCTs is that they are able to maintain external validity 
(generalisability). This is often dependent on how representative the sample is of 
the target population. Many trials, particularly studies investigating drug efficacy, 
can have very specific inclusion criteria which can fail to encompass a significant 
proportion of the population of interest. This often becomes problematic in PD 
where many patients may suffer from age related comorbidities and cognitive 
impairment, excluding them from participating in research studies.  
 
Acknowledging this issue I endeavoured to select a set of inclusion criteria 
(described later) that best represents the PD population. With a representative 
sample, RCTs are able to provide a realistic compromise between observational 
studies (which often have high external validity) and more traditional experimental 
approaches (which often have good internal validity but can lack applicability to 
everyday life) (Chia, 2000).  
 
The findings from RCTs are also essential in healthcare in that the effect sizes 
generated for an intervention can be pooled together (i.e. findings are taken from 
independent studies testing the same treatment in the same way) within a 
systematic review or meta-analysis. This allows researchers to establish whether 
cumulatively the evidence suggests a particular intervention is effective for a given 
outcome (Borenstein et al., 2009). 
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6.3 Hypothesis and Study Aims 
When using a test of significance to compare two groups it is often appropriate to 
start with the null hypothesis that there is no difference between the sample 
populations. If this hypothesis is not true the alternative hypothesis must be true; 
that is, there is a difference. Since the null hypothesis specifies no direction for the 
difference, nor does the alternative hypothesis and so a two-sided test is 
appropriate. In a one-sided test the alternative hypothesis does specify a direction 
(i.e. an active treatment is better than a placebo) (Bland and Bland, 1994). 
Therefore, as the direction of a change cannot be specified in RCTs, a one-sided 
test (i.e. AT leads to improved adherence) was not appropriate in this trial. 
 
6.3.1 Alternate Hypotheses (H1) – Two-sided: 
There will be a statistically significant difference in medication adherence and QoL 
in people with PD who undergo a seven week programme of Adherence Therapy 
(AT) in addition to Treatment as Usual (TAU) compared to those receiving TAU 
only.  
 
6.3.2 Null Hypothesis (N0)   
There will be no statistically significant difference in medication adherence or QoL 
in people with PD who undergo a seven week programme of AT in addition to 
TAU compared to those receiving TAU only. 
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6.3.3 Primary Aims 
To investigate if a seven week programme of AT is effective for improving 
medication adherence and QoL in non-adherent people with PD immediately post 
intervention and at twelve weeks post randomisation. The decision to use two 
primary outcomes is discussed later in this chapter. 
 
6.3.4 Secondary Aims 
To investigate whether the AT and TAU groups differ immediately post 
intervention and at twelve weeks post randomisation in terms of: 
 
Person with Parkinson’s disease: 
 Overall disease state 
 Activities of daily living 
 Beliefs about medication 
 Health related quality of life 
 
Spouse/carer of Person with Parkinson’s disease: 
 Beliefs about medication 
 Caregiving distress 
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Additional Secondary Aims: 
 To investigate associations between baseline cognitive impairment and the 
efficacy of AT. I planned to explore this because the findings presented in 
Chapter 3 identified that cognitive impairment may be associated with 
medication non-adherence in PD. 
 
 To investigate associations between baseline anxiety and depression and the 
efficacy of AT. Once again, I planned to examine this based on the findings 
presented in Chapter 3 which identified that mood disorders may be associated 
with medication non-adherence in PD. 
 
 To investigate the acceptability/satisfaction of AT from the perspective of the 
trial participants who receive it. 
 
 To investigate whether a change in adherence from baseline to follow-up is 
associated with a change in ‘importance’ ‘confidence’ and ‘satisfaction’ with 
medication (part of the AT assessment). 
 
 To investigate whether the overall score and the individual domain scores on 
the Montreal Cognitive Assessment Scale correlate with poor adherence at 
baseline. 
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6.4 Selecting the Outcome Measures 
When developing the protocol for the RCT there were several issues to consider 
when selecting a suitable primary outcome measure. Firstly, I had to decide 
whether it was more appropriate to measure adherence to medication or a PD 
specific clinical marker. As AT was aimed primarily at enhancing adherence 
behaviours, I felt that medication adherence should represent the primary outcome 
of interest. However, the aim of improving adherence to medication in any long-
term condition is to impact positively in a clinical context. I therefore decided it 
was necessary to review the various methods of assessing both medication 
adherence and clinical markers in PD before an appropriate primary outcome could 
be selected. 
 
6.4.1 Direct Methods for Measuring Adherence 
Direct measures of assessing adherence to medication include mainly the 
evaluation of drug metabolite levels in blood plasma, urine or saliva samples. 
However the cost, relative discomfort/inconvenience to the patient and the ability 
to only determine adherence to doses consumed a short time prior to the samples 
being taken made this method impractical for the clinical trial (Nyholm, 2005).  
 
Furthermore, the stage of disease was another important consideration when 
discounting this assessment method. As stated in Chapter 2, patients in early stages 
of PD can experience a long duration of therapeutic effectiveness; dopaminergic 
tone in the nigrostriatal pathway can be maintained in some cases even if patients 
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omit doses (Lopez et al., 2001). As a result, non-adherence in these individuals 
may not be identified from the assessment of a patient’s plasma metabolite levels. I 
therefore decided against the direct methods of assessment.   
 
6.4.2 Indirect Methods of Measuring Adherence 
Indirect methods include pharmacy refill data, self-reports, simple pill counts and 
MEMS devices. In PD only a few studies have specifically investigated and 
compared methods of assessing adherence to medication (Grosset et al., 2006, Elm 
et al., 2007). Although it is widely reported in the adherence literature that MEMS 
devices are the ‘gold standard’ assessment technique, I decided not to use this 
method. MEMS devices are costly, especially when considering that at least one 
device would have been required for each participant. As I did not plan to exclude 
patients with severe PD, I envisaged that many patients would likely be taking 
more than one anti-parkinsonian medication and so a MEMS device would have 
been required for each prescription. This would have added significant cost to the 
study which made this approach unfeasible.  
 
More importantly, I decided that the use of MEMS in a PD population was 
impractical, potential unethical, and would go against the purpose of the 
intervention; that is, to encourage adherence behaviours. This was for the reasons 
outlined below. 
 
Firstly, many people with PD are elderly and the high prevalence of arthritis in this 
group may mean that the use of MEMS devices becomes problematic (Bainbridge 
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and Ruscin, 2009). This potentially could have resulted in patients being unable to 
access their medication, especially in those individuals with tremor dominant PD 
where the fine dexterity required to manipulate bottle tops may be burdensome. As 
a consequence, this could also have led to high participant attrition.  
 
Secondly, the main purpose of AT is to maximise adherence behaviour within the 
patient’s own context. Almost all PD patients do not have medication prescribed 
that comes in a bottle. It therefore seemed counterintuitive to insist on the use of 
MEMS bottles for the duration of the trial when it is not consistent with usual 
medication taking practices.  
 
Thirdly, I anticipated that problem solving strategies surrounding the use of 
medication would be the focus in some PD patients. Asking the patient to change 
their usual routine for the purpose of the trial I felt was unethical and would not 
promote engagement in problem solving exercises. For these reasons I decided 
against the use of the MEMS devices. 
 
Pill counts were shown by Elm and colleagues (2007) to offer a fair to moderate 
correlation with the Morisky Medication Assessment Scale (MMAS-4) self-report. 
Whilst the pill count approach would eradicate any concerns regarding the 
accuracy of self-report scales (patients can intentionally or unintentionally 
over/under report adherence), I decided that pill counts would be unfeasible from a 
pragmatic perspective.  
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For instance, without the use of a blinded rater this method would require me 
visiting the trial participants to count their pills. As patients would be aware that 
their tablets would be monitored in this way, they may have been more likely to 
take their medication rather than them doing so because of the effectiveness of the 
AT process. Assessing adherence in this way I believed would have represented a 
sizeable confounder when determining the efficacy of the AT intervention.  
 
Additionally, this approach would also require actively taking a patient’s drugs out 
of their packet (in many cases their dosette box) and dispensing them into the 
container from which they could be countered (to ensure standardisation 
throughout trial participants). This is not consistent with usual routine and therefore 
I decided against the method.  
 
This left me with self-reports. As Elm and colleagues (2007) were able to show a 
fair to moderate correlation between pill counts and the MMAS-4, I decided the 
self-report scale was the most appropriate and feasible method of adherence 
assessment to use in this particular trial. 
 
6.4.3 Clinical Outcome Measures 
The Unified Parkinson’s Disease Rating Scale (UPDRS) is the acknowledged gold 
standard assessment tool in PD. The UPDRS is reported to be the most frequently 
administered scale for both clinical and research purposes and is used widely in 
clinical trials investigating drug efficacy (Goetz et al., 2007). As stated, the purpose 
of improving adherence to medication is to impact positively on symptom control. 
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An assessment of symptom control would therefore represent a justifiable approach 
to evaluating the effectiveness of an adherence intervention, such as the one 
investigated in this clinical trial.  
 
However, after considering the use of the scale I realised that a clinical assessment 
that focused on PD symptoms may be problematic. This was for a variety of 
reasons. Firstly, part three of the scale requires a rater to undertake an assessment 
of motor function. Despite completing the Movement Disorders Society’s online 
assessment for becoming a trained rater of the UPDRS, and having sufficiently 
practiced administering the scale with patients during routine neurology clinic 
appointments, I felt that rating a patient’s motor function with the knowledge of 
their group allocation (i.e. active treatment or TAU) would lead to considerable 
bias. An alternative trained rater could have been used. However, this would have 
added significant cost to the study as the rater would have been required to visit 
each trial participant three times in their own home.  
 
Secondly, it is well established that both motor and non-motor function in PD can 
vary on a daily, or even hourly, basis. This is dependent on the severity of the 
disease, the response to therapy and whether the patient is in the ‘On’ or ‘Off’ 
phase at the time of assessment. Patients can experience regular motor fluctuations, 
dyskinesia, or simply just not feel as well controlled one day to the next (Ahlskog, 
2009). I felt this could represent a considerable problem if I was to use the UPDRS 
as a primary outcome for establishing the efficacy of Adherence Therapy. Whilst a 
participant’s adherence may have improved, even with a noticeable improvement 
to function in some cases, the potential for variation in UPDRS scores (particularly 
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the motor score) could result in a false negative (i.e. no difference in symptoms 
being detected even though there may be a small improvement).  
 
Finally, whilst symptom focused instruments such as the UPDRS are useful for 
clinical studies, they often do not provide a comprehensive overview of the impact 
of disease. Crucially, such forms of assessment often lack the capability to 
determine how PD effects QoL from the perspective of the patient (Peto et al., 
1998).  
 
Treatment of PD is often aimed at improving motor function. However, PD is often 
complicated by additional problems such as treatment related complications, falls, 
depression and dementia which may have far greater impact on QoL than the 
characteristic motor symptoms of PD (Schrag et al., 2000b). In acknowledging 
these limitations I reviewed widely used PD QoL scales that I believed could be of 
use in the trial as a primary outcome measure. 
 
Many features to QoL have been identified and it is well established that QoL as a 
conceptual framework represents a combination of clinically relevant, patient 
focused dimensions that should be the focus of healthcare interventions. Various 
QoL assessment scales have been tested in patients with PD and generic scales like 
the 36-Item Short-Form Health Survey (SF-36) have been widely used across 
disease populations (Ebersbach et al., 2006). However, a limiting factor in generic 
scales is the lack of specificity and sensitivity to disease specific problems. Quality 
of life measures have therefore been developed for use specifically in PD patients. 
Notably, specific PD QoL scales allow for small, but clinically important, changes 
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to be detected following intervention which generic scales may be unable to detect 
(Fitzpatrick et al., 1997). 
 
The most widely used PD QoL scale is the Parkinson’s Disease Questionnaire 
(PDQ-39). Many researchers have used the PDQ-39 in clinical trials and have 
found it to be sensitive to a variety of treatments including drugs delivery, deep 
brain surgery and therapeutic rehabilitation interventions (Fitzpatrick et al., 1997). 
Its disease specificity and the single summary index offer the opportunity to assess 
the overall impact of illness. Additionally, findings have shown that domains such 
as depression, cognition and mood might be more relevant to PD patients in-terms 
of QoL than impaired motor function (Schrag et al., 2000b). Therefore, an easy to 
interpret QoL measure may provide greater focus on the problems patients report 
as being most impactful on their daily life. This is opposed to simply assessing 
motor function which may not be principally concerning for many patients. 
 
As the PDQ-39 is a well-established outcome measure, and considering that the 
scale is completed as a self-report, I decided that its use as a primary outcome 
would be more pragmatic and feasible in the trial than a predominantly symptom 
driven instrument (e.g. UPDRS) that may not show clinical improvement due to 
potential symptom variability. 
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6.4.4 Deciding Upon the Primary Outcome Measure 
In view of the discussed measures for assessing adherence and clinical change (e.g. 
QoL), I had to decide which outcome was most appropriate to measure for the 
evaluation of the clinical trial. In making this decision I considered the individual 
scales of choice (i.e. the MMAS-4 and the PDQ-39) and the theoretical mechanism 
of AT in a non-adherent PD population.  
 
As the MMAS consists of only four items (Appendix 5), I was mindful that the 
scale might not possess the required sensitivity to detect a subtle change in 
adherence, even though patients may in fact verbally report improved pill taking. 
For example, the first two items on the MMAS-4 relate to problems remembering 
to take medication. Whilst a patient may verbally report improved adherence in that 
they forget fewer doses than prior to participating in the therapy process, the 
wording of the first two items (i.e. do you ‘ever’ forget to take your Parkinson’s 
disease medication / do you ‘ever’ have problems remembering to take your 
medication) may prevent patients from answering differently than at baseline.  
 
Despite some patients potentially reporting improvement in remembering to take 
medication, patients may still feel obliged to answer ‘yes’, indicating no change. 
This may be because patients do occasionally forget doses or miss dose timings, 
even though they may be substantially better than prior to receiving AT. Despite 
feeling that the assessment of adherence should be a primary outcome in the 
clinical trial, I believed this potential insensitivity of the items to detect change 
represented a problem. 
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When considering the PDQ-39, although the scale has been extensively tested 
clinimetrically (Peto et al., 1998, Peto et al., 2001), like the MMAS-4 I feared the 
scale may not be sensitive to change in this particular trial. Whilst symptoms/motor 
function may theoretically improve as a consequence of greater adherence, such 
improvements may not result in a clinically significant impact on QoL. My 
reasoning for this assumption related to a hypothesised mechanism of action of AT 
in PD; that is, improved adherence to anti-parkinsonian medication leads to 
improved function as symptoms become better managed. This ability to function 
more optimally then translates into greater reported QoL.  
 
However, as improved adherence and QoL are arguably at opposite ends of the 
theoretical model (i.e. patients may require a substantial improvement in 
symptoms/function prior to it impacting positively on QoL), I thought it may be 
ambitious to assume that the short adherence intervention in this trial could impact 
significantly on QoL.  
 
Furthermore, this simplistic theoretical model assumes that increasing motor 
function will enhance QoL. As stated earlier, in PD many non-motor symptoms 
such as depression, cognition, sleep and autonomic dysfunction impact greatly on 
QoL, more so than motor symptoms in many individuals (Martinez-Martin et al., 
2011). It may therefore be the case that improving the motor symptoms which are 
most sensitive to anti-parkinsonian medication (i.e. rigidity and bradykinesia), and 
thus are more likely to benefit from greater medication adherence, may in fact not 
impact significantly on QoL.  
 
171 
 
Contrary to this theory, however, I was mindful that improving adherence to 
medication may actually impact positively on the dimensions of QoL that are not 
motor symptom focused; recent findings suggest that non-motor symptoms can be 
responsive to targeted treatments, including dopaminergic agents (Honig et al., 
2009, Zesiewicz et al., 2010).  
 
Furthermore, it is suggested that control of non-motor symptoms can change 
depending on whether a patient is in the ‘On’ or ‘Off’ phase, similar to motor 
symptoms (Chaudhuri et al., 2010). Therefore, it is reasonable to suggest that if 
enhancing adherence to medication improves symptom control, it may well 
improve ‘On’ time for people with PD. Therefore, as a consequence, greater 
adherence may also be beneficial for managing some non-motor symptoms and this 
may be identified by improved QoL scores (Honig et al., 2009, Nissen et al., 2010, 
Zesiewicz et al., 2010).  
 
For the reasons discussed above I felt that assessing QoL was equally as important 
as measuring adherence to medication. I therefore made the decision to use both 
the MMAS-4 and PDQ-39 as primary outcome measures in the clinical trial 
investigating the efficacy of AT. Although the use of two primary outcome 
measures is unorthodox, I believed the decision was justified and could be 
accounted for when calculating the study sample size. 
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6.4.5 Primary Outcome Measures       
Morisky Medication Adherence Scale: 
The MMAS-4 is a self-report scale developed by Morisky and colleagues (1986) 
for identifying medication non-adherence that has been used previously in PD (Elm 
et al., 2007). The scale has four items which can be answered by ‘yes’ or ‘no’. 
Three or four ‘yes’ responses signifies very poor adherence and four ‘no’ responses 
signifies high adherence. Participants scoring ≥ 1 were eligible for the trial as 
validated by the scale authors (Morisky et al., 1986) Originally a score of ≥ 2 was 
used but this criteria was subsequently changed by the Trial Steering Committee 
(TSC) members. This is discussed later in the chapter under protocol amendments. 
 
Parkinson’s Disease Questionnaire - 39: 
The PDQ-39 (Appendix 6) is a PD-specific QoL questionnaire that uses 39 items to 
assess eight dimensions of health: mobility, ADL, emotional wellbeing, stigma, 
social support, cognition, communication and bodily discomfort. 
 
6.4.6 Secondary Outcome Measures 
Movement Disorder Society - Unified Parkinson’s Disease Rating Scale:  
The MDS-UPDRS (Appendix 7) is the revised version of the widely used and cited 
UPDRS (Goetz et al., 2007, Goetz et al., 2008). The MDS-UPDRS comprises of 
sixty-five items in four parts; namely, I: Non-motor Experiences of Daily Living; 
II: Motor Experiences of Daily Living; III: Motor Examination; IV: Motor 
Complications. Clinimetrically the scale has been shown to have high internal 
consistency, reliability/validity and correlates well with the original UPDRS (Goetz 
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et al., 2008). Part I, II and IV were completed at each data collection point in the 
trial. MDS-UPDRS Part III (the motor examination) was not assessed due to 
practical limitations. Specifically, as I would have been required to assess part III 
instead of a blinded rater, I believed this would result in a high risk of bias. 
 
Beliefs about Medication Questionnaire: 
The BMQ (Appendix 8) is comprised of two scales, one with eight items and one 
with eleven items. Together, these assess beliefs about the necessity of prescribed 
medication for controlling symptoms, concerns about taking medications and 
concerns about general medication overuse and harm (Horne et al., 1999). 
Respondents rate each item on a five point Likert scale ranging from one to five 
(one being strongly disagree and five being strongly agree) depending on their 
degree of agreement. Higher scores indicate more positive attitudes towards 
medication. Scores obtained from the eight and eleven item scales are summated. 
 
The questionnaire has four sections which evaluate attitudes about: 
 
1. Specific Concerns (S-C) i.e. concerns about the harmful effects of medicines 
prescribed for a specific condition (six questions). 
 
2.  Specific Necessity (S-N) i.e. beliefs about the necessity of medicines prescribed 
for a specific condition (five questions). 
 
3. General Overuse (G-O) i.e. beliefs about the way in which medicines are used by 
doctors (four questions). 
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4. General Harm (G-H) i.e. beliefs about the intrinsic nature of medicines in 
general (four questions). 
 
EuroQoL (EQ-5D): 
The EQ-5D (Appendix 9) is an established, standardised generic health utility 
index instrument used extensively in clinical studies (Brooks, 1996). It comprises 
of five domains covering mobility, self-care, usual activity, pain/discomfort and 
anxiety/depression. A visual analogue scale represents one final characteristic of 
the instrument. The scale provides a simple descriptive profile and can be used to 
estimate a single index value for a respondent’s health status and change in Quality 
Adjusted Life Years (QALYs). 
 
Caregiving Distress Scale: 
The CDS (Appendix 10) is a concise measure designed to assess and profile levels 
of distress in informal caregivers (Cousins et al., 2002). The scale was developed 
from various caregiving measures which included a wide range of items associated 
with distress for caregiving. The CDS comprises of five distinct dimensions which 
cover 17 separate items. Answers are provided on a Likert scale ranging from 0-4. 
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6.4.7 Additional Baseline Assessments 
As the findings presented in Chapter 3 revealed that cognitive impairment and 
mood disorders (anxiety and depression) are associated with medication non-
adherence in PD, I decided to screen all randomised participants at baseline for 
these symptoms. Cognition was assessed using the Montreal Cognitive Assessment 
Scale. Symptoms of anxiety and depression were assessed using the Hospital 
Anxiety and Depression Scale. 
 
Montreal Cognitive Assessment Scale (MoCA): 
The MoCA (Appendix 11) is a 30-point scale covering a range of executive 
functions. Although a plethora of cognitive batteries exist, in a review on behalf of 
the PD study group the MoCA was recommended for use in clinical trials where 
screening of cognitive impairment was necessary (Chou et al., 2010). The scale has 
six orientation questions and a five word memory recall task. A clock drawing task 
and a cube copy test assess visuospatial function. Attention/concentration is 
assessed using serial 7’s, target mapping and forwards and backwards digit span 
tasks. Confrontation naming and repetition tasks assess language. Executive 
functions are evaluated using a shortened version of the Trail Making B Test, 
phonemic fluency, and a verbal abstraction task. 
 
Hospital Anxiety and Depression Scale (HADS): 
The HADS (Appendix 12) is a self-screening questionnaire for anxiety and 
depression (Zigmond and Snaith, 1983). It consists of fourteen questions, seven for 
each anxiety and depression and has been widely used and validated (Bjelland et 
al., 2002).  
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Where patients scored moderate/severe on the HADS (i.e. a score above ten on the 
depression scale) I recommended they contact their GP. I also provided the patient 
with an ethics approved information sheet (Appendix 13). Where only mild 
symptoms were identified (i.e. a score between eight and ten on the depression 
scale), I provided patients with information relating to self-help websites 
(Appendices 14). Patients scoring seven and below satisfied the criteria for no 
depressive symptoms. These participants were therefore not given any further 
information.  
 
Where participants did show signs of depression as determined by the HADS, a 
letter was posted to the patient’s General Practitioner informing them of their 
patient’s HADS score and of what recommendations the research team had made to 
the patient (Appendix 15). 
 
6.4.8 Patient Demographics and Clinical Characteristics    
The following demographic and clinical data were collected at baseline using a 
standardised baseline participant demographics form (Appendix 16). These 
characteristics were recorded to determine the success of the randomisation process 
and in order to present the demographical distribution of the sample: 
 
 Age 
 Gender 
 Ethnicity 
 Duration of PD 
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 Disease severity (Hoehn and Yahr Scale, Appendix 17)  
 Medication profile:  
 Prescriptions (PD and non-PD drugs) 
 Levodopa Equivalent Daily Dose 
 Dose and regimen 
 Whether medication was self-administered 
 Co-morbidities 
 Whether a spouse/carer was present in the home 
 Occupation 
 Socioeconomic status (estimated using the first half of a patient’s postcode) 
 
Each participant’s Levodopa Equivalent Daily Dose (LEDD) was calculated using 
a standard method as described by Tomlinson et al (2010). For each anti-
parkinsonian medication taken by trial participants, a conversion factor was used to 
calculate the equivalent Levodopa dose. For example, the conversion factor for the 
dopamine agonist Ropinirole is reported by Tomlinson and colleagues to be a 
factor of twenty. Therefore, the LEDD for a participant prescribed 30mg daily 
Ropinirole was 600mg (30mg x factor of 20). 
     
6.5 Methods 
6.5.1 Study Design 
This study was a parallel group, RCT to compare AT with TAU for non-adherent 
people with PD and their spouse/carers. The study compared the two groups 
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immediately post intervention and at twelve weeks post randomisation (primary 
follow-up point). The RCT was conducted from September 2011 to March 2013 
within the departments of Neurology and Medicine for the Elderly (MFE) at a 
University Hospital in the East of England.  
 
The trial protocol was registered with the International Standard Randomised 
Controlled Trial Register (ISRCTN07830951) and published in the TRIALS 
Journal (Daley et al., 2011). 
 
6.5.2 Study Participants 
Study participants were people with idiopathic PD attending Medicine for the 
Elderly or Neurology outpatients for a routine appointment with their Neurologist 
or Consultant physician. Spouse/carers of PD patients wishing to participate were 
also invited into the study. 
 
6.5.3 Inclusion Criteria 
All patients meeting the following selection criteria who attended either of the 
outpatient clinics were invited to participate: 
  
1. Adults diagnosed with Idiopathic PD - three out of four of the chief UK Brain 
Bank Criteria (Appendix 18) had to have been satisfied (Gibb, 1988). This 
information was determined by careful review of Consultant clinic letters. Where 
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there was doubt, for instance whether a patient had idiopathic PD or a 
Parkinsonism, the treating physician was consulted for verification. 
 
2. Were prescribed one or more anti-parkinsonian medications by a Consultant 
Neurologist or Consultant physician with specialist knowledge of movement 
disorders. 
 
3. Were English speaking and literate (participants were required to actively 
engage in the therapy process). 
 
4. Were on a stable medication regime i.e. not altered within the previous month 
and not expected to change during the period of the RCT (twelve weeks). 
 
5. Were not diagnosed with dementia or significantly cognitively impaired. Where 
there was reasonable doubt in the clinic letters the clinical team made a judgement 
as to whether the patient had the cognitive capacity required to participate fully in 
the trial; that is, be able to read patient information, complete self-report 
questionnaires and engage actively in the therapy process. 
 
6. Showed poor adherence as determined by a MMAS-4 score ≥ 1. 
 
As the review presented in Chapter 3 showed that both young and older age was 
associated with medication non-adherence, likely for different reasons as discussed, 
I did not feel it appropriate to have an age restriction. What’s more, I was keen to 
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ensure the sample was as representative as possible. I therefore felt that exclusion 
because of older age was not justifiable for this clinical trial. 
 
6.5.4 Exclusion Criteria 
Patients were excluded if either of the below criteria were satisfied: 
 
1. Patients did not have a diagnosis of PD (i.e. I was unable to attribute the 
movement disorder to Parkinson's disease). This included patients with a diagnosed 
Parkinsonism (e.g. Vascular Parkinsonism, Multiple Systems Atrophy, Progressive 
Supranuclear Palsy and Dementia with Lewy body disease). 
 
2. Patients whose medication regimen had altered within the previous month. 
 
3. Patients being treated with anti-parkinsonian medications for a mental health 
problem e.g. psychosis. 
 
4. Were diagnosed with dementia. 
 
5. Patients who had a life expectancy of < 6 months. 
 
6.5.5 Recruitment Procedure 
Patients fulfilling the screening criteria were informed of the study by post. A 
member of the clinical team (PD nurse specialist), acting in the capacity as a data 
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clerk, posted an information pack to PD patients meeting the screening criteria 
two/three weeks prior to their upcoming routine outpatient appointments with a 
Neurologist or movement disorder specialist.  
 
Each information pack contained the MMAS-4, an invitation letter (Appendix 19), 
a patient information sheet (Appendix 20) and a consent form for the MMAS-4 
(Appendix 21). Spouse/carer specific information was placed in a separate 
envelope within the patient pack. This contained an information sheet (Appendix 
22) and an initial consent form indicating interest in the study (Appendix 23). 
Patients were asked to return the MMAS-4 and the consent form accompanying the 
scale prior to their upcoming routine outpatient appointment if they were initially 
interested in the study.   
 
Upon receiving the MMAS-4, those showing poor adherence to medication as 
determined by a score ≥1 were deemed eligible for further participation. In this 
instance I contacted the patient by phone and informed them of their eligibility. In 
most instances I arranged a suitable time to visit the patient and their spouse/carer 
at home to discuss the study in greater detail before a decision to participate fully 
was made. This was often because I did not receive the MMAS-4 and the 
accompanying consent form prior to their clinic appointment.  
 
Where I did receive the MMAS-4 and consent form before the arranged clinic visit, 
I made suitable provisions to see patients in a private room directly before or after 
their appointment with their Consultant. If still wishing to participate after 
discussing the study in greater detail and having had the opportunity to ask 
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questions, patients signed an informed consent form (Appendix 24) and completed 
all baseline outcomes measures. Consenting spouse/carers also signed an informed 
consent form (Appendix 25) and completed relevant outcome measures. Eligible 
patients not seen on their appointment day completed the consent forms and 
baseline measures during their home visit. Patients not scoring ≥1 were informed 
by phone of their ineligibility and thanked for their participation. 
 
6.5.6 Randomisation and Allocation Concealment 
All study participants were randomly assigned to either the AT or TAU group 
following the completion of baseline measures. This was to ensure that a patient’s 
baseline response to the self-report questionnaires did not change as a result of 
being randomised into the TAU group. 
 
Where patients were seen directly following their outpatient appointment, 
randomisation took place in a private room following signed informed consent and 
completion of baseline measures. Randomisation and allocation concealment were 
completed using computer generated random numbers accessed via a web-based 
randomisation system developed by the Clinical Research Trials Unit (CRTU) at 
the University of East Anglia (UEA). Participants were allocated a unique 
identifier number which was sent to CRTU where allocation was undertaken by 
permuted random blocks of four and six (explained earlier in this chapter).  
 
Participants were stratified into ‘spouse/carer present’ or ‘no spouse/carer present’ 
strata at randomisation in order to investigate the potential effect modification 
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(interaction) of the spouse/carer on the treatment effect. This was also described 
earlier in this chapter. 
 
All randomised participants were assigned a randomisation number by CRTU. 
Additionally, each participant who was initially invited into the study (regardless of 
whether they were non-adherent or subsequently randomised) was given a unique 
‘study’ identification number. This number, in addition to CRTU’s randomisation 
number, was placed on all participant documents for the remainder of the trial 
allowing me to track and record patient data anonymously without the need of 
patients’ names. All Excel/SPSS spread sheets contained these personal identifiers 
to maintain anonymity.  
 
6.5.7 Treatment Groups 
Treatment as Usual Group (TAU): 
To conduct a robust RCT there is a need to have a group that is matched with 
individuals in the active treatment group in all aspects except the intervention 
under investigation. This group is usually referred to as the control group. A 
control group is an essential part of the RCT design, functioning to ensure that any 
changes observed in an active treatment group are due only to the experimental 
intervention (Akobeng, 2005).  
 
A limitation of the control group, however, is that it may lead to difficulties when 
interpreting the results. Specifically, the findings may only show whether a 
particular intervention offers benefit when it is compared to no intervention at all, 
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as implied by the control group. The findings will not however show if the 
intervention under investigation offers greater efficacy than existing treatments. 
For this reason many researchers now refer to TAU as an alternative where patients 
randomised into the TAU group receive current best practice. Whilst this removes 
full power from the researchers as it may not always be clear what information is 
given to patients in this group from various health professionals, this approach does 
show the efficacy of the intervention against current best practice treatment. 
Furthermore, the concept of TAU is ethically more acceptable as participants are 
not left untreated. 
 
In this study patients in the TAU group received no additional information 
regarding medication adherence from members of the clinical team. Care continued 
as usual according to routine practice. This largely consisted of Consultant 
outpatient appointments and input from PD nurse specialists. I specifically did not 
provide any guidance to the clinical team as to the content of the TAU package. 
However, the clinical team were asked not to discuss treatment adherence and were 
to avoid any intervention relating to this topic, unless they deemed it necessary for 
the wellbeing of the patient. In this instance they were asked to record what 
information had been provided. 
 
Active Treatment (AT) Group: 
In addition to TAU, patients allocated to the active treatment group received seven 
30-45 minute sessions at weekly intervals of AT delivered in their own home. 
Where a patient’s carer consented to the trial, AT was also delivered to the carer at 
the same time (hence Carer Assisted AT, (CAAT-PARK)). Ten sessions of AT 
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over the course of the trial were audio recorded to determine treatment fidelity. 
Participants were made aware of this in the participant information sheet and were 
asked to consent for this at the particular visit. 
 
6.5.8 Follow-up Outcome Assessment 
Baseline outcome measures were repeated immediately post intervention (week 
seven or eight) and at twelve weeks post randomisation (primary follow-up point), 
as depicted in Figure 6.2. For the group receiving TAU, assessments were at week 
seven and week twelve. For the active treatment group, post intervention 
assessments were at week seven or eight and then at week twelve. This additional 
week at the immediate post intervention time point accommodated potential 
sickness or time spent away from home, providing flexibility to the process from a 
pragmatic perspective. Table 6.2 shows when each outcome was assessed 
throughout the trial duration and the average time for completion. 
 
          Post-intervention follow-up periods 
            Randomisation/ Baseline Ax                        Weeks   7   8                week 12 Ax              
 
T. group 
 
TAU group 
  
 
Figure 6. 2 - Outcome Measure Assessment Time Points 
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Table 6. 2 - Outcome Measure Assessment Points 
Measures Baseline / 
randomisation 
Week 
seven 
Week 
Twelve 
Time for 
Outcomes 
(min) 
Patients     
MMAS-4 x x x 2.0 
PDQ-39 x x x 10.0 
EQ-5D x x x 2.0 
BMQ x x x 5.0 
MDS-UPDRS (I-III) x x x 15.0 
MoCA x   10.0 
HADS x   10.0 
Total Time 54 min 34 min 34 min  
     
Spouse/Carers     
BMQ x x x 5.0 
CDS x x x 5.0 
Total Time 10 min 10 min 10 min  
 
6.5.9 Adverse Events Monitoring 
Adverse events (AE) were recorded at each weekly visit and commenced from the 
point of randomisation up to week twelve follow-up. An AE checklist (Appendix 
26) was developed following consensus views of the TSC and medical specialists. 
AEs were reported to the TSC members (Appendix 27) and the clinical team 
responsible for the management of a specific PD patient for appropriate action.  
 
All AEs were addressed according to local Standard Operating Procedures (SOPs) 
for clinical trials of non-Investigational Medicinal Products (non-IMPs) developed 
in accordance with the Medicines for Human Use Regulations (2004) and the 
Department of Health’s Research Governance Framework for Health and Social 
Care for identifying, recording, and reporting adverse events in clinical trials. 
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6.6 Determination of Sample Size 
My aim was to recruit a total of ninety-two family units (patient/carer pairs or 
patients alone), forty-six per treatment group. This included an additional 15% (n = 
6) in each group for potential participant attrition. Where possible I aimed to recruit 
patients with a spouse/carer. I did not exclude participants who did not have a 
spouse/carer but who were themselves wishing to participate.  
 
Using the primary outcomes (MMAS-4 and PDQ-39) it was calculated that a 
sample size of forty participants per treatment group would provide 81% power, 
with an alpha of 0.05, to detect a difference of 25% improvement in medication 
adherence in the active treatment group against 0% in the TAU group. 
Improvement in the MMAS-4 was detected by a one point shift. This calculation 
also provided 80% power to detect a Cohen’s effect size of 0.69 (typically 
considered large) in the PDQ-39 overall score, based on the published standard 
deviation of 8.89 in a PD patient group (Peto et al., 2001). This calculation allowed 
for a minimally important clinical difference in means of 6.13 (8.89 S.D. × 0.69 
E.S.) in the PDQ-39 to be detected. 
 
6.7 Analysis 
6.7.1 Data Entry & Quality Control 
Double Data Entry 
To ensure the accuracy of data entry, all measurements for both primary outcomes 
(MMAS-4 and PDQ-39) taken at baseline, week-7 and week-12 were entered into 
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two separate Excel spread sheets (double data entry). Each participant had 9 cells 
containing PDQ-39 scores (8 sub-domains and 1 total score) and 1 cell for the 
MMAS-4 score. This provided a total of 760 cells (10 cells per participant 
multiplied by 76 participants) of data for each spread sheet at each of the three 
assessment time point. Each pair of spread sheets relating to baseline, week-7 and 
week-12 measurements were then overlapped to assess for differences in scores. 
Where scores differed, that participant’s raw data set was re-assessed for the 
correct value.  
 
Quality Assurance 
To ensure the accuracy of outcome measurement calculations, a 10% random 
sample of primary outcome data was independently calculated by a second rater 
naive to the study aims. The rater was given instructions on how to calculate a 
score for the MMAS-4 and PDQ-39. There were no discrepancies in scores 
between the initial calculations of the primary outcomes and that of the secondary 
rater. The MMAS-4 and PDQ-39 contained no participant identifiable information 
and did not reveal group allocation to the second rater. 
 
6.7.2 Baseline Comparisons 
The SPSS statistical program version 18 for windows was used to analyse the 
quantitative data. In addition to my independent analysis, a blinded medical 
statistician also analysed all data for accuracy. 
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Baseline comparability of the groups by demographics was described using 
descriptive statistics. Where data appeared to be non-normally distributed 
according to the Shapiro-Wilks test, medians and inter-quartile ranges were used to 
describe the data. Where data was normally distributed, means and standard 
deviations were used.  
 
The following discrete variables were recorded and tabulated: gender, occupation, 
numbers living with a spouse/carer, ethnicity and disease severity. All other 
recorded demographic data were continuous: age, duration of PD, number of 
comorbidities, number of PD drugs/non-PD drugs, number of daily PD/non-PD 
doses, number of PD tablets taken daily, LEDD, MoCA score and HADS score. 
 
6.7.3 Efficacy Analyses 
Determining the efficacy of AT was made by comparing baseline primary outcome 
measurement data to that of week-12 follow-up using inferential statistical analysis. 
Originally it was decided that the primary outcomes (MMAS-4 and PDQ-39) 
would be analysed using the parametric student-t test for comparing mean change 
between the two intervention groups. However, because the interaction between the 
subgroup factors (presence or absence of a spouse/carer, baseline HADS and 
baseline MoCA scores) and the treatment effect were to be investigated, responses 
for the MMAS-4 were used to form two outcome categories: ‘no change or 
increase’ and ‘decrease’. This meant the student-t test for comparing means was 
not appropriate. 
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For example, a patient who scored two on the MMAS-4 at baseline and again at 
week-12 follow-up satisfied the criteria for the ‘no change or increase’ category. 
Likewise, if a patient’s adherence worsened as indicated by a score of 1 at baseline 
and then ≥2 at week-12 follow-up, they also were categorised into the ‘no change 
or increase’ group. Alternatively, patients who improved in medication adherence 
(indicated by a lower MMAS-4 score from baseline to week-12 follow-up) were 
categorised into the ‘decrease’ group as their overall MMAS-4 score had reduced. 
Categorising the MMAS-4 score in this manner therefore produced a binary 
outcome: ‘no change or increase’ or ‘decrease’, regardless of the actual baseline 
and week-12 follow-up score. 
 
This binary outcome was then compared between treatment groups using a logistic 
regression model, which adjusted for the stratifying factors (i.e. presence of 
spouse/carer). Linear regression analysis is a way of predicting a future outcome 
variable from a predictor variable or several predictor variables for continuous 
outcomes (Field, 2009). Logistic regression is an extension of linear regression 
models in that it is designed to predict the outcome of a categorical variable from 
either continuous or categorical predictor variables. Regarding the MMAS-4, as the 
binary outcome was either ‘no change or increase’ or ‘decrease’ in adherence 
score, a logistic regression model was appropriate. 
 
As the logistic regression model was used in this study to predict a binary outcome 
(i.e. improvement in medication adherence or not) based on a categorical predictor 
variable (i.e. exposure to AT or not), I decided to present the findings statistically 
(P values) and using an effect size (ES). This was in order to provide greater 
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meaning to non-specialist audiences and to identify the magnitude of effect of AT 
which p-values are unable to confer. 
 
The Odds Ratio (OR) (a measure of ES) is an index that compares the likelihood of 
an event or outcome occurring in one group (e.g. active treatment group) compared 
with another group (e.g. TAU) (Ellis, 2010). Therefore, using this measure of ES 
allowed me to state how likely a person was to report improved medication 
adherence if they received the programme of AT compared to people who do not 
receive the therapy.  
 
Though this measure has several statistical advantages and is used extensively in 
both clinical research and epidemiology, the index may not be helpful in clinical 
decision making. In addition to presenting the findings for change in adherence as 
ORs, I wanted the results to be easily interpreted by clinicians who may wish to 
know how many patients need to be treated with AT before one patient’s 
medication adherence improves. I therefore also decided to present as an 
alternative level of effect the Numbers Needed to Treat (NNT).   
 
Numbers needed to treat is a method of summarising the effect of treatment in 
terms of the number of patients a clinician needs to treat with a particular 
intervention to expect to prevent one adverse event (Cook and Sackett, 1995). In 
RCTs the NNT is often a measure of treatment benefit where a binary outcome is 
used. As medication adherence in this trial was determined by a binary outcome, I 
used the logistic regression model to estimate the NNT for AT in order to show 
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how many patients would need to be treated before one extra person improved in 
medication adherence. 
 
As all other outcomes were continuous (PDQ-39, UPDRS, BMQ, EQ-5D, CDS), a 
linear regression model was used to compare the two groups from baseline to 
week-12 follow-up. Stratifying factors (i.e. carer or no carer) were adjusted for as 
with the logistic regression model. The assumptions of normality for both the 
logistic and linear regression models were checked by comparing the results of 
these parametric tests to those using the non-parametric bootstrap (where any 
distribution is assumed). The model results were found to be robust to the model 
assumptions, indicating that parametric regression models were justified.  
 
Intention to Treat (ITT) analyses were performed for all outcomes and comprised 
of all patients who had been randomised. For the active treatment group, this was 
irrespective of their compliance with AT. The principle of ITT was adopted as it 
provides a pragmatic estimate of the benefit of a change in treatment policy 
compared to the potential benefit in patients who receive treatment exactly as 
planned. As AT was planned for delivery over a seven week period, some 
participants may not have received all the planned sessions. As this is more likely 
to reflect usual practice, primary analyses of all outcomes were conducted 
according to the ITT principle.  
 
Per Protocol (PP) analyses were planned for participants who had not deviated 
from the AT protocol in such a manner that the assessment of efficacy could be 
biased. This was defined as patients completing at least five out of the seven 
193 
 
planned AT sessions. However, as no patient deviated from the intervention as 
defined, PP analysis was not undertaken.  
 
Imputation of missing/incomplete data was planned for using iteratively chained 
equations for all outcome measures. However, no primary outcome data was 
missing from the trial participant data sets and so multiple imputations were not 
required. 
 
6.7.4 Subgroup Analysis 
As the review presented in Chapter 3 suggested that mood disorders, impaired 
cognition and the lack of a spouse/carer may be associated with medication non-
adherence in PD, subgroup analyses were undertaken testing for the impact of these 
factors on the primary outcomes. Subgroup effects were tested for with the 
presence or absence of a spouse/carer, HADS anxiety, HADS depression and 
MoCA scores with respect to both primary outcomes. Logistic regression was used 
to test the interaction between the subgroups and MMAS-4 scores. Linear 
regression was used to test for the interaction between the subgroups and PDQ-39 
scores. 
 
6.7.5 Correlation Analyses 
As part of the AT assessment each patient provided a score for three separate 
scales: ‘importance’, ‘confidence’ and ‘satisfaction’. These were answered in 
relation to how a patient felt about their prescribed anti-parkinsonian medication. 
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All three scales were scored from 0-10 and were completed formally at baseline, 
week-7 and week-12 follow-up. In order to determine whether a change in these 
three domains was associated with baseline MMAS-4 scores or a change in 
MMAS-4 scores from baseline to week-12 follow-up, a Spearman’s rank 
correlation coefficient was calculated. 
 
As a separate analysis, the Spearman’s rank correlation coefficient was also used to 
determine whether the overall score on the MoCA and the seven individual sub-
domains (visuospatial/executive function, attention, naming, language, abstraction, 
delayed recall and orientation) were associated with poor adherence at baseline as 
determined by the MMAS-4. 
 
6.8 Ethical Considerations 
6.8.1 Declaration of Helsinki  
I ensured that this study was conducted in full conformity with the current revision 
of the Declaration of Helsinki (last amended October 2000, with additional 
footnotes added 2002 and 2004). 
 
6.8.2 International Conference of Harmonisation Good Clinical Practice 
I ensured this study was conducted in full conformity with the relevant regulations 
and the ICH Guidelines for Good Clinical Practice (CPMP/ICH/135/95) July 1996. 
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6.8.3 Participant Confidentiality 
All data was handled in accordance with the Data Protection Act (1998), which 
requires data to be anonymised as soon as it is practical to do so. Participants were 
identified only by participant ID numbers (CRTU and study ID). Each participant 
had their own Case Record File (CRF) containing consent forms, completed 
outcome measures, AE forms and demographic information as previously 
described. Only I, the direct study supervisors and the nurse specialists assisting in 
recruitment were able to access personal identifiable data.  
 
The study participants were identified in their CRF and in electronic databases only 
by their unique ‘study’ identification number. Only I had access to an encrypted 
Excel spread sheet containing patients names and addresses (required initially for 
study invitation and then for home visits if later randomised). Databases and all 
documents were stored securely on a password protected computer or in a locked 
cabinet. 
 
On an annual basis I completed Good Clinical Practice training. I also held a valid 
Honorary NHS Research Associates contract at all times throughout the duration of 
the clinical trial which facilitated access to clinical environments. 
 
6.8.4 Research Ethics and Governance 
Prior to commencing the study, a copy of the full trial protocol (Appendix 28) and 
all associated documents were submitted for ethical review by Cambridge Central 
NHS Research Ethics Committee. The study was awarded a favourable ethical on 
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June 7
th
 2011 (Appendix 29). Approval was also granted from Norfolk and 
Norwich University Hospital (NNUH) Research & Development (R&D) 
department. 
 
6.9 Protocol Amendments 
6.9.1 Amendment to Inclusion Criteria 
In the initial protocol it was stated that patients scoring ≥2 on the MMAS-4 would 
be considered eligible for inclusion in the trial. However, the authors of the 
MMAS-4 suggest that a score of ≥1 (i.e. one ‘yes’ response out of four) is adequate 
to signify non-adherence. This scoring system was validated by the authors and has 
been used in this light in other research studies.  
 
Originally I increased the cut-off from ≥1 ‘yes’ response to ≥2 ‘yes’ responses. 
However, increasing the cut-off in this way resulted in 11 patients who scored 1 
‘yes’ response being deemed ineligible for the study. Therefore, in order ensure the 
recruitment target was achieved I sought ethical approval to lower the MMAS-4 
score from ≥2 ‘yes’ responses to ≥1 ‘yes’ response. This request was reviewed by 
the ethics committee and was awarded a favourable ethical opinion on 29
th
 
November 2011 (Appendix 30). The 11 patients who were initially excluded were 
contacted again by post and asked to complete the MMAS-4 again if they still 
wished to participate in the clinical trial. Of the 6 who responded, all were 
subsequently randomised.   
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6.9.2 Protocol Breach 
During the trial period a protocol breach occurred, resulting in a temporary halt to 
study recruitment. This protocol breach happened when I provided the names and 
contact details of some study participants to another PhD student at UEA who had 
almost identical inclusion criteria. The information below provides further detail.   
 
Dr Katherine Deane (primary supervisor to another PhD student and secondary 
supervisor to myself) asked me to identify patients suitable for this student’s 
project from my RCT study data. These were the patients who replied to my study 
invitation, indicated their interest and returned the screening questionnaire but were 
adherent to their medication and thus not suitable for the RCT.  
 
Retrospective identifying of potential participants was permitted within the other 
student’s study protocol where it was intended that clinical staff would identify 
potentially eligible patients (both retrospectively and prospectively) and send them 
an invitation pack by post from the clinic. 
 
The error occurred when names and addresses of potentially eligible patients were 
transferred from me to the other PhD student by UEA email. This student received 
the names and addresses of 90 patients (with the implicit information that they had 
PD). The student then sent invitation packs to 44 of the patients inviting them to 
participate in their research. This activity breached both study protocols.  
 
The other student and I were informed by Dr Katherine Deane beforehand that this 
process was acceptable. This was because I held a valid NHS Honorary Contract 
198 
 
and it was believed that I represented a member of the clinical team (which the 
clinical leads of Neurology and Medicine for the Elderly departments had 
approved). As the other PhD student’s protocol specified a member of the clinical 
team could identify prospective study participants, I was therefore asked to do this 
which is where the error occurred. This unfortunate error was realised by the 
research teams within a few days of the letters being posted by the second PhD 
student. Both studies ceased recruitment on 10.02.12.  
 
At this juncture my role as a member of the clinical team was also queried with the 
NHS ethics committee, despite having approval from the NNUH R&D department 
that this was acceptable.  
 
6.9.2.1 Actions Taken to Rectify 
Initially advice was sought from NNUH and UEA Data Protection Officers 
regarding whether the Information Commissioner’s Office needed to be informed. 
The Caldicott Guardian was also informed via NNUH R&D in addition to UEA 
R&D and the sponsor (Sue Steel, Contracts Manager, UEA). The following actions 
took place: 
 
The Research Governance offices of both UEA and NNUH (having taken advice 
from the Data Protection Officers for UEA and NNUH) wrote a joint letter to all 90 
patients whose data had been inappropriately shared. None of the patients in receipt 
of this letter registered a complaint. 
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The NNUH Research Governance Committee met and recommended that those 
involved complete further training in ICH GCP and NHS Information Governance. 
All involved completed the appropriate training as requested.  
 
The NHS REC decided that it was not appropriate for me to continue in my 
capacity as a clinical team member and that approval for this should not have been 
granted by the NNUH R&D department. It was suggested that a data clerk 
employed by NNUH take over initial screening for my clinical trial. 
 
6.9.2.2 Conclusion to Protocol Breach 
Cambridge Central REC issued a favourable opinion letter for the restart of 
participant recruitment (Appendix 31). The NNUH Research Governance 
Committee stated that they were content for recruitment to restart for both studies 
once training certificates had been received. A letter was subsequently issued on 
27
th
 April 2012 from NNUH R&D office stating that recruitment was able to 
recommence (Appendix 32). 
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6.10 Chapter Summary 
This chapter commenced by introducing the RCT as a research design commonly 
employed in studies investigating the efficacy of interventions. The characteristics 
of the design that result in the high internal validity associated with RCTs was 
outlined and the use of stratification was highlighted. Having described the 
development of AT in Chapter 5, the hypothesis and aims for a RCT were 
presented. Justifications for the selection of the study outcomes were given and a 
detailed account of the trial methods and analytical techniques were reported. The 
chapter ended with a discussion of the main ethical considerations of the study. In 
the next chapter I present the findings of the clinical trial. 
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Part 3 
 
CHAPTER 7 
 
 
Trial Results 
 
 
Introduction 
Participant Flow 
Study Population 
Efficacy Analyses 
Sub-group Analyses 
Correlation Analyses 
Serious Adverse Events 
Cost of CAAT-PARK 
Summary of Results 
 
 
 
7.1 Introduction 
This chapter reports the findings of a RCT investigating the efficacy of a novel 
intervention (Adherence Therapy) for improving medication adherence and QoL in 
medication non-adherent patients with PD. A diagram of participant flow through 
the trial is presented and the baseline demographic and clinical characteristics of 
the trial participants are reported. Results for week-12 (primary analysis) and 
immediately post intervention (week-7) are presented and the findings of all sub-
group analyses are reported.  
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7.2 Participant Flow 
During the recruitment period (September 2011 to January 2013) a total of 2508 
patients were screened from Neurology and Medicine for the Elderly clinics. Of 
these, 1783 were excluded due to having no Parkinsonian condition. A further 298 
did not meet the remaining inclusion criteria. A total of 427 patients were invited 
by post to participate in the study. Of the 249 who responded, 173 (69%) reported 
sound adherence (MMAS-4 = 0). The remaining eligible patients (n=76) were 
randomly assigned to either the active treatment group (n=38) or TAU (n=38). 
 
Throughout the trial duration, no patients withdrew from either treatment group. 
Twenty-five (66%) of the patients in the active treatment group were randomised 
with a spouse/carer compared to 23 (61%) in the TAU group. One carer 
discontinued the trial from both groups due to not being able to attend many of the 
scheduled sessions.  
 
No patient or spouse/carer who completed the trial received less than 5 of the 7 
therapy sessions. Five patients (13%) completed 5 out of the 7 sessions and 8 
(21%) completed 6 out the 7 therapy sessions. For the spouse/carers, 6 (25%) 
completed 5 of the 7 AT sessions and 8 (33%) completed 6 of the 7 sessions. The 
mean duration of an AT session was 40 minutes (range 30-60). Figure 7.1 displays 
the CONSORT diagram (Schulz et al., 2010) showing the flow of participants 
through the trial. 
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Figure 7. 1 - Trial CONSORT Participant Flow Diagram 
PD patients randomised (n = 76) 
Neurology and Medicine for the 
Elderly clinic notes screened 
(n = 2508) 
Not iPD: 
- Multiple System Atrophy             (n = 2) 
-       Vascular PD                   (n = 17) 
-       Progressive Supranuclear Palsy  (n = 1) 
-       Not definitive PD (unclear)  (n = 117) 
 
Diagnosed with Dementia   (n = 48) 
Only recent diagnosis of PD    (n = 10) 
Major depression    (n = 1) 
No PD medication prescribed     (n = 24) 
Meds not self-administered     (n = 58) 
Refused participation in any research   (n = 20) 
 
Did not respond            (n = 178) 
 
Medication adherent   (n = 173) 
(MMAS = 0)       
 
 
Received allocated intervention 
(n = 38) 
 
Lost to follow-up         (n = 0) 
Discontinued          (n = 1 carer) 
Invited by post to participate  
(n = 427) 
Allocated to Adherence Therapy 
 
PD patients         (n = 38) 
Spouse/carers         (n = 25) 
Allocated to Treatment as Usual 
 
PD patients        (n = 38) 
Spouse/carers        (n = 23) 
Received allocated intervention 
(n = 38) 
 
Lost to follow-up         (n = 0) 
Discontinued          (n = 1 carer) 
Analysed  
 
PD patients         (n = 38) 
Spouse/carers         (n = 22) 
 
 
Analysed 
  
PD patients          (n = 38) 
Spouse/carers         (n = 24) 
 
Excluded due to non-parkinsonian 
condition 
(n = 1783) 
Excluded due to not meeting  
remaining inclusion criteria 
(n = 298) 
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7.3 Study Population 
7.3.1 Baseline Demographic & Clinical Characteristics 
Demographic and clinical characteristics of the study participants by treatment 
allocation at baseline are presented in Table 7.1. Baseline demographics and 
clinical characteristics were mostly balanced evenly between the two treatment 
groups, indicating randomisation had been successful. There was a difference in the 
numbers reporting dyskinesia at baseline. As this did not relate to either of the 
study primary outcomes, the TSC did not deem this to be problematic.  
 
The mean age of the trial participants was 72 years. Almost all participants were 
Caucasian and British, typical of the geographical area from which they were 
recruited. Both treatment groups were similar in relation to MoCA and HADS 
scores at baseline. Medication profiles for both treatment groups were almost 
identical for Levodopa Equivalent Daily Doses and both groups shared a 
comparable number of daily PD tablets/doses. Slightly more of the active treatment 
group were retired and had slightly longer disease duration. However, for disease 
duration the between group difference was small compared to the within group 
standard deviations (variance). Hence, I did not consider that this would confound 
the effect of the intervention. 
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Table 7. 1 - Baseline Demographic & Clinical Characteristics 
Characteristic 
 
Active 
Treatment 
n=38 
TAU  
n=38 
P= 
Age in years (mean & s.d.) 72.2       (9.5) 71.6       (8.3) 0.78 
Male (%) 25          (65.8) 24          (63.2) 0.81 
Hoehn & Yahr (mean & s.d.): 2.1 (1.1) 2.2 (1.1) 0.96 
Duration of PD in years (mean & s.d.) 8.7         (6.4) 7.8         (4.2) 0.50 
Reported dyskinesia (%)* 15 (39) 9 (24) - 
Reported motor fluctuations (%)* 18 (47) 18 (47) - 
Retired (%) 37          (97.4) 32          (84.2) 0.71 
Living with spouse/carer (%) 25          (65.8) 23          (60.5) 0.81 
White British (%) 38          (100) 36          (94.7) 0.49 
MoCA  27.0        (3.0) 26.0       (4.0) 0.20 
HADS – anxiety  4.0          (5.0) 3.5         (6.0) 0.77 
HADS – depression  5.0          (3.0) 5.0         (6.0) 0.55 
Number of comorbidities  2.0          (3.0) 1.0         (3.0) 0.39 
LEDD (mg)  669.4      (629.8) 660.6     (634.4) 0.87 
Number of PD drugs prescribed  2.0          (1.0) 2.0         (1.0) 0.57 
Number of PD Tablets Taken Daily  6.0          (5.0) 6.5         (5.0) 0.92 
Number of PD Daily Doses  4.0          (1.0) 4.0         (1.0) 0.94 
Number of Non-PD Tablets Taken Daily 6.0          (7.0) 4.0         (7.0) 0.13 
Number of Total Tablets Taken Daily 13.0        (9.0) 11.5       (8.0) 0.18 
 
Median & IQR: Interquartile Range, unless stated otherwise; MoCA: Montreal 
Cognitive Assessment Scale; HADS: Hospital Anxiety & Depression Scale;  
LEDD: Levodopa Equivalent Daily Doses; *: Movement Disorders Society – 
Unified Parkinson’s Disease Rating Scale part IV 
 
 
 
7.3.2 Baseline Outcome Measures 
Baseline outcome measure scores for each treatment group are presented in Table 
7.2. All outcome scores were reasonably comparable between the groups with 
exception of the MMAS-4, where there was a slight imbalance in the number of 
patients scoring 3 or 4 with no participants in the TAU group scoring either at 
baseline. 
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Table 7. 2 - Baseline Outcome Measure Scores 
Characteristics  
 
Active  
Treatment 
n=38 
TAU  
n=38 
P= 
MMAS-4 (%): -         - -          - 0.46 
1 9 (23.7) 8 (21.1) - 
2 24 (63.2) 30 (78.9) - 
3 3 (7.9) 0 (0.0) - 
4 2 (5.3) 0 (0.0) - 
PDQ-39: (Total score) 33.9 (13.3) 31 (14.2) 0.35 
PDQ-39: mobility 47.9 (25.9) 40.1 (28.1) 0.21 
PDQ-39: Activities of daily living 42.6 (23.0) 37.6 (23.6) 0.36 
PDQ-39: Emotional wellbeing 30.7 (19.8) 27.3 (20.0) 0.46 
PDQ-39: Stigma 21.7 (23.0) 23.2 (22.1) 0.76 
PDQ-39: Social support 14.3 (18.9) 13.1 (16.5) 0.76 
PDQ-39: Cognition 41.7 (18.9) 41.6 (21.3) 0.98 
PDQ-39: Communication 27.9 (19.7) 24.6 (20.7) 0.47 
PDQ-39: Body discomfort 45.0 (24.8) 39.9 (24.8) 0.38 
BMQ: Specific concerns 17.3 (4.2) 18.5 (3.7) 0.19 
BMQ: Specific necessity 19.8 (3.2) 19.5 (2.6) 0.63 
BMQ: General overuse 11.6 (2.4) 11.2 (2.4) 0.48 
BMQ: General harm 9.9 (1.9) 9.7 (1.7) 0.53 
MDS-UPDRS: part 1 3.9 (3.3) 3.9 (2.9) 0.97 
MDS-UPDRS: part 2 29.9 (11.8) 26.5 (10.0) 0.17 
MDS-UPDRS: part 4 3.8 (4.8) 2.8 (3.5) 0.34 
EQ-5D (utility) 0.6 
 
n=25 
(0.3) 0.6 
 
n=23 
(0.2) 
 
0.47 
CDS (total) 22.5 (12.6) 21.1 (13.0) 0.90 
BMQ Overuse (Carers) 12.1 (2.7) 12 (2.6) 0.89 
BMQ Harm (Carers) 9.1 (2.1) 9.7 (2.6) 0.79 
 
Means & s.d. unless stated otherwise; MMAS-4: Morisky Medication Adherence 
Scale; PDQ-39: Parkinson’s disease Questionnaire-39; BMQ: Beliefs about 
Medication Questionnaire; MDS-UPDRS: Movement Disorders Society – Unified 
Parkinson’s Disease Rating Scale 
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7.4 Efficacy Analyses 
7.4.1 Primary Outcomes 
Medication Adherence (MMAS-4): 
Week-12 primary analysis showed that 60.5% of the active treatment group 
improved in medication adherence from baseline compared to only 15.8% in the 
TAU group, with those in the active treatment group having more than 8 times the 
odds of decreasing their MMAS-4 score than those in the TAU group (Odds Ratio 
[OR] 8.2; 95% confidence interval [CI] 2.8, 24.3; p<0.001). Week-12 analysis 
revealed the NNT was 2.2, indicating that for every 2.2 patients treated with AT 1 
more would experience a decrease in their MMAS-4 score than if treated with TAU 
alone (95% CI: 1.6, 3.9) (Table 7.3a/b).  
 
Separate analysis from baseline to week-7 (directly post intervention) showed that 
64.8% of the active treatment group improved in medication adherence compared 
to 26.3% in the TAU group, with those in the active treatment group having more 
than 6 times the odds of decreasing their MMAS-4 score than those in the TAU 
group (OR 6.1; 95% CI: 2.2, 16.4; p<0.001). Week-7 analysis revealed the NNT 
was 2.4 (95% CI: 1.6, 4.6) (Table 7.4a/b). 
 
 Quality of Life (PDQ-39): 
The PDQ-39 improved from 33.9 at baseline to 27.1 at week-12 follow-up (-6.8) in 
the active treatment group, but worsened from 31.0 to 33.3 (+2.3) in the TAU 
group. This between group difference was statistically significant (-9.0; 95% CI: -
12.2, -5.8; p<0.001). 
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The PDQ-39 also improved from 33.9 to 30.1 at week-7 follow-up (-3.8) in the 
active treatment group, but worsened from 31.0 to 31.5 (+0.5) in the TAU group. 
This between group difference was also statistically significant (-4.2; 95% CI: -7.2, 
-1.3; p=0.004).  
 
Separate analyses from baseline to week-12 follow-up for the eight domains of the 
PDQ-39 showed that participants in the active treatment group significantly 
improved in mobility (-10.9; 95% CI: -16.0, -5.9; p<0.001), activities of daily 
living (-13.2; 95% CI: -19.4, -7.0; p<0.001), emotional wellbeing (-5.4; 95% CI: -
10.0, -0.9; p=0.020), cognition (-9.9; 95% CI: -16.1, -3.9; p=0.002), 
communication (-8.5; 95% CI: -14.4, -2.6; p=0.005) and body discomfort (-13.2; 
95% CI: -22.1, -4.3; p=0.004) compared to participants in the TAU group. 
 
7.4.2 Sensitivity Analysis 
As stated above, the active treatment group had a slight imbalance towards higher 
MMAS-4 scores compared to the TAU group at baseline (5 active treatment group 
patients scored >2 compared to no controls). Due to the large magnitude of effect 
observed in the MMAS-4 between the two treatment groups, I did not believe that 
this small between group imbalance was sufficient to significantly confound the 
results. However, as this may have resulted in a greater potential for change in the 
active treatment group, I decided to conduct a sensitivity analysis by removing 
these five patients. The findings showed that whilst the odds ratios are slightly 
smaller for both week-7 (OR 5.6; 95% CI: 2.0, 15.6) and week-12 (OR 7.2; 95% 
CI: 2.4, 22.0) analyses, a highly significant effect (P<0.002) was still observed. 
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7.4.3 Secondary Outcomes 
For secondary outcomes, the BMQ (general harm domain) improved from 9.9 at 
baseline to 9.1 (-0.8) at week-12 follow-up in the active treatment group, but 
worsened from 9.7 to 9.9 (+0.2) in the TAU group. This between group difference 
was statistically significant (-1.0; 95% CI: -1.9, -0.2; p=0.019). There was no 
statistically significant difference between the groups from baseline to week-12 
follow-up for the BMQ general overuse, specific concern and specific necessity 
domains. Only the MDS-UPDRS part II (motor experiences of daily living) 
differed significantly between the groups from baseline to week-12 follow-up (-4.8; 
95% CI: -8.1, -1.4; p=0.006), with the active treatment group improving from 29.9 
to 28.3 (-1.6) compared to the TAU group who worsened from 26.5 to 29.7 (+3.2). 
There was no statistically significant difference between the groups from baseline 
to week-12 follow-up in the EQ-5D or either of the two spouse/carer outcomes (i.e. 
BMQ and CDS). 
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Table 7. 3a - Adjusted Outcomes (Baseline to Week-12 Follow-up) 
Outcome Measure 
 
Active Treatment 
n=38 (24 carers) 
TAU  
n=38 (22 carers) 
Adjusted for Carer 
 
  
 N (%) N (%) Odds ratio (95% CI) P-value NNT 95% NNT 
MMAS-4 no change or increase 15 (39.5) 32      (84.2)      
MMAS-4 decrease 23 (60.5) 6 (15.8) 8.2 (2.8 - 24.3) <0.001 2.2 (1.6 - 3.9) 
          
 mean (s.d.) mean (s.d.) difference (95% CI) P-value   
PDQ-39: (Total score) -6.8 (6.4) 2.3 (7.4) -9.0 (-12.2, -5.8) <0.001   
PDQ-39: mobility -8.4 (12.7) 2.5 (8.9) -10.9 (-16.0, -5.9) <0.001   
PDQ-39: Activities of daily living -8.7 (11.5) 4.6 (15.1) -13.2 (-19.4, -7.0) <0.001   
PDQ-39: Emotional wellbeing -5.3 (9.9) 0.2 (9.9) -5.4 (-10.0, -0.9) 0.020   
PDQ-39: Stigma -6.1 (13.3) -0.6 (13.9) -5.4 (-11.4, 0.7) 0.080   
PDQ-39: Social support -4.7 (12.4) -1.8 (9.2) -2.8 (-7.8, 2.2) 0.267   
PDQ-39: Cognition -4.1 (14.0) 5.9 (12.6) -9.9 (-16.1, -3.9) 0.002   
PDQ-39: Communication -5.3 (13.5) 3.3 (12.1) -8.5 (-14.4, -2.6) 0.005   
PDQ-39: Body discomfort -11.3 (19.9) 1.2 (19.0) -13.2 (-22.1, -4.3) 0.004   
BMQ: Specific concerns -1.0 (4.2) 0.03 (2.6) -1.1 (-2.6, 0.5) 0.179   
BMQ: Specific necessity 0.4 (3.4) 0.3 (2.1) 0.2 (-1.1, 1.4) 0.779   
BMQ: General overuse -0.6 (2.7) 0.4 (1.8) -0.9 (-1.9, 0.1) 0.079   
BMQ: General harm -0.8 (2.2) 0.2 (1.4) -1.0 (-1.9, -0.2) 0.019   
MDS-UPDRS: part 1 -1.0 (2.7) 0.1 (2.2) -1.1 (-2.2, 0.02) 0.054   
MDS-UPDRS: part 2 -1.6 (8.8) 3.2 (5.4) -4.8 (-8.1, -1.4) 0.006   
MDS-UPDRS: part 4 -0.3 (3.6) -0.1 (2.6) -0.2 (-1.6, 1.2) 0.787   
EQ-5D (utility): 0.04 0.3 -0.03 0.3 0.07 (-0.1, 0.2) 0.055   
CDS (total): median (IQR) -2.0 (4.5) 0.5 (5.0)   0.064   
BMQ Overuse: median (IQR) -1.0 (2.0) -0.5 (2.0)   0.250   
BMQ Harm: median (IQR) -1.0 (1.0) 0.0 (0.0)   0.181   
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Table 7. 4b - Unadjusted Outcomes (Baseline to Week-12 Follow-up) 
Outcome Measure 
 
Active Treatment 
n=38 (24 carers) 
TAU  
n=38 (22 carers) 
Unadjusted for Carer 
 
  
 N (%) N (%) Odds ratio (95% CI) P-value NNT 95% NNT 
MMAS-4 no change or increase 15 (39.5) 32      (84.2)      
MMAS-4 decrease 23 (60.5) 6 (15.8) 8.2 (2.8 - 24.3) <0.001 2.2 (1.6 - 4.0) 
          
 mean (s.d.) mean (s.d.) difference (95% CI) P-value   
PDQ-39: (Total score) -6.8 (6.4) 2.3 (7.4) -9.1 (-12.2, -5.9) <0.001   
PDQ-39: mobility -8.4 (12.7) 2.5 (8.9) -10.9 (-16.0, -5.9) <0.001   
PDQ-39: Activities of daily living -8.7 (11.5) 4.6 (15.1) -13.3 (-19.4, -7.1) <0.001   
PDQ-39: Emotional wellbeing -5.3 (9.9) 0.2 (9.9) -5.5 (-10.0, -0.9) 0.020   
PDQ-39: Stigma -6.1 (13.3) -0.6 (13.9) -5.6 (-11.8, 0.6) 0.080   
PDQ-39: Social support -4.7 (12.4) -1.8 (9.2) -2.9 (-7.9, 2.2) 0.256   
PDQ-39: Cognition -4.1 (14.0) 5.9 (12.6) -10.0 (-16.1, -3.9) 0.002   
PDQ-39: Communication -5.3 (13.5) 3.3 (12.1) -8.6 (-14.4, -2.7) 0.005   
PDQ-39: Body discomfort -11.3 (19.9) 1.2 (19.0) -13.1 (-22.0, -4.2) 0.004   
BMQ: Specific concerns -1.0 (4.2) 0.03 (2.6) -1.03 (-2.6, 0.6) 0.202   
BMQ: Specific necessity 0.4 (3.4) 0.3 (2.1) 0.13 (-1.2, 1.4) 0.841   
BMQ: General overuse -0.6 (2.7) 0.4 (1.8) -0.9 (-2.0, 0.1) 0.081   
BMQ: General harm -0.8 (2.2) 0.2 (1.4) -1.03 (-1.9, -0.2) 0.018   
MDS-UPDRS: part 1 -1.0 (2.7) 0.1 (2.2) -1.1 (-2.2, 0.007) 0.054   
MDS-UPDRS: part 2 -1.6 (8.8) 3.2 (5.4) -4.8 (-8.1, -1.5) 0.005   
MDS-UPDRS: part 4 -0.3 (3.6) -0.1 (2.6) -0.2 (-1.6, 1.2) 0.005   
EQ-5D (utility): 0.04 0.3 -0.03 0.3 0.07 (-0.05, 0.2) 0.250   
CDS (total): median (IQR) -2.0 (4.5) 0.5 (5.0)   0.064   
BMQ Overuse: median (IQR) -1.0 (2.0) -0.5 (2.0)   0.250   
BMQ Harm: median (IQR) -1.0 (1.0) 0.0 (0.0)   0.181   
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Table 7. 5a - Adjusted Outcomes (Baseline to Week-7 Follow-up) 
Outcome Measure 
 
Active Treatment 
n=38 (24 carers) 
TAU  
n=38 (22 carers) 
Adjusted for Carer 
 
  
 N (%) N (%) Odds ratio (95% CI) P-value NNT 95% NNT 
MMAS-4 no change or increase 12 (31.6) 28      (73.7)      
MMAS-4 decrease 26 (64.8) 10 (26.3) 6.1 (2.3 - 16.4) <0.001 2.4 (1.6 - 4.6) 
          
 mean (s.d.) mean (s.d.) difference (95% CI) P-value   
PDQ-39: (Total score) -3.8 (7.3) 0.5 (5.7) -4.3 (-7.2, -1.3) 0.004   
PDQ-39: mobility -5.7 (10.8) 1.2 (9.4) -6.8 (-11.5, -2.2) 0.005   
PDQ-39: Activities of daily living -7.1 (14.0) 2.1 (14.6) -9.1 (-15.7, -2.5) 0.007   
PDQ-39: Emotional wellbeing -4.5 (9.9) 0.7 (8.5) -5. (-9.4, -0.9) 0.019   
PDQ-39: Stigma -4.7 (13.4) -1.3 (10.3) -3.2 (-8.4,  2.1) 0.232   
PDQ-39: Social support -0.6 (15.8) -1.6 (7.7) 1.1 (-4.6, 6.8) 0.701   
PDQ-39: Cognition -1.2 (15.8) 3.2 (10.1) -4.4 (-10.5, 1.7) 0.159   
PDQ-39: Communication -0.9 (12.4) 0.9 (13.5) -1.8 (-7.8, 4.2) 0.548   
PDQ-39: Body discomfort -5.9 (15.8) -0.9 (19.2) -5.2 (-13.3, 2.8) 0.199   
BMQ: Specific concerns -0.3 (3.9) 4.9 (32.4) -5.4 (-15.9, 5.2) 0.313   
BMQ: Specific necessity 0.2 (2.7) 0.4 (2.2) -0.2 (-1.2, 0.9) 0.779   
BMQ: General overuse -0.4 (2.2) 0.2 (1.9) -0.5 (-1.5, 0.4) 0.276   
BMQ: General harm -0.6 (2.3) -0.2 (1.5) -0.4 (-1.3, 0.5) 0.361   
MDS-UPDRS: part 1 -1.2 (2.9) -0.3 (2.0) -0.8 (-1.9, 0.3) 0.154   
MDS-UPDRS: part 2 -1.6 (5.9) 1.7 (5.5) -3.4 (-5.9, - 0.7) 0.015   
MDS-UPDRS: part 4 -0.03 (3.3) -0.2 (2.7) 0.2 (-1.2, 1.5) 0.828   
EQ-5D (utility): 0.01 0.3 0.01 0.2 0.003 (-0.1, 0.1) 0.962   
CDS (total): median (IQR) -0.5 (6.5) 1.0 (7.0)   0.269   
BMQ Overuse: median (IQR) 0.0 (1.5) 0.0 (2.0)   0.354   
BMQ Harm: median (IQR) -0.5 (2.5) 0.0 (1.0)   0.637   
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Table 7. 6b - Unadjusted Outcomes (Baseline to Week-7 Follow-up) 
Outcome Measure 
 
Active Treatment 
n=38 (24 carers) 
TAU  
n=38 (22 carers) 
Unadjusted for Carer 
 
  
 N (%) N (%) Odds ratio (95% CI) P-value NNT 95% NNT 
MMAS-4 no change or increase 12 (31.6) 28      (73.7)      
MMAS-4 decrease 26 (64.8) 10 (26.3) 8.2 (2.8 - 24.2) <0.001 2.4 (1.6 - 4.6) 
          
 mean (s.d.) mean (s.d.) difference (95% CI) P-value   
PDQ-39: (Total score) -3.8 (7.3) 0.5 (5.7) -4.3 (-7.3, -1.3) 0.006   
PDQ-39: mobility -5.7 (10.8) 1.2 (9.4) -6.8 (-11.5, -2.2) 0.004   
PDQ-39: Activities of daily living -7.1 (14.0) 2.1 (14.6) -9.2 (-15.7, -2.6) 0.007   
PDQ-39: Emotional wellbeing -4.5 (9.9) 0.7 (8.5) -5.2 (-9.4, -0.9) 0.017   
PDQ-39: Stigma -4.7 (13.4) -1.3 (10.3) -3.4 (-8.8,  2.1) 0.224   
PDQ-39: Social support -0.6 (15.8) -1.6 (7.7) 1.1 (-4.6, 6.8) 0.706   
PDQ-39: Cognition -1.2 (15.8) 3.2 (10.1) -4.4 (-10.4, 1.7) 0.155   
PDQ-39: Communication -0.9 (12.4) 0.9 (13.5) -1.8 (-7.7, 4.1) 0.543   
PDQ-39: Body discomfort -5.9 (15.8) -0.9 (19.2) -5.1 (-13.1, 2.9) 0.209   
BMQ: Specific concerns -0.3 (3.9) 4.9 (32.4) -5.2 (-15.8, 5.3) 0.326   
BMQ: Specific necessity 0.2 (2.7) 0.4 (2.2) -0.2 (-1.3, 0.9) 0.742   
BMQ: General overuse -0.4 (2.2) 0.2 (1.9) -0.5 (-1.5, 0.4) 0.281   
BMQ: General harm -0.6 (2.3) -0.2 (1.5) -0.4 (-1.3, 0.5) 0.355   
MDS-UPDRS: part 1 -1.2 (2.9) -0.3 (2.0) -0.8 (-2.0, 0.3) 0.147   
MDS-UPDRS: part 2 -1.6 (5.9) 1.7 (5.5) -3.3 (-5.9, - 0.7) 0.015   
MDS-UPDRS: part 4 -0.03 (3.3) -0.2 (2.7) 0.2 (-1.2, 1.5) 0.818   
EQ-5D (utility): 0.01 0.3 0.01 0.2 0.003 (-0.1, 0.1) 0.953   
CDS (total): median (IQR) -0.5 (6.5) 1.0 (7.0)   0.269   
BMQ Overuse: median (IQR) 0.0 (1.5) 0.0 (2.0)   0.354   
BMQ Harm: median (IQR) -0.5 (2.5) 0.0 (1.0)   0.637   
214 
 
7.5 Sub-group Analyses 
For the analyses testing for an interaction between the subgroup factors 
(spouse/carer or no spouse/carer, baseline HADS and baseline MoCA scores) and 
the treatment effect of AT, only a score of <8 on the HADS anxiety domain 
(indicating no anxiety) compared to ≥8 (indicating symptoms of anxiety) predicted 
greater medication adherence. Those in the active treatment group had more than 
21 times the odds of decreasing their MMAS-4 than participants in the TAU group  
(OR 21.1; 95% CI: 4.1, 107.6; p=0.05). There was no statistically significant 
interaction of either subgroup factor on PDQ-39 scores (Table 7.5). 
 
 
Table 7. 7 - Sub-group Interactions with Primary Outcomes 
Outcome 
Measure 
Subgroup Odds 
ratio 
(95% CI) Interaction  
p-value 
MMAS-4 change Carer 12.4 (2.9, 53.6) 
0.35 
 No carer 4.3 (0.8, 22.9)  
 HADSA (0 – 7) 21.1 (4.1, 107.6) 
0.05 
 HADSA (8 +) 1.4 (0.2, 9.8) 
 HADSD (0 – 7) 6.9 (1.9, 25.1) 
0.36 
 HADSD (8 +) 34.1 (2.0, 581.5) 
 MoCA (0 – 25) 7.6 (0.7, 79.5) 
0.92  MoCA (26 +) 9.1 (2.3, 36.1) 
 
PDQ-39 change Subgroup Mean 
difference 
(95% CI) Interaction  
p-value 
 Carer -10.4 (-15.0, -5.9) 
0.24 
 No carer -6.5 (-10.15, -2.8) 
 HADSA (0 – 7) -8.4 (-11.74, -5.0) 
0.40 
 HADSA (8 +) -11.7 (-20.47, -2.9) 
 HADSD (0 – 7) -9.5 (-12.4, -6.6) 
0.92 
 HADSD (8 +) -9.0 (-20.13, 2.1) 
 MoCA (0 – 25) -9.6 (-15.8, -3.4) 
0.89  MoCA (26 +) -9.2 (-12.82, -5.5) 
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7.6 Correlation Analyses 
7.6.1 MMAS-4 & Importance, Confidence and Satisfaction  
At baseline each patient participant in the active treatment group provided a score 
for three separate ordinal scales (i.e. importance of, confidence with, and 
satisfaction with medication). These scales were completed as part of the AT 
assessment and were answered based upon how participants perceived their anti-
parkinsonian medication. All three scales were scored from 0-10 and were 
completed formally at baseline, week-7 and week-12 follow-up. Table 7.6 shows 
the mean values for each three domains for participants in the intervention group at 
each of the three assessment points (baseline, week-7 and week-12). 
 
Table 7.6 - Importance, Confidence and Satisfaction Scores 
Domain n = 38 
 Baseline Week-7 Week-12 
 Mean  Mean  Mean 
Importance 8.5 9.2 9.3 
Confidence 6.5 8.2 8.2 
Satisfaction 7.0 7.7 7.7 
 
 
To determine whether a change in MMAS-4 score was associated with a change in 
score for either of the three domains from baseline to week-12 follow-up, a 
Spearman’s rank correlation coefficient was calculated. Additionally, I used the 
Spearman’s rank test to determine whether a change in MMAS-4 from baseline to 
week-12 follow-up was associated with baseline scores for importance, confidence 
and satisfaction. Table 7.7 shows the differences in MMAS-4 scores from baseline 
to week-12 follow-up. Negative scores imply a higher score at baseline. For 
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example, a change of -2 indicates a 2 point reduction in MMAS-4. This could be 
from 4 to 2, from 3 to 1, or from 2 to 0. 
 
Table 7. 7 - Difference in MMAS-4 from Baseline to Week-12 
Change in  
MMAS-4 
Number of participants 
(total n=38) 
Percentage of 
participants 
-3 2 5.3 
-2 6 15.8 
-1 15 39.5 
0 14 36.8 
1 1 2.6 
 
The analysis revealed that a change in MMAS-4 score from baseline to week-12 
follow-up was not correlated with a change in importance (Spearman’s:  r= -0.14, 
p=0.39); change in confidence (r = 0.15, p=0.37) or change in satisfaction (r = -
0.11, p=0.51) from baseline to week-12 follow-up. Similarly, there was no 
statistically significant association between the change in MMAS-4 scores from 
baseline to week-12 follow-up and baseline scores for importance (r = 0.01, 
p=0.95); confidence (r = -0.02, p=0.91) and satisfaction (r= -0.1, p=0.55). 
 
7.6.2 MMAS-4 and MoCA Overall and Sub-domain Scores 
Additionally, I used the Spearman’s rank correlation coefficient to determine 
whether the overall score on the MoCA and the seven sub-domains 
(visuospatial/executive function, attention, naming, language, abstraction, delayed 
recall and orientation) were associated with poor adherence at baseline, as 
determined by the MMAS-4. Table 7.8 presents the Spearman’s rank coefficients 
between MMAS-4 scores at baseline and the MoCA total score and the individual 
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sub-domains. The findings revealed there was no significant association between 
baseline MMAS-4 scores and the MoCA total score or either sub-domain score. 
 
Table 7. 8 - Association between MMAS-4 and MoCA at Baseline 
MoCA total and sub-domain Correlation coefficient  p-value 
Overall score -0.03 0.82 
Visuospatial/executive function -0.10 0.38 
Attention -0.15 0.19 
naming -0.06 0.63 
Language 0.19 0.10 
Abstraction 0.12 0.29 
Delayed Recall 0.07 0.52 
Orientation -0.08 0.51 
 
7.7 Serious Adverse Events 
Throughout the duration of the trial there was one serious adverse event. One 
participant from the active treatment group was admitted to hospital resulting from 
general deterioration. The admission was non-parkinsonian related and was not 
thought to be associated with participation in the clinical trial. The TSC was 
informed and NNUH’s Standard Operating Procedures for reporting of AE’s was 
adhered to. This participant had been allocated to the active treatment group and 
had completed all AT sessions prior to the hospital admission. The patient agreed 
to complete week-12 outcome measures as an inpatient. 
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7.8 Cost of Adherence Therapy in PD 
The average time of each AT session was around 40 minutes (range 30–60). Based 
on an NHS mid-range band seven salary (£35,536/$54,121) (the typical salary of a 
PD nurse specialist), a 40 minute session of AT is anticipated to cost 
(£12.21/$18.60). Therefore, to deliver the seven sessions of AT this would cost 
around (£85/$129.46) per patient.  
 
The average time to travel to the trial participants in this study was around 30 
minutes in each direction. Using this average time this would cost around £128 
($194.9) to complete the seven visits. When added to the cost of time spent 
conducting the AT sessions, this totals £213 ($324.40) per patient. 
 
The cost of fuel also needs to be acknowledged. Based on the average distance 
travelled for a return journey in this study (44 miles) and the typical claim of 45p 
per mile travelled, for seven patient visits this would cost around £139 ($211.70). 
 
Therefore, the total cost of seven AT sessions when delivered in a patient’s own 
home by a band 7 PD nurse specialist is estimated to be around £352 ($536.10) per 
patient. 
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7.9 Summary of Results 
The trial results demonstrate that a seven week programme of AT plus TAU 
significantly improved medication adherence and QoL compared to TAU alone in 
medication non-adherent patients with PD.  
 
Improvements were shown in the PDQ-39 overall score and in a range of sub-
domains. The improvement in the PDQ-39 overall score was both statistically 
significant and clinically relevant; that is, the differences from baseline to week-12 
follow-up were greater than the minimal clinically important difference reported in 
a PD sample (Peto et al., 2001). 
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8.1 Introduction 
In Chapter 7, I presented the findings of a parallel-group RCT investigating the 
efficacy of a novel intervention, Adherence Therapy, for improving medication 
adherence and QoL in people with PD. I hypothesised that there would be a 
statistically significant difference in medication adherence and QoL in people with 
PD who received a seven week programme of CAAT-PARK in addition to TAU, 
compared to those who received TAU only. 
 
During the recruitment period (September 2011 to January 2013) a total of 76 PD 
patients were randomly assigned to the active treatment group (n=38) or TAU 
(n=38). No patients withdrew from the trial. Twenty-five of the PD patients in the 
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active treatment group were randomised with a spouse/carer compared to 23 in the 
TAU group. One spouse/carer from each group did not complete the study.  
 
Study measurements were completed at baseline, directly post intervention (week-
7) and at week-12, the primary analysis point. Primary outcomes were a change 
from baseline to week-12 follow-up in medication adherence (MMAS-4) and QoL 
(PDQ-39). Secondary outcomes were a change from baseline to week-12 follow-up 
in the MDS-UPDRS (parts I, II, IV), BMQ and the EQ-5D. Spouse/carer outcomes 
were a change in BMQ and CDS. 
 
For primary outcomes, week-12 analysis showed that the active treatment group 
significantly improved in medication adherence compared to participants in the 
TAU group. Similarly, participants in the active treatment group showed a 
statistically significant improvement in QoL compared to those in the TAU group.  
 
This chapter discusses the findings of the trial within the context of related 
literature. The study strengths and limitations are highlighted and the clinical and 
research implications of the findings are discussed. 
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8.2 Discussion of Results 
8.2.1 Efficacy Analyses (Medication Adherence) 
The findings of the RCT presented in Chapter 7 confirm the usefulness of AT for 
improving medication adherence and clinical outcomes. These findings replicate 
those shown in other chronic disease areas. An RCT of AT in patients with 
hypertension showed that better adherence post intervention significantly lowered 
blood pressure (Alhalaiqa et al., 2011). When AT was investigated in patients with 
schizophrenia, psychotic symptoms and attitudes towards medication significantly 
improved (Maneesakorn et al., 2007).  
 
In both of these studies, shifting patients’ beliefs about medication was suggested 
to result in the improved adherence behaviours observed. However, in the RCT 
presented in this thesis only a small improvement in beliefs was detected. This may 
suggest that beliefs and concerns about treatment play a less significant role as a 
factor contributing to medication non-adherence in people with PD.  
 
Before this theory is dismissed however, the statistically significant difference 
between the groups in the BMQ general harm domain must not be ignored. This 
finding may suggest that beliefs about medication use in general are an important 
factor for enhancing adherence behaviours in PD. One of the BMQ general harm 
domain items relates to whether patients feel people should intermittently stop their 
treatment. It is possible therefore that the active treatment group participants scored 
more positively on this item as a result of improved understanding and acceptance 
of the need for treatment in PD (discussed later in this thesis). This may provide 
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some support for the importance of enhancing beliefs about medication in PD and 
may explain, at least in part, the improved rates of adherence identified in this trial.  
 
It is important to note however, that considering many trial participants did not 
have negative beliefs at baseline regarding the necessity of PD specific medicines 
(BMQ specific necessity domain), it is unlikely that the statistically significant 
improvement in the general harm domain accounted for the improved rates of 
adherence in this trial. Alternative explanations may however explain such 
findings.    
 
For example, most PD patients in the active treatment group missed or miss-timed 
doses due to forgetfulness and/or poor drug management. This was especially 
prevalent in patients where cognitive impairment and/or treatment regimen 
complexity was apparent. It is known that PD can affect a variety of cognitive 
processes such as attention, planning and problem-solving. Therefore, it is possible 
that such cognitive deficits may have led to difficulties in drug management in 
some individuals with PD in this study. This may then have resulted in poor 
adherence (Green et al., 2002).  
 
Furthermore, in PD patients may be prescribed intricate drug regimens to manage 
symptoms and maximise ‘On’ time. This can soon become a polypharmacy which 
can complicate treatment (Grosset et al., 2005a). Problem solving interventions are 
believed to work by assisting individuals in developing meaningful strategies to 
help themselves, such as findings methods to improve adherence behaviours (Gray, 
2011). Therefore, using AT techniques to facilitate problem solving strategies 
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within a patient’s own context may explain some of the observed improvements in 
adherence in PD.  
 
Importantly however, unlike the problem solving strategies adopted in usual CBT 
approaches where self-generation of ideas is greatly emphasised, the known 
deficits in problem solving ability in PD patients may mean that self-generated 
ideas might not always be a realistic goal. It is worth noting that many patients in 
the active treatment group often required several prompts during the problem 
solving sessions to help facilitate the generation of useful strategies. Therefore, in 
PD problem solving is likely to be more effective and relevant if assisted by a 
therapist and/or spouse/carer, as was the case in the current study. This should 
therefore be acknowledged when addressing sub-optimal adherence in PD where 
poor problem solving abilities are thought to be contributory. 
 
The AT assessment (a structured interview) showed ambivalence towards 
medication, symptoms of depression, denial concerning the indication for treatment 
and poor understanding of basic anti-parkinsonian pharmacodynamics were all 
reasons for non-adherence to medication in the active treatment group sample. As 
these factors are consistent with the systematic review findings presented in 
Chapter 3 and with proposed reasons for poor adherence described in the existing 
literature (Bainbridge and Ruscin, 2009, Grosset, 2010), I incorporated my greater 
understanding of these issues into the AT intervention.  
 
In this trial many patients often miss-timed drug doses as they were unaware of the 
reasons for medicating according to prescribed time intervals. Facilitating a greater 
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appreciation of pharmacodynamics, by visual reference to the cumulative effect of 
erratic dosing (using a simple graphical representation of how fluctuating 
dopamine concentrations relates to symptom control), greatly enhanced adherence 
behaviours as patients could visualise how their pill taking practices may affect 
their unique symptom control. 
 
8.2.2 Efficacy Analyses (QoL) 
In addition to improving medication adherence, AT had a statistically significant 
effect on QoL including a range of PDQ-39 sub-domains. Due to the relatively 
small sample and the known variability in PD symptoms, this finding was not 
expected. Although I did not assess MDS-UPDRS motor function (part 3) as part 
of the clinical trial, the mobility sub-domain did improve on the PDQ-39. As 
rigidity and bradykinesia are sensitive to anti-parkinsonian medication (Schapira et 
al., 2009b), and therefore are arguably most likely to respond to optimal treatment, 
it is reasonable to suggest that the improved adherence observed may account for 
the identified improvement in mobility. This assumes a linear mechanism of action 
for AT; that is, improving medication adherence improves symptoms which then 
impacts positively on QoL. This may not however represent the only mechanism of 
action of AT, as I will discuss later in this thesis.  
 
Surprisingly, cognition significantly improved according to the PDQ-39. This 
result was also surprising. Although major cognitive dysfunction is recognised as 
being refractory to dopamine replacement, bradyphrenia (slowed thinking) is 
however levodopa responsive with patients often reporting regaining their mental 
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edge when sufficiently medicated. Researchers have shown improvement in 
neuropsychological tests following optimisation of dopamine replacement therapy 
in patients with PD (Kulisevsky et al., 2000, Molloy et al., 2006). As the trial 
participants were not substantially cognitively impaired, it may be possible 
therefore that the identified improvements in cognition result from participants 
feeling mentally more alert due to improved medication adherence. This however 
is speculative and requires specific investigation. 
 
8.2.3 Sub-group Analyses 
The sub-group analyses testing for an interaction between the presence of a 
spouse/carer, baseline depression and baseline MoCA scores and the treatment 
effect of AT were all non-significant in this study. It is worth noting that these 
analyses, as with all sub-group analyses, used small samples. Such analyses are 
therefore likely to be underpowered to detect a statistically significant effect. For 
this reason these non-significant associations were expected. However, as the lack 
of a spouse/carer, symptoms of depression and the presence of cognitive 
impairment have been found to be associated with non-adherence by previous 
researchers (as shown in the findings of Chapter 3), greater statistical power may 
show an interaction between these factors and the treatment effect of AT. A larger 
RCT that is specifically powered for these sub-group analyses is required to 
determine whether a significant interaction exists. 
 
Unlike symptoms of depression and poor cognition, a score of <8 on the HADS 
anxiety scale (no symptoms of anxiety) compared to ≥8 (indicating symptoms of 
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anxiety) predicted greater medication adherence, with those in the active treatment 
group found to have significantly greater odds of improving their MMAS-4 score. 
While symptoms of anxiety appear to be associated with poor adherence in PD (as 
shown in Chapter 3), due to the underpowered sample and considering that all 
other interaction analyses were non-significant, this finding was surprising.  
 
Although depression is the most common neuropsychiatric disturbance in PD 
(Bainbridge and Ruscin, 2009), anxiety is also considerably prevalent; 25-40% of 
people with PD are reported to experience symptoms of anxiety (Simuni and 
Fernandez, 2013). Researchers have shown anxiety to be one of the most highly 
reported non-motor symptoms affecting QoL (Chaudhuri and Martinez-Martin, 
2008, Barone et al., 2009, Martinez-Martin et al., 2011). Furthermore, anxiety has 
been associated with poor medication adherence in the general elderly population, 
in which PD is most prevalent (Coons et al., 1994). Considering that AT was aimed 
specifically at patients’ unique reasons for non-adherence, it is reasonable to 
suggest that patients may have felt less anxious as a result of the individualised 
intervention. As anxiety is associated with QoL in PD, improving the symptoms 
may also partly explain the improvements in QoL observed in this trial.  
 
It is important to note that the HADS was only completed at baseline in this study. 
Future investigations of AT in PD should therefore ensure that both symptoms of 
anxiety and depression are specifically assessed at follow-up as a formal study 
outcome. 
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8.3 Correlation Analyses 
8.3.1 Correlation: MMAS-4 & Importance, Confidence and Satisfaction 
Correlation analyses revealed that a change in MMAS-4 scores from baseline to 
week-12 follow-up was not statistically associated with a change in scores for 
either ‘importance’, ‘confidence’ or ‘satisfaction’ with medication. Additionally, 
analyses showed there was no statistically significant correlation between a change 
in MMAS-4 scores from baseline to week-12 follow-up and baseline scores for 
‘importance’, ‘confidence’ or ‘satisfaction’ with medication. These findings were 
mostly not surprising and several factors may offer explanation for the non-
significant associations. 
 
Firstly, as reported in Chapter 7, beliefs and concerns about medication did not 
change substantially in this trial. Only beliefs about the use of medication in 
general and the degree to which they are perceived as fundamentally harmful 
(BMQ general harm domain) showed a statistically significant difference between 
the groups. Although the AT assessment identified that some participants held 
negative beliefs concerning the use of medication, mainly PD patients in this study 
had positive attitudes towards treatment. For this reason the ‘importance of 
medication’ scale was already scored highly by participants at baseline. Therefore, 
even where medication adherence did improve from baseline to follow-up, the 
inability of patients to score sufficiently higher on the ‘importance of medication’ 
scale may offer an explanation for the non-significant finding in this analysis. 
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The ‘satisfaction with medication’ scale was also scored highly by almost all active 
treatment group participants at baseline. Once again, the inability for a large degree 
of change and the small numbers involved in the analysis (n=38) suggest that it is 
not surprising the result was statistically insignificant.  
 
Furthermore, although poor understanding of the indication for treatment may be a 
factor for non-adherence in PD, whether a relationship between non-adherence and 
low satisfaction with treatment exists is unknown. Whilst people with PD may be 
dissatisfied with medication perhaps because of a perceived lack of efficacy or due 
to the development of motor complications (resulting in them becoming non-
adherent to medication), this was not supported in the current study. Therefore, 
when taking account of these factors, the lack of association between satisfaction 
with medication and a change in adherence was not unexpected. 
 
Although it was not surprising that a change in MMAS-4 score was not associated 
with a change in importance of and satisfaction with medication, a significant 
association between a change in MMAS-4 and the ‘confidence in taking 
medication’ scale was expected. As stated above, many patients reported that 
forgetfulness and poor drug management led to them being non-adherent. 
Furthermore, issues with problem solving or feeling ambivalent towards 
medication were apparent in several trial participants. Considering that patients in 
the active treatment group described feeling more confident after receiving AT 
(discussed later in this thesis), it is surprising that this was not reflected in the 
association analysis. The small (n=38), underpowered sample may be a likely 
explanation for this. 
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An alternative explanation must also be acknowledged however. As there was a 
significant effect of AT on QoL, it may be that the enhanced feelings of confidence 
reported in the post intervention interviews (discussed later) relate specifically to 
an increased confidence in daily life, and not specifically to confidence in using 
medication. This may explain the discrepancy between participants verbally 
reporting increased confidence and the non-significant association between 
‘confidence in taking medication’ and change in adherence. 
 
This offers an important insight into a possible mechanism for the improved QoL 
observed in this trial. Specifically, this suggests that QoL may be improved in PD 
after receiving AT without the need for improvements in confidence using/taking 
medication. The linear mechanism of action of AT proposes that improving 
medication use/adherence is a pre-requisite to improving clinical outcomes. 
However, this theory suggests that an alternative mechanism of AT may exist; that 
is, improving confidence in general, and not specifically confidence using 
medication, may be an effective method for improving QoL. This will be discussed 
in greater detail later in this thesis. 
 
The analysis investigating a possible association between a change in MMAS-4 
scores from baseline to week-12 follow-up and baseline scores for ‘importance’, 
‘confidence’ and satisfaction’ was also not statistically significant. Again, due to 
the small sample (n=38), this was expected.  
 
When planning this analysis there was no indication that low scores for either 
‘importance’, ‘confidence’ or ‘satisfaction’ would in fact be associated with little 
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or no improvement in adherence. Likewise, there was no indication that higher 
scores for these three domains would be associated with greater improvements in 
medication adherence. Despite this, it may be possible that some patients with low 
scores are less likely to show improvement in adherence.  
 
For example, it is acknowledged that depression is associated with poor medication 
adherence in PD (as discussed in Chapter 3). As a consequence, it is reasonable to 
argue that depressed patients may potentially have lower baseline scores for 
‘importance’, ‘confidence’ and satisfaction’ with medication than their non-
depressed counterparts. Therefore, in such patients it is possible that low scores at 
baseline may result in patients being less likely to improve in adherence when 
receiving AT, due to underlying symptoms of depression. This theory however is 
largely theoretical, especially when considering that the interaction analysis 
discussed earlier between baseline HADS scores and the effectiveness of AT was 
non-significant for depression. A greater powered study with a depressed PD 
sample would be required to establish whether depression is associated with lower 
baseline scores for ‘importance’, ‘confidence’ and satisfaction’ and whether this 
then correlated with little or no change in adherence behaviour. 
 
8.3.2 MMAS-4 and MoCA Overall & Sub-domain Scores 
Analyses revealed that neither the MoCA overall score nor any of the seven sub-
domains were associated with poor medication adherence at baseline (as 
determined by the MMAS-4). It is known that people with PD can suffer from a 
variety of cognitive deficits and researchers have found the MoCA to be sensitive 
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to the detection of cognitive dysfunction in PD (Zadikoff et al., 2008, Nazem et al., 
2009). However, to my knowledge the possible association between specific 
cognitive domains on the MoCA and medication non-adherence in PD has not been 
investigated previously.  
 
Due to the small numbers involved in this analysis the insignificant findings were 
not unexpected. Additionally, considering that adherence was determined using 
only the four item MMAS, detecting a correlation between cognitive dysfunction 
and poor adherence was not likely. Despite the non-significant findings, it is 
possible that certain cognitive deficits may be more likely to result in sub-optimal 
pill taking than others. For example, it is reasonable to suggest that patients who 
have particular problems with attention may be more likely to miss and/or miss-
time doses than a patient who performs less well on the naming and language 
domains. Therefore, a larger sample of cognitively impaired patients using a more 
sensitive adherence outcome could show that a poor score on certain domains on 
the MoCA may be prognostic of sub-optimal adherence. Such a finding may be 
clinical useful for identifying PD patients most likely to not adhere to treatment. 
 
8.4 Implications of the Trial Findings 
The beneficial effect of AT observed in this trial has an important clinical 
implication. Optimising adherence to anti-parkinsonian medication in PD is just as 
essential as optimising dosage. It is therefore critical to ensure that adherence is 
optimised before dose escalation is considered by clinicians. This highlights the 
233 
 
requirement to consider drug adherence when medications are reviewed in PD in 
both in-patient and out-patient settings. Furthermore, acknowledging the factors 
associated with medication non-adherence in PD may help clinicians to identify 
medication non-adherent patients in clinical settings.  
 
Adherence Therapy is a brief intervention that can be delivered by professionals 
with just a short training period. Ideally healthcare professionals should be able to 
facilitate optimal medication taking by utilising the principles of AT from 
diagnosis. This is especially important when considering that early PD is a 
potential risk factor for non-adherence, as was discussed previously in this thesis. 
 
Grosset and Grosset (2007) showed improvements in medication adherence after 
providing PD patients with didactic educational material. Whilst such approaches 
may be effective for some PD patients, as discussed earlier in Chapter 4, the 
diversity of factors associated with medication non-adherence means that people 
with PD may require a more patient focused intervention such as that described in 
this thesis. This is particularly likely to be necessary for those individuals where 
poor knowledge of PD and its treatment may not represent the main reason for their 
non-adherent behaviour.  
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8.5 Strengths and Limitations 
This clinical trial had several strengths. Firstly, the sample recruited was largely 
representative of the PD population. Trials of drug efficacy in PD often exclude 
patients due to older age (>65), greater disease severity and impaired cognition 
(Wheatley et al., 2002). I purposely did not exclude such patients and therefore the 
findings are generalisable for older patients in whom PD is prevalent.  
 
A further strength to this trial is that unlike many adherence interventions, AT was 
delivered in participants’ own homes. As a consequence, severely affected patients 
were able to participate that could not have done so if required to attend clinic.  
 
Furthermore, deficits in set-shifting (defined as the process of updating cognitive 
strategies for changing environments/tasks) are prevalent and are associated with 
poor problem solving abilities in PD (Cronin-Golomb et al., 1994). Therefore, it is 
possible that the delivery of AT in the familiar home environment, where set-
shifting can be minimised by focusing on specific tasks in the correct home 
context, may have helped patients to problem solve more effectively. Delivering 
AT in this manner may therefore enable patients to develop meaningful strategies 
to facilitate improved adherence behaviours. This helps to emphasise the 
importance of administering adherence promoting interventions in the patient’s 
own home, especially when poor problem solving ability is suspected. 
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The use of the self-report PDQ-39 as a primary outcome was a significant strength 
in this study. As described earlier in this thesis, this allowed clinical improvement 
to be quantified on a scale relevant to patients.  
 
Finally, delivery of AT within the home environment resulted in patients being 
highly committed. This helps to emphasise the acceptability of and engagement 
with the AT intervention. This will be discussed in greater detail later in this thesis. 
 
Despite the strengths of this study, there are also some limitations. Firstly, a longer 
follow-up period would have been desirable to evaluate whether improved 
adherence was sustained over time. Furthermore, if adherence did show signs of 
declining over time, a longer period of study would have showed how this 
correlated with clinical outcomes. This requires specific investigation in future 
research of AT in PD.  
 
Secondly, the TAU group did not receive an intervention outside of usual care. 
This makes it difficult to determine whether improvement in outcomes in the active 
treatment group resulted from the efficacy of AT, or simply due to increased 
patient-professional interaction. Therefore, a TAU placebo intervention that offers 
increased professional contact (e.g. such as regular phone calls) would be ideal in 
larger scale investigations.  
 
Thirdly, I noted that the active treatment group had a slight imbalance towards 
higher MMAS-4 scores compared to the TAU group at baseline (5 active group 
patients scored >2 compared to no TAU patients). This might have resulted in a 
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greater potential for change in the active treatment group. Due to the observed 
magnitude of effect, I believed it was unlikely that this small imbalance accounted 
for the significant between group differences in adherence observed at follow-up. 
However, despite this, I removed these five patients in a sensitivity analysis as 
described in the previous chapter. Whilst the odds ratios were slightly smaller (5.6 
and 7.2 for week-7 and week-12, respectively), a highly significant effect of the 
intervention on adherence to medication was still observed. 
 
A further limitation to the study is the potential effect of bias. As I was the only 
person who delivered the seven sessions of AT, bias may have been introduced. 
For example, as a highly committed PhD student patients may have responded to 
the AT process differently than if another trained therapist had delivered the 
intervention. Furthermore, despite all completed measures being self-reports, the 
lack of blinding of myself to group allocation may have resulted in participants in 
the active treatment group over-reporting adherence rates in order to please me. 
Collection of follow-up measures by an individual masked to group allocation 
would have been desirable and is recommended in future studies of AT. 
 
A final limitation in this trial was the lack of MDS-UPDRS part III (an objective 
assessment of motor function). As this clinician rated assessment would have been 
completed by me, this would have led to a large risk of bias. Therefore, future 
investigations of AT in PD should ensure that the entire MDS-UPDRS is assessed 
by a rater who is masked to treatment allocation. Additionally, self-efficacy was 
not assessed as an outcome in this trial. As self-efficacy is linked closely with QoL 
in chronic conditions, and considering that the findings presented in the next part of 
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this thesis suggests that improving self-efficacy might be important for optimising 
adherence in PD, future studies should ensure that this is assessed as a key outcome 
measure. 
 
8.6 Adverse Events 
As stated in the previous chapter, only one adverse event occurred throughout the 
duration of the clinical trial. This event was not believed to be associated with the 
AT intervention. This suggests that AT delivered in patients own homes is likely to 
be an intervention associated with low patient risk.  
 
During the planning of the clinical trial I anticipated that improving medication 
adherence in some PD patients may lead to the development of motor 
complications, and in rare situations the onset of psychosis. It is known that these 
responses to treatment can occur when patients over medicate with dopaminergic 
therapies. Grosset (2010) suggested that where non-adherence to medication in PD 
is undetected in clinical settings, this may result in clinicians over prescribing anti-
parkinsonian agents in attempt to control symptoms. Acknowledging this, it was 
reasonable to believe that increased adherence to medication as a result of the AT 
intervention may lead to complications due to overdosing on anti-parkinsonian 
agents. Although this was not apparent in the current study, larger scale 
investigations of AT in PD should acknowledge this potentiality. 
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8.7 Cost of Adherence Therapy in PD 
Although no formal health economic analyses were conducted, the cost for an NHS 
band seven PD nurse specialist to deliver seven sessions of AT to one patient is 
estimated to be around £352 ($521). When acknowledging the small NNT outlined 
in Chapter 7 and considering the potential future cost savings of increased 
adherence in PD, this suggests AT is likely to be a cost effective treatment. 
Kulkarni et al. (2008) showed that sub-optimal medication adherence in PD was 
associated with poor symptom control, increased unplanned hospital visits for PD 
related problems and a poorer overall prognosis compared to medication adherent 
PD patients. It is possible therefore that optimising symptom control through 
improvement in medication adherence may be financially beneficial to healthcare 
systems globally. 
 
As reported in Chapter 7, the EQ-5D did not show a statistically significant 
difference between the intervention groups at week-12 follow-up. As with all the 
secondary outcomes, lack of statistical power may explain the non-significant 
result. However, an alternative explanation is also likely. Unlike the PDQ-39, the 
EQ-5D is not disease specific. Therefore, a large change in a patient’s perception of 
their symptoms and their ability to perform ADL’s is likely to be required for 
change to be detected in a PD sample using the EQ-5D. This may explain why the 
PDQ-39 showed a significant between group difference and the non-specific EQ-
5D did not. As there was no change in the EQ-5D, I did not assess health utility. 
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It is important to note that the average length of an AT session in this clinical trial 
was greater than in studies of AT in other chronic conditions. Due to the older age 
of many trial participants and the known impairments in attention and set-shifting 
in PD, it is important that adequate time is provided for AT to be effectively 
delivered in this patient population. Although AT may be a cost effective 
intervention in PD, conducting a health economic analysis in larger scale studies 
where sufficient time is allocated to each session is required. 
 
8.8 Conclusion 
In summary I conclude that AT may be an effective therapy for improving 
medication adherence and QoL in people with PD. Health professionals could 
easily be trained to utilise the core principles of AT as part of their routine clinical 
practice. The small NNT observed and the anticipated low cost of the intervention 
suggests AT is likely to be a cost effective treatment, especially when considering 
the potential future cost savings of increased adherence.  
 
A larger scale study is therefore required to examine the clinical and cost 
effectiveness of this intervention in routine clinical settings when delivered by 
multiple therapists using a placebo control group. Whether the efficacy of this short 
seven week intervention is sustained for longer periods of time also requires further 
evaluation. 
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CHAPTER 9 
 
 
Investigating the Experience & 
Acceptability of Adherence Therapy 
 
 
Introduction 
Data Collection in Qualitative Research 
Methods 
The Analytical Process 
Results 
 
 
 
9.1 Introduction 
The systematic review presented in Chapter 4 revealed only one RCT had been 
published that specifically aimed to improve medication adherence in people with 
PD (Grosset and Grosset, 2007). Despite this paucity of evidence in PD, 
interventions for improving medication adherence in other chronic conditions have 
been widely investigated (Peterson et al., 2003, Nunes et al., 2009). For example, 
researchers have evaluated a variety of intervention types, ranging from 
pharmacological approaches such as dose simplification to complex behavioural 
therapies. However, despite the array of strategies investigated in other chronic 
conditions, the effect on adherence and clinical outcomes are largely inconsistent 
between studies (Haynes et al., 2008).  
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The findings presented in Chapter 7 showed AT was effective for improving 
medication adherence and QoL in PD. As the improvement in QoL exceeded the 
minimally important difference reported in a PD population (Peto et al., 2001), the 
findings suggest the effect size of AT is likely to be clinically relevant. 
 
Despite various adherence enhancing treatments being investigated, few 
researchers have evaluated their interventions. This is both in terms of the 
treatments underlying mechanism of action and the acceptability of the intervention 
from the perspective of patients. Consequentially, for many interventions the 
mechanism of action remains theoretical. This is the case in PD. Although the 
results presented in Chapter 7 suggest AT may be an effective treatment, the 
mechanism of action is unclear.  
 
Alhalaiqa et al. (2013a) evaluated the experience of receiving AT in patients with 
hypertension. Findings showed that modifying attitudes and beliefs about 
medication was an important component of the therapy which may have led to the 
reported improvement in medication adherence. In PD, as prescribed medication 
and the factors associated with non-adherence are likely to be disease specific, it is 
probable that the mechanism of action of AT may differ from hypertension. For 
example, despite showing significant improvements in adherence and QoL in PD, 
patients’ beliefs about medication did not change substantially. This is in contrast 
to patients with hypertension. 
 
Therefore, the aim of this part of my thesis was to investigate the experience of 
people with PD receiving AT. In particular, I was interested in evaluating the 
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acceptability of AT and determining which elements of the therapy PD patients 
found most useful. 
 
In the next part of this chapter I briefly outline two commonly used data collection 
methods in qualitative research and provide justification for deciding to conduct 
interviews in this study. I outline the interview procedure used and justify my 
choice of thematic analysis for analysing the interview transcripts. I also describe 
the analytical method used.  
 
9.2 Data Collection in Qualitative Research 
Researchers often use qualitative approaches to better understand effects that 
cannot easily be measured by quantity, frequency or intensity. Two methods most 
commonly employed in qualitative data collection are participant observation and 
interviewing (Glesne, 2006). 
 
9.2.1 Participant Observation 
Observation is a fundamental technique used in qualitative research for studying 
behaviour (LoBiondo-Wood and Haber, 2006). This method of collecting data is 
particularly useful in studies using ethnographic or grounded theory based 
methodological approaches (Macnee, 2004). 
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9.2.2 Interviews 
Interviewing is widely used in healthcare research because it can be either 
structured or semi-structured, depending on the study purpose (Macnee, 2004). The 
flexibility provided by a semi-structured interview enables participants to express 
their unique perspective (LoBiondo-Wood and Haber, 2006). For this reason 
interviews are highly appropriate for exploring patients experiences in healthcare 
(Glesne, 2006).  
 
9.3 Methods 
9.3.1 Aim 
The aim of this aspect of work was to understand PD patients experience of 
receiving a seven week programme of AT as part of the RCT reported earlier in 
this thesis. Specifically I was interested in patient satisfaction with, and 
acceptability of, the therapy process. 
 
9.3.2 Design 
The design of this study was a qualitative approach using semi-structured 
interviews. As semi-structured interviews are flexible and encourage participants to 
discuss openly (Boyatzis, 1998), I believed its use was appropriate for the study 
aim. 
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The purpose of the qualitative interviews was to evaluate the AT intervention 
described earlier in this thesis from the perspective of the RCT participants. 
 
Although qualitative methodological theories; that is, phenomenology, grounded 
theory and ethnography can be useful for generating new insight, as stated by Avis 
(2003), it is not always necessary to adopt such approaches when undertaking 
qualitative investigations. Due to the specific study aims (i.e. determining the 
acceptability of AT), I therefore used a pragmatic approach. By focusing on these 
aims I intended to explain the quantitative findings presented in Chapter 7, without 
being required to adhere to the philosophies of a particular methodological theory.   
  
9.3.3 Participants 
The first ten PD patients that agreed to be interviewed after their course of AT had 
finished was taken as the study sample. Where the PD patient’s spouse/carer 
participated in the AT sessions, they too were invited to take part in the interview. 
 
9.3.4 Procedure 
After completing the seven AT sessions, I informed participants about the 
qualitative study. Patients who expressed initial interest were given a participant 
information sheet specifically for the interview after the seventh AT session 
(Appendix 33). Participants were asked to read the information sheet relating to the 
interview. If a participating spouse/carer also showed interest in the interview, a 
separate spouse/carer information sheet was provided (Appendix 34). Participants 
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were contacted by phone one week after being provided with the interview specific 
information sheet. Those who were still interested in participating in the interview 
were visited again at home and informed consent was obtained using study specific 
informed consent forms for both patients and spouse/carers (Appendix 35 & 36). 
 
9.3.5 Data Collection 
All interviews were audio recorded and continued until saturation of data had been 
obtained. I subjectively determined this point when participants were providing no 
new information of relevance to the study aim. On average interviews were 30 
minutes in duration. The informed consent form included consent to audio record 
the interview.  
 
During each interview I made brief notes to accompany the audio data. Each 
interview was conducted in the participants’ own homes where AT had taken place. 
Interviews were conducted on a one-to-one basis, unless a spouse/carer also 
participated. Lay person’s language was used throughout the interview process. 
However, due to the variability in patients understanding of PD and treatment 
approaches, where possible I mirrored the patients’ own choice of vocabulary as 
appropriate to encourage a relaxed, informal atmosphere.  
 
All participants were informed that the nature of the interview was not to assess 
their own understanding or recollection of AT, but was to ascertain their opinion of 
the AT programme. At the time of completing the interviews both I and the 
participants were unaware of the RCT results. 
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The interview schedule explored the following broad topics: 
 Components of the AT intervention 
 Communication style and therapy environment 
 Participant’s perceptions of the therapy 
 What participants had learnt  
 
The prompt questions used in the semi-structured interviews are presented in 
Appendix 37. 
 
9.3.6 Thematic Analysis 
There are numerous methods for analysing interview transcripts, many of which 
depend on the philosophical qualitative approach adopted (Aronson, 1994). 
Thematic analysis is a method which focuses on identifying and reporting patterns 
(themes) within data sets (Braun and Clarke, 2006, Green and Brown, 2008). Data 
sets are not only organised by this analytical method, but additionally the processes 
inherent in thematic analysis facilitate the interpretation of data that may not be 
directly observable from initial transcripts (Boyatzis, 1998). 
 
Thematic analysis is widely used by healthcare researchers because it provides an 
accessible form of analysis that can be used across a variety of qualitative research 
philosophies (Braun and Clarke, 2006). Furthermore, there is definitive instruction 
on how thematic analysis should be undertaken when analysing interview 
transcripts (Attride-Stirling, 2001). 
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As this piece of work was not based on a qualitative philosophical approach such 
as grounded theory or phenomenology, the use of thematic analysis was entirely 
appropriate (Attride-Stirling, 2001, Braun and Clarke, 2006). The next part of this 
chapter details the analytical process. 
 
9.4 The Analytical Process 
The stage by stage procedures used for analysing interview transcripts in this study 
are summarised in Table 9.1 below. Data analysis was not conducted in a linear 
process by moving from one phase to the next. Instead I used an iterative process, 
moving back and forth as the data required, as described by Braun and Clarke 
(2006).  
 
Table 9. 1 - Phases of Thematic Analysis 
Phase Description of the phase 
 
1. Familiarising 
oneself with the 
collected data 
 
Transcribing data, reading and re-reading the data, noting 
down ideas. 
 
2. Generating initial 
codes 
Coding interesting features of the data in a systematic 
fashion across the entire data set, collating data relevant 
to each code. 
 
3. Searching for 
themes 
Collating codes into potential themes, gathering all data 
relevant to each potential theme. 
 
4. Revising themes Checking if the themes work in relation to the coded 
extracts (level 1) and the entire data set (level 2).  
 
5. Defining and 
naming themes 
On-going analysis to define the specifics of each theme, 
and the overall story the analysis tells, generating clear 
definitions and names for each theme. 
(Source: Braun and Clarke (2006) 
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9.4.1 Phase One: Familiarisation of the Data 
To ensure full immersion in the data, each transcribed interview was read several 
times in an active manner; that is, searching for meaning and patterns in the data. 
This continued until I was familiar with the content of each interview. Braun and 
Clarke (2006) suggest that maintaining comprehensive notes is a fundamental 
procedure to adopt throughout the entire analysis process. Therefore, note keeping 
began in phase one with the documentation of ideas for potential coding schemes. 
 
9.4.2 Phase Two: Initial Code Generation 
The main topics of interest from within the data were used to generate initial codes. 
These codes formed the basis of repeated patterns (sub-themes) across the data set. 
The meaning of an interview extract, and an appropriate code to suit that meaning, 
was written in the margins of the interview transcripts. Codes were given a 
definition of its correct use and misuse (coding rules), which were referred to 
continuously. Often code definitions were tweaked or re-named to accommodate 
new, but similar, text segments. Once the entire data set had been coded, extracts 
with the same code were copied into a separate document. Inevitably, some 
extracts appeared to portray so much meaning during the coding process that they 
were placed under a variety of codes. This meant they appeared throughout the 
coded categories.  
 
The coding framework described above was based mainly on the data itself, as 
opposed to preconceptions about the data. Appendix 38 shows an example of some 
of the common codes and their respective description. Appendix 39 shows a 
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segment of an interview transcript. Codes were written in the margins of the 
interview transcripts.    
 
9.4.3 Phase Three: Searching for Themes 
Phase three began once coded extracts had been assigned to code specific 
categories. This resulted in a glossary of codes accompanied by definitions for their 
use. The emphasis of this phase was to develop themes that encompass related 
codes. To facilitate this I arranged the codes into plausible sub-themes and then 
collated all data extracts relevant to each sub-theme. This was a similar process to 
that described in phase two. The end of this phase was marked by a collection of 
candidate sub-themes housing all codes and related data extracts. 
 
9.4.4 Phase Four: Revising the Themes  
This phase involved two levels of reviewing and refining sub-themes. In level one I 
reviewed the collated extracts from each sub-theme to ensure they followed a 
logical pattern. Level two involved a similar process, but in relation to the entire 
data set. Specifically, I re-read the entire data set to ensure that the generated 
themes were consistent with the original interview data. 
 
9.4.5 Phase Five: Defining and Naming Themes 
Once a working collection of sub-themes had been compiled, broader themes were 
generated and defined according to their overall meaning. When defining themes I 
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tried to emphasise what was interesting about the theme, as opposed to simply 
paraphrasing it. Names given to the working themes were short, but nevertheless 
portrayed enough information for any reader to have an understanding of the broad 
content of each theme. A clear identification of distinct themes marked the end of 
this phase. 
 
9.4.6 Quality Assurance of the Analysis Process 
When creating the codes and sub-themes I was mindful that my interpretation may 
be biased by preconceptions about the meaning of the data. Therefore, to ensure the 
analysis was free of such bias, a second analyst naive to PD and AT reviewed all 
the transcripts independently.  
 
This individual, an experienced qualitative researcher, coded the interview 
transcripts according to the data set using the method described above. After I and 
the second rater had completed our independent analysis, we met to discuss the 
findings. Despite often generating different code names for the same interview 
extract, the meaning of the codes were consistent. Each code was discussed further 
and the most appropriate was selected for use.  
 
In the next part of this chapter I outline the demographic and clinical characteristics 
of interviewed participants and I provide the results of the thematic analysis. 
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9.5 Results 
9.5.1 Study Population 
Baseline demographic and clinical characteristics of the patients who participated 
in the interviews are presented in Table 9.2. All interview participants were white 
Caucasian. All of the participants were retired from work besides participant 10 
who did not work on the grounds of ill health (due to her PD). It is unknown how 
many retired prematurely due to their PD. The mean age of the interviewees was 
69.1 (s.d 10.2) years. The mean time since PD diagnosis was 6.6 (s.d 4.5) years. 
All were taking at least one levodopa preparation. No patient refused to participate 
in the interviews. The spouse of participant 10 was not available to be interviewed 
due to work commitments. 
 
9.5.2 Codes and Themes 
From the ten interview transcripts a total of 175 codes were generated. These codes 
were used to produce 11 sub-themes. These sub-themes were then grouped under 3 
main overarching themes:  
 
1. Perceptions prior to Adherence Therapy 
2. Positive effects of Adherence Therapy   
3. Attributes of Adherence Therapy  
 
Table 9.3 displays the themes and sub-themes generated by the codes.    
  
2
5
2
 
 
Table 9. 2 - Baseline Characteristics of Interview Participants 
Interview 
Participant 
Age Sex H&Y Duration of 
PD (yrs) 
MoCA HADS 
Anxiety   Depression 
LEDD PD 
Drugs 
Daily 
Doses 
1 56 Male 3 7 25 6 11 640 1 4 
2 69 Male 2 7 28 6 3 740 2 7 
3 72 Female 1 2 18 10 6 1038 2 4 
4 63 Male 3 4 27 5 2 1758 4 12 
5 71 Female 3 14 26 4 5 2319 5 18 
6 68 Female 1 6 30 4 3 247.5 2 4 
7 72 Female 4 14 25 9 7 900 3 9 
8 87 Female 0 2 24 3 1 187.5 1 3 
9 80 Female 3 2 28 8 7 312.5 2 5 
10 53 Female 1 8 27 13 10 480 3 13 
 
H&Y: Hoehn & Yahr; MoCA: Montreal Cognitive Assessment Scale; HADS: Hospital Anxiety & Depression Scale; LEDD: Levodopa 
Equivalent Daily Doses 
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Table 9. 3 - Themes and Sub-themes 
 
Theme Sub-theme N
o
 of 
patients  
1. Perceptions prior to  
       Adherence Therapy 
1. Poor knowledge & understanding of PD and meds 9 
2. Low mood / confidence 5 
 3. Decreased support / Isolation 5 
   
2. Positive effects of  
       Adherence Therapy 
1. Increased acceptance 5 
2. Increased self-awareness 5 
 3. Increased confidence  4 
 4. Increased knowledge / understanding of PD / meds 10 
 5. Increased control / self-discipline 6 
 6. Improved relationships 4 
   
3. Attributes of  
       Adherence Therapy 
1. Therapy Attributes  
- Flexibility, continuity & timing 6 
 - Involved spouse 3 
 - Face to face /  in home environment 10 
 - Time to talk / openness 8 
   
 2. Therapist Attributes  
 - Specialist knowledge 10 
 - Understanding & interest 6 
 - Equal relationship 7 
 - Easy to understand 5 
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9.6 Perceptions Prior to Adherence Therapy 
Most participants talked about their experiences and perceptions prior to therapy. 
Specifically, participants referred to their previous poor knowledge and 
understanding of PD and its treatment, how the disease impacted on their mood and 
confidence and how they felt isolated with little support. 
  
9.6.1 Poor Knowledge & Understanding of PD and Medication 
Almost all of the participants described having poor knowledge of their PD prior to 
receiving AT, attributing this to lack of previous explanation and opportunity to be 
informed in a way that was personally meaningful to them: 
 
“Explaining the nature of the disease, and what it is. Nobody had ever explained 
that. I know the affect it has on me, but nobody had explained it”. 
 
 (Participant 1, male, 56 yrs, depressed on HADS) 
 
The lack of knowledge and understanding prior to AT was not specific to the 
disease. Similarly, participants described how poor previous knowledge specific to 
medication use was also problematic: 
 
“Whereas before I would pop a pill and not understand the reason for it, now I 
understand the peaks and troughs and why it’s essential to maintain a steady line, 
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concentration, to keep equilibrium of the system level for the chemical that I’m 
missing”. 
(Participant 2, male, 69 yrs) 
9.6.2 Low Mood / Confidence 
Half the interviewees talked about their experiences of mood states prior to AT 
which they associated with their diagnosis of PD. Having low mood or feelings of 
depression before the start of the AT process also appeared to be related to their 
lack of acceptance of the disease, which impacted negatively on medication use in 
some participants: 
 
“I was very low in mood when we met. Actually, I think I was depressed. When I 
filled my medication wallet up for the week I used to hate myself and hate my pills. 
I felt guilty for having it (PD), like I’d let my family down. Those feelings made me 
hate the situation so I’d say oh well stuff the pills. I felt resentful towards the pills” 
(Participant 10, female, 53 yrs, depressed on HADS) 
 
The spouse of one participant spoke of the devastating effect that PD had had on 
the patient’s mood and confidence to remain engaged in general life: 
 
“After he was diagnosed he just wanted to be left. With that he became depressed. 
He wanted me to take him to Switzerland to end it all. He became non-compliant 
and under confident in everything, not just medication.” 
(Spouse of participant 1) 
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9.6.3 Decreased Support / Isolation 
Half the PD patients expressed that before AT they had felt isolated from people 
who may be able to help them better understand what they were going through. 
This feeling of isolation and perception of living alone with the disease had a 
detrimental impact on day to day life: 
 
“Even though you go to see the doctor, you’re still living it alone inside yourself. 
There is nobody that you can point to and say that’s what’s happening to me. 
Before this (AT) I felt isolated and lonely living with PD, even though Peter is here 
with me.” 
(Participant 5, female, 71 yrs) 
 
In addition, people perceived having a lack of professional support and felt that 
they were left alone to face their disease: 
 
“Before we felt isolated and neglected. We didn’t know where to turn or anything 
about what was coming. We felt we were the only people facing this.” 
(Spouse of participant 1) 
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9.7 Positive Effects of Adherence Therapy 
Of the three generated themes, positive effects of AT represented the largest. 
Participants spoke of having increased acceptance of PD and the need for 
medication. This increased acceptance appeared to be related to the impact of 
acquiring greater knowledge and understanding of PD and its treatment. 
Furthermore, many participants described how self-awareness, confidence in daily 
life, support, self-control, relationships with others, self-discipline and an ability to 
function and cope in daily life were all improved after experiencing the AT 
intervention. 
 
9.7.1 Increased Acceptance 
Several patients spoke of how they had come to develop an increased acceptance 
of, and relationship with, PD. This increased acceptance of living with PD 
appeared to be associated with a developed understanding and acceptance of the 
indication for medication to control PD related symptoms: 
 
“Before I was very much in denial. I couldn’t off-load anything. Fear was the 
biggest thing for me, being frightened of my future. I then tried to ignore it and that 
included the symptoms and the pills. Now though, I think my relationship with 
medication has changed and improved because of how we spoke about it. I’m no 
longer scared you see." 
(Participant 10, female, 53 yrs, depressed on HADS)  
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Participants described how the experience of talking about PD and its treatment as 
part of the AT interaction helped them to develop a new perspective of living with 
their disease: 
 
“It made me look at the situation for the first time through fresh eyes. I’ve tried to 
keep it contained, the fact that I’ve got Parkinson’s. Suddenly I see I’ve got to look 
at it. I certainly felt that week we spoke about it I wasn’t in fear of anything”. 
 (Participant 5, female, 71 yrs) 
 
Some participants described how being involved in AT and developing a new 
perspective of life with PD helped them to re-evaluate their attitudes towards the 
use of medication to control their symptoms: 
 
“I realise now I’ve got to take more control of the medication I’m taking. Had you 
not come I would still be in the same situation. I’d still be ambivalent to the 
medicines. The very point that we’ve talked about it has somehow changed me. 
Without talking about it to you I would not have changed how I felt inside.” 
(Participant 5, female, 71 yrs) 
 
As part of developing an increased acceptance of the diagnosis of PD, a few 
patients talked about how after receiving AT they no longer felt the need to hide 
their condition from others: 
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“I am not afraid now to say I’m disabled can you help me please. Before, I 
wouldn’t even go outside. People do help you. I am much better at explaining what 
I’ve got now.” 
(Participant 1, male, 56 yrs, depressed on HADS) 
9.7.2 Increased Self-awareness 
Some interviewees discussed feeling an enhanced sense of self-awareness 
following participation in the AT process. Specifically, a greater attentiveness of 
their own PD related symptoms was portrayed by some patients: 
 
“Perhaps I should go to see the specialist because I do stagger quite a lot which 
I’ve become more aware of since I’ve been thinking about Parkinson’s.” 
(Participant 9, female, 80 yrs) 
 
A few participants further described how prior to AT possible episodes of poor 
therapeutic control, such as ‘going off’, were perceived as not being related to sub-
optimal medication use. However, an increased self-awareness on one’s own 
symptom control seemed to result from the enhanced knowledge and understanding 
gained during the AT process: 
 
“Before I had the onslaught of eating constantly when I felt tired, exhausted, to try 
and get some energy. Now though I realise the sinking feeling is the Parkinson’s. I 
am going off. Having the medicines more strictly, I haven’t felt it as much.” 
 (Participant 3, female, 72 yrs, MoCA 18) 
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9.7.3 Increased Confidence 
Some participants spoke of how their experience of receiving AT had improved 
their overall confidence in living with PD. Specifically, perceptions of improved 
symptom control, attributed by patients and carers to better medication adherence 
and acceptance of the diagnosis, enhanced feelings of confidence in one’s ability to 
manage life with PD: 
 
“Once I was taking my meds as we agreed, I did feel a huge difference. I didn’t 
stop freezing but the length of freezing was much less. I felt more confident to go 
outside and not worry about getting back. I went for a coffee alone. It felt great to 
be honest. I haven’t done that for three years. I just felt more confident to do it.” 
(Participant 1, male, 56 yrs, depressed on HADS) 
 
Some patients also described how their increased confidence in daily life led to 
greater social participation and engagement with others: 
 
“Even though it’s not something we talked about, it’s helped me personally and 
socially. I think it’s increased my confidence, definitely. I suppose I feel that I’ve 
started to accept the condition. Before we met I wouldn’t tell anyone. Now I don’t 
mind talking to strangers about it.” 
(Participant 2, male, 69 yrs) 
 
Additionally, the spouse/carers of a few patients spoke of how increased 
confidence to manage PD was used by patients to encourage optimal medication 
adherence in others who routinely take medication for other chronic conditions: 
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“He is now promoting what you’ve said to other people, telling them how it’s 
helping him. It’s getting their brains ticking now. So when they say once the 
session is over you forget, I’m sorry but he has never forgotten. He now talks to 
others about it.” 
(Spouse of participant 2) 
9.7.4 Increased Knowledge & Understanding of PD Meds 
All participants spoke of how they had come to develop an increased understanding 
of PD and its pharmacological treatment approaches. Patients described how after 
receiving AT they could appreciate the importance of medication for controlling 
their own symptoms. Specifically, all participants talked about how improved 
knowledge and understanding of basic anti-parkinsonian pharmacodynamics 
greatly enabled them to see the relevance of medication to their own lives: 
 
“The way I view medication has definitely changed now. I didn’t know much about 
it before and I didn’t realise the effects it had on me. Now I know that it’s because 
I’m putting the dopamine into the brain and I can see now how that makes a 
difference.” 
(Participant 8, female, 87 yrs) 
 
A few patients described how they greatly appreciated having a more scientific 
explanation of how their medication exerted its therapeutic effect: 
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“The most helpful was the information I gained about taking drugs, the effect that 
they have and how they specifically work. That was interesting to me. The scientific 
bits I wanted to know.” 
(Participant 6, female, 68 yrs) 
 
Although a few wanted scientific explanations for their own drugs mechanism of 
action, many preferred to better understand the importance of correct time interval 
dosing. Most patients described how gaining an improved understanding of the 
continuous dopaminergic theory greatly resonated with them, particularly when 
this was discussed in relation to their own symptom control (the diagram used for 
this explanation can be seen in Appendix 40): 
 
“I have learnt about peaks and troughs regarding the medication and why it’s 
important to take your medicine at certain times. In a way I’ve learnt that in some 
respects I am governed by the clock. I know that I need to be somewhere so that I 
can take the medication at the time required.” 
(Participant 2, male, 69 yrs) 
 
Some patients appeared to link their increased knowledge and understanding of PD 
medication to their improved self-awareness of symptoms: 
 
“The peaks and troughs diagram you showed me was one of the most fascinating 
explanations I’ve ever come across. It was very powerful for me. 
 
263 
 
I can now feel it you see. I realise now that I am dipping, and I recognise what it is. 
I can see me falling so it spurs me to take the medication correctly.” 
(Participant 1, male, 56, depressed on HADS)  
 
Some spouse/carers also described how an improved understanding of basic 
antiparkinsonian pharmacodynamics led them to be more mindful of how the PD 
patient was medicating: 
 
“I think learning about the peaks and troughs were important, the picture you 
showed us was helpful. It helped us realise. I understood he would deteriorate if he 
didn’t take the medication altogether. But I didn’t know that his medication if taken 
properly could keep him on an almost even keel, so to speak. Whereas if he takes it 
late or misses it he can drop too low.” 
(Spouse of participant 1) 
 
Additionally, some spouses felt that the increased understanding of PD and its 
treatment gave them more confidence to discuss their relative’s symptoms in a 
clinical setting: 
 
“Now I have a much better understanding. I know what is happening when he 
misses his medication and how medication affects him. I feel I can have a 
conversation now and state my point, especially with the GP.” 
(Spouse of participant 1) 
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 9.7.5 Increased Control / Self-discipline 
Several participants discussed how their experience of receiving AT increased their 
perceived self-control and self-discipline with using anti-parkinsonian medication. 
This appeared to be linked with a greater recognition of the importance of 
medication to one’s self. Specifically, participants spoke of how they felt they had 
become stricter with themselves regarding their medication use, describing a sense 
of increased power and ability to cope: 
 
“The discussion we had made me strict with myself, because I know now that by 
doing that I know it’s going to benefit me. I think it (AT) made me think about 
things, rather than you telling me things I must do.” 
(Participant 6, female, 68 yrs) 
 
Others spoke about how they felt the AT process had helped them to fight back 
against the symptoms of PD, stating that this was due to their improved awareness 
of their symptoms and the need to use medication optimally: 
 
“It’s given me the strength to bounce back. It’s shown me I can adapt and 
challenge PD, by being smart with medication and recognising my symptoms. It’s 
not pleasant but it’s not as dark as it was.” 
(Participant 1, male, 56 yrs depressed on HADS) 
 
Furthermore, some patients described how specific problem-solving strategies, 
identified collaboratively through shared decision making, helped them to develop 
a sense of control over the use of their medication: 
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“I’m remembering now which I wasn’t before. Actually, I often think about it 
before the alarm goes off. It’s like in the morning when you wake up before your 
alarm wakes you. Now I sometimes remember the pills before the alarm gets 
chance to remind me. It’s almost like sometimes, I don’t feel I need the alarm to 
remind me anymore.” 
(Participant 8, female, 87 yrs) 
9.7.6 Improved Relationships 
Some participants talked about how receiving AT improved their relationships with 
family members. Patients put this down to an increased sense of symptom control, 
which was associated with feeling happier and more confident to do things: 
    
“When I was non-compliant I could hardly move so I convinced myself I couldn’t 
do anything. I used to sit there thinking I can’t even decide what pots to use. But 
then I sat there thinking I can do this. Then, for the first time in years I cooked my 
own dinner and the wife’s too. She cried when she got home from work and saw 
what I’d managed to do” 
(Participant 1, male, 56 yrs, depressed on HADS)  
 
A few participants also spoke of how formal community healthcare assistants and 
family members (including children) had noticed a difference in the patient’s 
ability to be more active and participatory: 
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“My granddaughter would come round and whereas I’d say sit there, we were out 
going to the park. So I was doing more things and she noticed as well. I thought 
well this has only happened in the last few weeks.” 
 (Participant 4, male, 63 yrs) 
 
This increased sense of control over symptoms and the heightened confidence in 
one’s ability to be more active was described by some patients as having had a 
positive effect on their relationships when within a caring role. This helped to instil 
confidence in them from their direct relations: 
 
“My daughter, she is now firmer with me and my medication. She saw the effect it 
sometimes had on how I was with the granddaughter. That helps her because she 
knows I’m getting the meds on time and then she doesn’t have to worry, especially 
when I’m babysitting.” 
(Participant 4, male, 63 yrs) 
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9.8 Attributes of Adherence Therapy 
All participants talked about their experiences of going through the AT process. 
Participants spoke of the positive attributes of the AT intervention itself and of the 
individual therapist attributes that they believed to be key to the patient-
professional interaction.  
 
9.8.1 Therapy Attributes 
Patients talked about how they believed their success from participating in the 
therapy resulted from the range and flexibility of the topics discussed. The method 
in which the topics were introduced was also believed to be fundamentally 
important. Patients felt that the inclusion of the spouse/carer was helpful for 
different reasons. Furthermore, all participants described how the collaborative, 
participatory and face-to-face nature of the AT interaction was essential for the 
successful uptake of the therapy. The honesty and openness encouraged during the 
patient-professional interaction was also described as being critical to the process. 
 
9.8.1.1 Flexibility, Continuity & Timing 
Participants talked about how the continuity of linking sessions together with the 
same therapist, the timing of the AT sessions and the flexible approach adopted 
were all important factors that they believed contributed positively to the AT 
experience. 
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Some patients described how the AT sessions could have been longer to facilitate 
greater in-depth discussion: 
 
“They were too short. It hardly seemed to start and then it was gone. You were just 
getting the momentum and then it ended. It was interesting, but too short.” 
(Participant 2, male, 69 yrs) 
 
Although a few talked about how having a more staggered approach would have 
been helpful, such as sessions every two or three weeks, most favoured the weekly 
delivery of AT: 
 
“I helped having you come each week. It gave me time to think about what we’d 
discussed and try out a few things before you came back again.” 
(Participant 6, female, 68 yrs) 
 
Spouse/carers also praised the flexibility and continuity of the AT process, stating 
that the ability to adapt the therapy to individual need was an important component 
of the therapy: 
 
“It depends on the person, whether they think it’s enough for them. Some people, 
like us, may want a few extra weeks. It’s a case of getting the balance right.” 
(Spouse of participant 2) 
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Linking the AT sessions by going over what had been previously discussed was 
commented on by most patients as being important. This helped patients to 
remember what had been discussed and made the experience of AT feel less 
formal: 
 
“I like the way you said we’ll go over last week. It felt like we started from where 
we left which was helpful. It made a big difference and it also reinforced to me that 
you were listening.” 
(Participant 10, female, 53 yrs, depressed on HADS) 
9.8.1.2 Involved Spouse 
All three participants described how the presence of a spouse/carer in the AT 
sessions was helpful, especially when the spouse/carer took an active role in 
medication management. Specifically, spouse/carers described how being involved 
in the AT process was vital to acquiring an increased understanding of medication 
issues: 
 
“There was a lot for me as the carer because you opened my eyes to many key 
points which at the time didn’t seem as important as they are now.” 
(Spouse of participant 7) 
9.8.1.3 Face to Face / In the Home Environment 
Most participants talked about how the delivery of AT face to face in their own 
homes was important. All participants spoke of how they felt other forms of 
delivery such as phone calls would not be as effective as one to one dialogue:  
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“The way in which it (AT) was presented I’ve got to say made a hell of an impact 
on me. How can you judge someone and their reactions over the phone? You need 
to see the person." 
(Participant 2, male, 69 yrs) 
 
A few patients suggested that AT would be helpful as part of routine care. 
Specifically, patients talked about how having AT sessions between consultant and 
PD nurse appointments would be very helpful: 
 
“It (AT) could be incorporated in-between seeing the doctor and nurse. Somewhere 
this sort of thing needs to slot in so that when you go to the hospital on a one to one 
basis you are not afraid of opening up.” 
(Participant 2, male, 69 yrs) 
 
9.8.1.4 Time to Talk / Openness 
Amongst the various aspects of AT that participants reported upon favourably, 
having time to speak in an open, unstructured manner was acknowledged by 
several participants as being particularly beneficial. This facilitated a relaxed 
atmosphere that enabled more in-depth discussion: 
 
“Sometimes I wasn’t sure if I was on the right track. But you welcomed me every 
time to say exactly what I thought. That helped me to be  
less anxious and so I could talk freely, so to speak.” 
(Participant 10, female, 53 yrs, depressed on HADS) 
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Additionally, patients described how having the time to talk and feel that they were 
being listened to had a positive impact: 
 
“It felt like I was given the time in my own home so I wasn’t under pressure like in 
hospital appointments. With you, knowing you had more time to sit and listen made 
a big difference. Talking the way we did was the first time I felt able and ready to 
do that since getting it (PD) nine years ago.” 
(Participant 10, female, 53 yrs, depressed on HADS) 
9.8.2 Therapist Attributes 
In addition to the positive attributes of the intervention, all interviewees further 
described how they believed the characteristics of the therapist providing AT were 
also vitally important for inspiring confidence and building a rapport. Specialist 
knowledge of PD and its treatment by the therapist delivering AT was regarded as 
being of paramount importance. Participants reported how important it was to feel 
that the therapist understood their perspective and was not judgemental, even if 
they disagreed. The ability of the therapist to explain topics in a way that was easy 
to comprehend by patients was also considered to be an essential trait that helped 
facilitate the therapy process.  
 
9.8.2.1 Specialist Knowledge 
All participants spoke of how they believed people administering AT should 
possess specialist knowledge of PD, stating that this was essential for 
understanding patients’ issues with medication: 
272 
 
“Because you had an understanding of PD I was halfway there with you. There 
were so many issues I had within me that when one came out talking with you it 
often rolled into another one. I’ve not been able to do that with other people at the 
hospital.” 
(Participant 10, female, 53 yrs, depressed on HADS) 
9.8.2.2 Understanding & Interested 
Several participants talked about how they believed it was important that the 
therapist could understand a patient’s perspective of what it is like living with PD: 
 
“To have somebody that you can talk to that seems to understand where you’re 
coming from was very helpful.” 
(Participant 5, female, 71 yrs)       
 
Patients also felt that the ability of the therapist to understand their issues and show 
genuine interest was a key component to encouraging meaningful conversation 
about PD and treatment: 
 
“You being interested in what having Parkinson’s is like I think made you ask 
questions in such a way that made me want to give you an answer. It made me look 
at the situation differently for the first time.” 
(Participant 9, female, 80 yrs)  
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9.8.2.3 Equal Relationships 
Several participants spoke of how honesty and a non-judgemental approach were 
key for encouraging open dialogue: 
 
“It was welcoming not having to justify some of my actions. I felt I could say what 
was on my mind without you judging what I was saying.” 
(Participant 2, male, 69 yrs) 
 
One spouse described how the rapport that was developed between the patient and 
therapist was essential and helped to instil a level of trust which helped to facilitate 
the AT interaction: 
 
“I think you learnt to trust David didn’t you? You know inviting strangers into your 
own house isn’t easy and you’ve got to learn to converse with them. You’ve got to 
feel that you’re equals.” 
(Spouse of participant 2) 
 
Several participants also discussed how building a rapport with the therapist was 
paramount for gaining the trust that was required to facilitate open and honest 
discussion: 
 
“I felt comfortable with you to tell you my fears that I’d held inside for so long. 
You think oh that sounds silly so you put things to the back of your mind. I didn’t 
feel that with you. I was able to say the simplest things and you put me at ease.” 
(Participant 10, female, 53 yrs, depressed on HADS) 
274 
 
9.8.2.4 Easy to Understand 
Many interviewees described how having a therapist who was easy to understand 
and was able to explain things clearly on a patient’s level was an essential 
component of the patient-professional interaction within AT: 
 
“You explained things clearly and functionally without a lot of big fancy words. 
You used everyday language, not like sitting behind a desk and quoting out long 
medical terms. That means nothing to me.” 
(Participant 2, male, 69 yrs) 
9.9 Summary of Results 
Of the 175 codes generated from the ten interview transcripts, 11 sub-themes were 
developed. These sub-themes were arranged to form 3 over-arching themes: 
perceptions prior to AT, positive effects of AT and attributes of AT.  
 
In the next chapter of this thesis I will use these findings to propose a possible 
mechanism of action for AT specific to people with PD. 
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Introduction 
Perceptions Prior to Adherence Therapy 
Positive Effects of Adherence Therapy 
Attributes of Adherence Therapy 
Strengths and Limitations 
Summary 
 
 
 
10.1 Introduction 
In the previous chapter I reported the findings of a qualitative study. The aim of this 
aspect of work was to investigate the experience of receiving a seven week 
programme of AT in people with PD who participated in the clinical trial described 
earlier in this thesis. Determining the acceptability of AT was also an important 
objective of this evaluation.  
 
In this chapter I will discuss the qualitative study findings within the context of 
related literature. Furthermore, I will discuss a potential mechanism of AT specific 
to PD that may be helpful in explaining the RCT findings presented previously in 
this thesis. 
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10.2 Perceptions Prior to Adherence Therapy 
Although the intention of this study was to evaluate the experience and 
acceptability of receiving AT, most patients talked about their experiences and 
perceptions of life with PD prior to the therapy process. Specifically, participants 
referred to their previous poor knowledge and understanding of PD and its 
pharmacological treatment. Having low mood and confidence and feeling isolated 
with little support was also reported by several interviewees as being significant 
prior to the therapy. 
 
In many chronic disease areas patients can become expert at managing their 
symptoms and recognising their reaction to medication (Badcott, 2005). As this 
developed expertise results from taking medication for a considerable time to 
manage symptoms, sound adherence to treatment is often assumed (Badcott, 2005). 
However, despite this assumption, the findings described in Chapter 3 suggest non-
adherence in PD may be associated with longer disease duration. Although many 
factors can impact on adherence behaviours, the lack of knowledge about disease 
and treatment in patients who have had PD for several years may indicate that the 
expert patient concept should not always be presumed in PD.  
 
Drey and colleagues (2012) showed that whilst patients were vaguely familiar with 
treatment goals, their understanding of PD medication was often not adequate 
enough to sufficiently manage their condition. In particular, patients did not 
appreciate that to achieve symptom control strict timing of doses may be 
imperative, especially in later stages of disease. As the interviewed patients from 
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the current study reported having poor knowledge of disease management prior to 
participating in the AT process, these findings appear to be consistent. 
 
Whilst comprehensive knowledge of PD is not essential, the ability to recognise 
one’s own response to treatment and have a sufficient understanding of basic anti-
parkinsonian pharmacodynamics is important. Despite many patients having access 
to nurse specialists or being regular attenders at PD community groups/networks 
(where information is often provided), the findings presented in Chapter 9 suggest 
that this essential knowledge is lacking in many people with PD. Although only ten 
PD patients were interviewed from the clinical trial sample, considering that most 
described having poor prior knowledge suggests that lack of understanding may be 
common in the general PD population. Specific investigation is required however 
to confirm this.  
 
In addition to having poor knowledge prior to AT, some interviewees talked about 
how they felt their low mood was associated with their diagnosis of PD and their 
dependence on treatment. Low mood or feelings of depression also seemed to be 
related to their lack of acceptance of the disease, which impacted negatively on 
medication adherence in some participants. 
 
As described earlier in this thesis, the burden of living with a chronic condition can 
lead to the development of depressive symptoms. It is also well established that 
depression is associated with poor adherence to medication in chronic conditions 
(DiMatteo et al., 2000). Specifically, depression is a factor most strongly associated 
with non-adherence in PD, as was identified in Chapter 3. It was therefore not 
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surprising that low mood was reported by some participants, especially as research 
suggests that depression is prevalent in as many as 40% of people with PD (Shiba 
et al., 2000). 
 
A general feeling of low confidence was apparent from the interview data. As low 
confidence and self-esteem are associated with low mood (Charmaz, 1991), this 
was once again not unexpected; it is known that low confidence in one’s ability to 
cope and function optimally (low self-efficacy) is common in people living with a 
chronic condition (Charmaz, 1991).  
 
Researchers have shown that interventions aimed at enhancing self-efficacy may be 
beneficial for improving self-management behaviours in chronic conditions (Farrell 
et al., 2004). Although not specifically investigated in PD, this may include 
adherence to treatment. Therefore, considering that low confidence and low mood 
are related and can impact negatively on adherence to medication and general 
participation/engagement in life, this may explain why patients reported this as 
being significant when participating in the post intervention interviews.     
 
Additionally, patients expressed a strong feeling of isolation from other people. 
Feeling isolated and lacking general support was reported to have a detrimental 
impact on patients’ day to day life. This may suggest that current service provision 
for people with PD, such as access to nurse specialists, may not be sufficient to 
adequately deal with the concerns of some people with PD. Considering that AT 
was a seven week intervention that encouraged participation in a way that 
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previously patients may not have experienced, this may explain why many 
interview participants felt it was important to discuss their experiences prior to AT. 
 
Furthermore, by discussing experiences and feelings prior to receiving AT, it is 
possible that participants were comparing this with how they felt after the AT 
process. This suggests that poor knowledge of disease and treatment, low 
mood/confidence and feelings of isolation may have been improved by receiving 
the AT intervention.  
 
In the next part of this chapter I will discuss such potential positive effects of AT, 
as reported by the interview participants. In so doing, this will lead me to propose a 
mechanism of action for AT which may be useful for explaining the beneficial 
effects in some PD patients in the clinical trial.   
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10.3 Positive Effects of Adherence Therapy 
All participants talked about the positive effects of the AT intervention. 
Specifically, patients spoke of having an increased acceptance of PD and an 
enhanced understanding of the indication for treatment. Acquiring greater 
knowledge of the importance of PD medication was also reported as being 
beneficial by all interviewed participants. Interestingly, many participants 
described how self-awareness, confidence in daily life, self-control, relationships 
with others, self-discipline and an ability to function and cope (e.g. social 
participation/engagement) also improved after experiencing the AT process. 
 
10.3.1 Improving Knowledge and Understanding 
All participants described how receiving AT had enabled them to better understand 
PD and the need for treatment. Specifically, a greater understanding of the 
requirement for correct dose timings was acknowledged by many patients. 
Interestingly, rather than simply enhancing understanding of basic 
pharmacodynamics, patients described how this acquired knowledge had led them 
to develop an increased sense of self-awareness and self-discipline.  
 
Considering that poor self-awareness of symptoms has been reported in PD (Vitale 
et al., 2001, Sitek et al., 2008), the fact that patients described having an increased 
sense of self-awareness may suggest that discussing medication use in relation to 
patients specific symptoms provides greater meaning because it is relevant at a 
personal level. This may account for the improved adherence behaviours in patients 
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who may not have been aware of the relevance of medication for managing their 
symptoms prior to AT. 
 
An enhanced feeling of self-discipline to take medication correctly was also 
described by participants in the current study. This may propose that the process of 
AT not only helps to improve adherence to treatment, but additionally encourages 
and educates patients how to successfully self-manage their condition. Some 
participants described adapting their problem-solving strategy, while others 
described using their greater insight of pharmacodynamics to plan correct drug 
dosing. Therefore, this may propose that after receiving AT patients are confident 
and competent to self-manage; that is, patients might use their enhanced symptom 
awareness and knowledge of treatment to better manage PD, without the need for 
continuous input from a health professional.  
 
Furthermore, as a lack of awareness is known to be a factor for poor self-
management in patients with a chronic condition (Jerant et al., 2005), it is possible 
that AT helped the trial participants to better manage their condition by enhancing 
self-awareness of symptoms and the importance of medication use.    
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10.3.2 Improving Acceptance of PD and Confidence in Daily Life 
The interview data revealed that a lack of acceptance of PD and denial concerning 
the indication for treatment was prevalent in some participants. When 
acknowledged alongside underlying symptoms of anxiety and depression, these 
factors appear to represent some of the main reasons for poor adherence to 
treatment in these individuals. 
 
As previously described, low mood and anxiety are known to detrimentally impact 
on adherence behaviours. Additionally, the lack of acceptance of a condition and 
denial concerning the need for treatment is common in chronic conditions 
(Charmaz, 1991, Telford et al., 2006).  
 
Although participants stated that improving their knowledge and assisting them 
with problem solving strategies was beneficial, several patients also talked about 
how improving their acceptance of PD and improving their confidence in daily life 
was essential. Although medication adherence and QoL significantly improved in 
participants who received AT, improving factors such as the acceptance of PD and 
confidence in daily life was not expected and nor was it the intention in the clinical 
trial. 
 
As described earlier, the linear mechanism of action for AT proposes that 
improving attitudes and beliefs about treatment, exchanging information and 
assisting in problem solving strategies leads to improved adherence behaviours 
(Horne and Weinman, 1999, Gray, 2011). Better adherence leads to improved 
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clinical outcomes as a consequence. A diagram of this linear mechanism can be 
seen in Figure 10.1. 
 
 
 
 
 
 
 
 
Gray (2011) 
Figure 10. 1 - Linear Mechanism of Action of Adherence Therapy 
 
Considering that enhancing adherence to medication was the main objective of AT, 
it is unlikely that a greater acceptance of PD and greater confidence in daily life 
improved as a result of improved adherence behaviours. Furthermore, as 
acceptance of a condition and confidence in one’s ability to cope (self-efficacy) are 
likely to be important for optimising QoL (Charmaz, 1991), this may suggest that 
some of the improvements in QoL observed in the clinical trial may result from 
other mechanistic pathways, and not just the linear pathway described above. 
Although the linear mechanism of action is important in PD, the improvements in 
acceptance and confidence reported by participants may suggest that QoL can be 
enhanced by delivering AT, but without the requirement for enhanced adherence to 
medication.  
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As with the linear model, these distinct mechanistic pathways are likely to 
commence with the identification of a patient’s unique reasons for not adhering to 
treatment. This may include, for example, a lack of acceptance of PD and 
underlying symptoms of anxiety/depression. However, unlike the linear model 
where addressing such factors for non-adherence is suggested to lead directly to 
improved medication taking, addressing the lack of acceptance of PD and 
exploring symptoms of anxiety/depression may take an alternative route by first 
improving one’s confidence to cope with PD (i.e. improving self-efficacy). It is 
worth noting that greater self-efficacy has been associated with better reported QoL 
in people with chronic obstructive pulmonary disease and chronic heart failure 
(Arnold et al., 2005). Thus, it is possible that an enhanced sense of control and 
perceived ability to cope may lead to improved medication adherence in PD. 
 
Therefore, unlike the linear model of AT which is uni-directional (i.e. improving 
adherence leads to better clinical outcomes), acknowledging the importance of 
enhancing self-efficacy to improve QoL suggests that the mechanism of AT may in 
fact be bi-directional in PD.  
 
This may propose that patients with PD have unique pathways to improved clinical 
outcomes such as QoL. Therefore, although adherence to medication was the 
principal target of AT in the clinical trial, the intervention’s therapeutic effect could 
be more holistically beneficial. Figure 10.2 shows a diagram of this proposed bi-
directional mechanistic pathway of AT in PD. 
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Figure 10. 2 - Bi-directional Model of AT Mechanism in PD
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10.4 Attributes of Adherence Therapy 
10.4.1 Therapy Attributes 
Participants described how they felt the range of topics, flexibility in delivery, 
continuity and timing of the AT sessions were all key to the success of the therapy. 
This is consistent with findings reported by Alhalaiqa et al. (2013a) who showed 
that participants with hypertension who received AT also favoured this style of 
delivery. Although the qualitative interviews described in this thesis represent only 
the second evaluation of AT from the perspective of patients, the evidence seems to 
suggest that the intervention is well accepted. 
 
Some patients specifically spoke about session continuity, stating that they felt it 
was vital for the same therapist to deliver the therapy. This proposes that AT is 
likely to provide the most benefit when delivered by a single therapist for a given 
patient. Furthermore, considering that many patients particularly liked how each 
AT session appeared to naturally follow on from the previous session, this would 
again propose that a single therapist is needed. Gray et al. (2004) showed that 
training community mental health nurses to deliver AT resulted in statistically 
significant improvements in medication adherence, attitudes towards medication 
and psychotic symptoms in patients with schizophrenia. Researchers should 
therefore investigate whether training multiple nurse specialists to provide AT as a 
service for people with PD leads to similar positive effects on outcomes as was 
shown in the current clinical trial (where only one therapist was used). 
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Most patients reported that the length of each AT session was sufficient. Some 
patients expressed that more sessions would have been helpful whereas others felt 
they required fewer sessions. Furthermore, some participants believed that AT 
would have greater benefit if delivered every few weeks, whereas others suggested 
that this type of intervention would be helpful if delivered in phases (i.e. as and 
when patients felt they needed it).  
 
In the current clinical trial AT was administered once a week for seven consecutive 
weeks. This is similar to many trials of AT, as was outlined earlier in this thesis. 
However, when acknowledging the interview findings it may be that AT is likely to 
be better received by patients when delivered in a style more consistent with 
individual patient need. Such an approach is consistent with various guidelines for 
managing chronic conditions (WHO, 2003, DH, 2005, NICE, 2009) and with 
findings showing that medication adherence is enhanced when sufficient time is 
allocated for exploration of patient problems (Sookaneknun et al., 2004). It may be 
therefore that some patients require ‘top-up’ sessions whereas others only need a 
short duration of therapy to achieve the same therapeutic effect.  
 
Thus, rather than being prescriptive in the number and time of each session, the 
findings of the qualitative interviews may infer that AT is more of a pragmatic, 
principles based intervention. Future research of AT should investigate whether the 
positive effects on adherence and QoL observed in the current clinical trial are 
maintained when the intervention is delivered in a flexible manner according to the 
need of individual patients (as judged by the treating therapist).  
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To my knowledge, the clinical trial described in this thesis was the first study of 
AT to incorporate a spouse/carer. Considering that carers can take on an active role 
in managing medication in people with PD, I believed their inclusion in the AT 
programme was important. Although the interaction between the presence of a 
spouse/carer and the treatment effect of AT was not statistically significant, 
patients believed that their inclusion in the therapy process was helpful. Similarly, 
the three spouse/carers interviewed reported how beneficial acquiring greater 
knowledge of anti-parkinsonian pharmacodynamics was to them in their capacity 
as a carer.  
 
It is known that spouse/carers can be crucial for helping patients to manage their 
condition and that they themselves require support and education to facilitate them 
in their role (A'Campo et al., 2010a, A'Campo et al., 2010b). Furthermore, it is 
recognised that depression in caregivers of people with PD is prevalent and can 
impact detrimentally on their ability to cope (Caap-Ahlgren and Dehlin, 2002). As 
the inclusion of spouse/carers in the clinical trial appeared to be an important 
component of the process according to the interviewed participants, it is important 
that this is acknowledged when investigating AT in future research.  
 
All participants described how they believed the face-to-face nature of the AT 
interaction, set within the home environment, was essential for the successful 
uptake of the therapy. Furthermore, having time to talk and feeling encouraged to 
discuss concerns openly was viewed by many as contributing to the success of the 
intervention.  
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Whilst patients favoured the flexibility in time and content of AT sessions, such 
findings may infer that delivery of AT outside of the home environment is not 
anticipated by patients to be as effective. As described earlier in this thesis, it is 
likely that helping patients to problem solve issues around medication use in their 
own home has a greater impact than if undertaken in a clinical setting.  
 
Furthermore, the honesty and openness encouraged during the patient-professional 
interaction was also described as being critical to the process. Patients reported 
feeling more comfortable to discuss their problems than if asked to do so in a 
clinical setting. This is particularly in scenarios where they suspected the 
healthcare professional would not agree with their perspective.  
 
It is likely therefore that delivering AT in patients’ homes offers several benefits. 
Firstly, problem solving is likely to be more easily facilitated, particularly where 
cognitive impairment is evident. Secondly, patients may feel more at ease to 
discuss topics that would normally make them anxious when discussed in a clinical 
setting. Thirdly, unlike clinical environments where patient-professional 
interactions are often directed by professionals, the flexibility and patient focused 
nature of AT in the home may mean that patients perceive the power dynamic to 
shift. This may explain why many participants felt comfortable to discuss honestly 
and openly in a way that they might not have done so. 
 
According to the interviewed participants, it therefore appears that AT delivered in 
the home is likely to have greater benefit than if delivered by a different method 
(i.e. over the phone or in a clinical setting). However, alternative to this theory, 
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Alhalaiqa et al. (2013a) showed a statistically significant improvement in 
medication adherence and blood pressure in patients with hypertension who 
received AT in either the home environment or an outpatient department. 
Treatment evaluation through one-to-one interviews showed that patients were 
comfortable receiving AT in both environments. This may suggest that AT 
delivered in clinical settings is just as effective as when delivered in patients’ 
homes. Therefore, considering the potential cost of travel to patient’s homes, AT 
delivered in clinic is likely to be more cost effective and thus more attractive to 
policy makers and service commissioners.  
 
Nevertheless, it is important to acknowledge that considering the multiplicity of 
reasons for non-adherence in PD, it is unknown whether AT delivered in a clinical 
context will be as effective as in patients’ homes. It may be beneficial therefore for 
researchers to investigate the efficacy of AT in PD when delivered via alternative 
means (e.g. over the phone or in a clinical setting). However, since the interviewees 
in the current clinical trial felt that delivery of AT in the home environment was a 
significant strength of the intervention, it is unlikely that the therapeutic effect 
observed will be maintained if delivered outside of the home environment in 
people with PD.  
 
10.4.2 Therapist Attributes 
Participants stated that certain characteristics of the individual providing AT were 
extremely important to the therapy process. Specifically, specialist knowledge of 
PD was regarded as being paramount. Considering that some causes of non-
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adherence to medication may be specific to PD (e.g. poor problem solving ability 
resulting from cognitive impairment), it is probable that AT can only be delivered 
by a professional with sufficient knowledge of the disease. Furthermore, this may 
suggest that AT is likely to be more effective and better received by patients when 
delivered by PD nurse specialists or individuals with significant experience dealing 
with PD patients.   
 
Participants further reported how it was essential to feel that the therapist 
understood their perspective and was non-judgemental. The motivation of the 
therapist and ability to explain topics in a motivational way that was easy to 
understand was also considered to be an essential trait that helped facilitate the 
therapy process. Once again, this suggests that specialist knowledge of PD is vital 
for successful delivery of AT.  
 
Légaré et al. (2008) showed in a systematic review of barriers and facilitators to 
implementing shared decision-making that a motivational communication style was 
important to encouraging patient participation and an equal patient-professional 
relationship. Furthermore, Alhalaiqa et al. (2013a) found that hypertensive patients 
who received AT greatly appreciated the communication style and motivational 
approach of the therapist. It is therefore important that professionals delivering AT 
are able to engage patients sufficiently in the therapy process. As patient 
engagement is an essential element of AT, this may partly explain why PD patients 
were comfortable with the communication style and felt confident openly 
discussing their issues and concerns. 
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10.5 Strengths and Limitations 
This evaluation of AT in PD using a qualitative methodology has several strengths. 
Firstly, all participants were interviewed within one week of completing the AT 
process and so their memory of the sessions content would have been maximised. 
Secondly, selection bias was minimised as participants were the first ten to 
complete the seven AT sessions who subsequently consented to be interviewed. 
Thirdly, although there is a large body of literature relating to the experience of 
caring for a person with PD, the work presented in this thesis is the first to 
investigate spouse/carer experiences of receiving an adherence promoting 
intervention. The final strength of this study rests in the quality assurance 
procedure used as part of the analysis process. As I was the person who delivered 
AT and then completed the interviews, my opinion of the meaning of the data was 
likely to be biased. Thus, the secondary analysis by an expert qualitative researcher 
naive to AT and PD ensured that the findings were a true reflection of the data and 
not a result of my own preconceived ideas. 
 
There are also some limitations to this evaluation of AT. Firstly, only 10 
participants were interviewed. Although this sample size is not considered small in 
qualitative research, it is possible that the views of the other trial participants may 
differ. I did not use the saturation of data as a point to determine the sample size. 
Rather, a prior sample size of 10 was determined. However, considering that the 
demographics of the interviewed patients appeared to reflect the overall RCT 
sample, it is possible that the views of other participants would not be substantially 
different. Secondly, although the interview transcripts were robustly analysed by 
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more than one researcher, the study themes and sub-themes were not verified for 
accuracy by the interviewed participants.  
 
Symptoms of anxiety and depression were assessed in the RCT but as a baseline 
measure only. Self-efficacy, however, was not assessed at all in the study. As the 
interview findings suggest that enhancing self-efficacy and exploring symptoms of 
anxiety and depression may be beneficial for improving confidence to cope with 
PD, it is important that these are assessed at baseline and follow-up in future 
investigations of AT in PD. 
 
Finally, considering that I delivered AT and conducted the post intervention 
interviews, it is possible that participants may have been reluctant to raise negative 
views of the therapy. Therefore, the interview content may be subject to positive 
reporting bias. An independent interviewer would be desirable in future evaluations 
of AT.  
 
10.6 Summary 
This study explored the experiences of people with PD and their spouse/carers who 
received a seven week programme of AT as part of the previously described 
clinical trial. The aim was to determine the acceptability of the intervention and to 
identify what patients found most beneficial. Analysis of the interview transcripts 
generated three main themes and eleven sub-themes. Evaluation of the patient 
experience and the identification of the three themes greatly enhanced the 
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understanding of what patients found most helpful. The data allowed a new 
mechanism of action of AT in PD to be proposed which future research should 
seek to confirm. The next chapter provides a summary of this thesis and discusses 
the implications for both future research and clinical practice.        
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CHAPTER 11 
 
 
Implications and Conclusions 
 
 
Summary of This Thesis 
The Cochrane Systematic Review Including CAAT-PARK 
CAAT-PARK within the Wider Adherence Literature 
Implications of This Work 
Dissemination of This Work 
Conclusions 
 
 
 
11.1 Summary of This Thesis 
In Chapter 3 of this thesis I conducted a systematic review of factors associated 
with medication non-adherence. Seven studies were identified that met the 
inclusion criteria. The risk of bias for each study was assessed using a novel quality 
appraisal tool that I specifically developed. Eleven factors were identified that were 
associated with medication adherence behaviours in people with PD, six clinical 
and five demographic: mood disorders, cognition, poor symptom control/ QoL, 
younger age/longer disease duration, regimen complexity/polypharmacy, risk 
taking behaviours, poor knowledge of PD/education, lack of spouse/partner, low 
income, desire to maintain employment and gender. These factors were ranked by 
weight of their overall evidence. 
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In Chapter 4 I conducted a Cochrane systematic review of interventions used to 
enhance adherence to medication specifically in people with PD. Following the 
evaluation of 38 full texts, only 1 study met the inclusion criteria indicating the 
paucity of high quality research in this area. The included study showed that 
simple, didactic patient education relating to the continuous dopaminergic theory 
significantly improved adherence to medication in people with PD. 
 
In Chapter 5 I outlined a variety of behaviour change theories. The disciplines of 
motivational interviewing and cognitive behavioural therapy were also outlined. 
Adherence therapy was introduced and a brief overview of the supporting evidence 
to date was provided. I used my greater understanding of adherence issues in PD 
and the core principles of motivational interviewing and cognitive behavioural 
therapy to develop a novel, PD focused version of AT. In Chapter 6 I provided the 
justification for, and research design of, a RCT to test the efficacy of this novel 
intervention for improving medication adherence and QoL in a PD sample (CAAT-
PARK).  
 
In Chapter 7 I reported the findings of the CAAT-PARK clinical trial. A 
statistically significant improvement in medication adherence and QoL was 
observed in the active treatment group compared to the TAU group. In Chapter 8 I 
provided a discussion of the results.  
 
In Chapter 9 I reported the findings of a qualitative study that aimed to explore the 
experience and overall acceptability of AT in ten PD patients and 3 spouse/carers 
who participated in the RCT. Eleven sub-themes were identified which generated 
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three main themes: perceptions prior to AT, positive effects of AT and attributes of 
AT. These findings were discussed in Chapter 10 where I proposed a mechanism of 
action for AT in PD. 
 
In this final chapter I will discuss how the findings of the Cochrane systematic 
review change when the results of the clinical trial are acknowledged. I will then 
outline how this work relates to the wider adherence literature. Finally, I discuss 
the overall implications of this work for future research and clinical practice. 
 
11.2 The Cochrane Systematic Review Including CAAT-PARK      
To my knowledge, CAAT-PARK is only the second clinical trial to test the 
effectiveness of an intervention for enhancing adherence to medication in PD. 
Grosset and Grosset (2007) showed that providing didactic information relating to 
the continuous dopaminergic theory significantly improved timing adherence in 
patients with PD. In the Cochrane systematic review this intervention type satisfied 
the criteria for patient education. The RCT described in this thesis is therefore the 
first study to use a complex, behaviourally targeted intervention to improve 
adherence in patients with PD.  
 
Both the study by Grosset and Grosset (2007) and CAAT-PARK were able to show 
a statistically significant improvement in adherence to medication. CAAT-PARK, 
however, also significantly improved QoL. As described in Chapters 8 and 10, 
there were several reasons why participants in my RCT did not adhere to 
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prescribed treatment regimens. For example, many patients reported having poor 
knowledge of the importance of correct dose timing. As exchanging information 
was an important element of AT, this may partly explain why the RCT findings 
presented earlier were consistent with Grosset and Grosset (2007). Therefore, 
although only two RCTs have aimed to enhance medication adherence in PD, the 
evidence from these studies suggests that improving knowledge and understanding 
is likely to be beneficial.  
 
However, considering that participants in my RCT presented with a variety of 
reasons for not adhering to treatment (e.g. ambivalence to medication, lack of 
acceptance of PD and impaired ability to problem solve), it is possible that 
behaviourally targeted interventions such as that described in this thesis may result 
in greater improvements in adherence to medication than when providing simple 
educational material as a standalone intervention. This is because not all patients 
non-adhere to treatment because of poor knowledge. For example, patients may 
hold negative beliefs about treatment which didactic educational material may not 
be capable of addressing. 
 
It is also important to note however, that due to the different methods used for 
assessing adherence to medication between Grosset and Grosset (2007) (where 
MEMS were used) and CAAT-PARK (where MMAS-4 was used), it is not known 
whether CAAT-PARK enhanced adherence behaviours in individual patients more 
than in the study by Grosset and Grosset (2007). Furthermore, it is not clear 
whether AT delivered as part of the CAAT-PARK trial had a positive impact on 
more individuals than in the RCT conducted by Grosset and Grosset (2007). 
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Therefore, whilst it is reasonable to argue that behaviourally targeted interventions 
such as AT may be more effective for enhancing adherence behaviours than simply 
providing educational material, from the current evidence this is speculative. 
 
Based on the findings of the two existing RCTs, behavioural interventions may be 
more likely to impact positively on clinical outcomes (shown in CAAT-PARK) 
than simple educational material. One reason for this may be because improving 
confidence and acceptance of the indication for treatment (which may be the focus 
of a behavioural intervention for some patients) could improve self-efficacy. In 
turn this could lead to improvements in QoL, as was described in Chapter 10.  
 
Therefore, whilst improving knowledge was shown by Grosset and Grosset (2007) 
to enhance adherence to treatment, as clinical markers did not improve in this study 
it is unknown whether providing educational material as a standalone intervention 
could lead to improvements in clinical outcomes. However, the current work 
presented in this thesis suggests that both adherence and clinical outcomes may 
improve when more patient focused, behaviourally targeted treatment approaches 
are utilised in PD. 
 
11.3 CAAT-PARK within the Wider Adherence Literature 
As discussed in Chapter 4, despite Grosset and Grosset (2007) reporting the benefit 
of a patient education intervention in PD, findings from large scale systematic 
reviews suggest that patient education is mostly ineffective for improving 
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adherence in chronic conditions in general (Haynes et al., 2008, Alhalaiqa et al., 
2013b).  
 
Unlike patient education approaches however, behaviourally targeted treatments 
have been shown to be beneficial in chronic conditions. Systematic reviews by 
Kripalani et al. (2007) and Haynes et al. (2008) both revealed that complex, 
behaviourally targeted interventions that explored patient beliefs and concerns 
about medication were more effective than simple treatments such as educational 
strategies for increasing adherence rates across a variety of chronic disease areas. 
Furthermore, a Cochrane systematic review by Alhalaiqa et al. (2013b) in patients 
with hypertension showed that behaviourally targeted interventions provide the 
greatest magnitude of effect for improving adherence behaviours. As the AT 
intervention evaluated in my RCT (CAAT-PARK) was a complex/behaviourally 
targeted treatment, the findings appear to be consistent with the various systematic 
review findings.  
 
However, as previously stated, considering that only one RCT was identified that 
had investigated an adherence enhancing intervention in PD (i.e. didactic patient 
education), it is not known whether AT is more effective than simple education in 
PD for enhancing adherence behaviours. Nevertheless, when acknowledging the 
findings of previous systematic reviews in other chronic disease areas, it is 
reasonable to argue that behavioural interventions such as AT may be more 
effective for improving adherence to medication in PD than simple educational 
strategies. 
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The findings from the RCT presented in this thesis therefore add to the current 
body of evidence supporting the use of complex/behavioural interventions for 
improving adherence to medication in chronic conditions. However, unlike many 
complex/behavioural interventions reported by Kripalani et al. (2007) and Haynes 
et al. (2008) which did not show an improvement in clinical outcomes (despite 
enhancing adherence behaviours), CAAT-PARK did show a clinically relevant 
improvement in QoL. This may result from AT in CAAT-PARK being specifically 
targeted towards a patient’s unique reasons for not adhering to treatment.  
 
Furthermore, factors associated with poor medication adherence in PD were 
acknowledged when developing the AT intervention. This suggests that 
complex/behavioural interventions may be more effective when developed and 
targeted for a specific disease area. Furthermore, it is possible that 
complex/behavioural treatments will have optimal benefit if delivered by the same 
therapist in the home environment, as was the case in CAAT-PARK. 
   
11.4 Implications of This Work 
11.4.1 Implications for Clinical Practice 
The RCT findings presented earlier suggest that a relatively short dose of AT may 
be effective for improving adherence and QoL in PD. Although the current paucity 
of evidence for adherence enhancing interventions in PD means that healthcare 
policy is unlikely to change as a result of the findings of CAAT-PARK, the core 
principles of AT could be adopted by clinicians. Many of the fundamental 
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characteristics of AT were developed from well-established motivational 
interviewing and cognitive behavioural therapy principles. Therefore, whilst a 
seven week programme of AT is unlikely to be delivered by clinicians in the near 
future, exercising the basic core skills of AT when undergoing routine patient 
consultations may be of benefit for maximising adherence to treatment. This is 
particularly relevant to healthcare professionals such as PD nurse specialists who 
are more likely to visit patients at home.  
 
Furthermore, my systematic review highlighted that a variety of factors are 
associated with non-adherence to treatment in PD. Considering the ramifications of 
poor adherence to medication, routinely assessing for non-adherence in clinical 
settings by acknowledging the factors described in Chapter 3 is likely to help 
clinicians identify non-adherent patients. As a lack of acceptance of PD and the 
indication for treatment was identified as being a reason for non-adherence in some 
of the interviewed CAAT-PARK participants, this should also be acknowledged 
when treating patients with PD. 
 
11.4.2 Implications for Future Research 
As identified in Chapter 8, there were some limitations to the CAAT-PARK trial 
that future investigations of AT in PD should attempt to address. Firstly, all 
CAAT-PARK sessions were delivered by one trained therapist. It is therefore 
unknown whether AT delivered on a larger scale by clinical team members 
knowledgeable about PD and its pharmacological treatment (i.e. PD nurse 
specialists) will be as effective as was demonstrated in the RCT presented in this 
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thesis. As AT does not require a large amount of training time, future studies 
should incorporate multiple therapists (such as PD nurse specialists) from a variety 
of movement disorder centres to establish the efficacy of AT when delivered as 
part of a wider NHS service. It is important to note, however, that patients should 
only receive AT from one trained individual, as was suggested by the qualitative 
study findings presented earlier in Chapter 9.  
 
Secondly, due to time limitations, CAAT-PARK had a short follow-up period. 
Future studies should therefore incorporate a longer follow-up period to evaluate 
whether improved adherence is sustained over time. The impact of sustained 
adherence on clinical outcomes should also be investigated. Specifically, future 
studies need to investigate the duration of AT sessions required in PD and how 
long sessions should continue for in order to sustain the therapeutic effect. It may 
be possible that ‘top-up’ sessions delivered intermittently are able to maintain the 
treatment effect of AT over time. This however requires specific investigation as 
part of a longitudinal study.  
 
Thirdly, the TAU group in the CAAT-PARK RCT did not receive an intervention 
outside of usual care. As previously described, this limitation makes it difficult to 
determine whether the improved outcomes resulted from the efficacy of AT or 
simply due to increased patient-professional interaction. A TAU placebo 
intervention that offers increased professional contact (e.g. such as regular phone 
calls) would therefore be ideal in future investigations of AT in PD.  
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Furthermore, despite estimating the cost to deliver AT, larger scale studies of AT in 
PD should undertake a formal health economic analysis to accurately determine the 
cost effectiveness of the intervention. 
 
Finally, the qualitative findings suggested that the mechanism of AT in PD may be 
bi-directional, as was discussed in Chapter 10. Future studies in PD should 
therefore seek to confirm this model by evaluating the effect of AT on self-efficacy 
as part of a RCT. Additionally, observational studies may reveal whether low self-
efficacy is associated with non-adherence to anti-parkinsonian medication. 
 
11.5 Dissemination of This Work 
11.5.1 Conference Presentations 
I was invited to speak at the 2012 East Anglia Movement Disorder Group 
Conference where I presented the protocol for the CAAT-PARK RCT. I also 
presented a poster of the systematic review outlined in Chapter 3 at the 2012 
Parkinson’s UK Research Conference. 
 
11.5.2 Published Papers 
1. The protocol for the RCT was published in the open access journal TRIALS. The 
reference for this publication is as follows: 
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Daley DJ, Deane KH, Gray RJ, Worth PF, Clark AB, Sabanathan K, Pfeil M, 
Myint PK. The use of carer assisted adherence therapy for people with Parkinson's 
disease and their carers (CAAT-PARK): study protocol for a randomised 
controlled trial. Trials 2011;12:251. 
 
This can be accessed at: http://www.trialsjournal.com/content/12/1/251 
 
2. The systematic review of factors associated with medication non-adherence in 
people with PD was published in Parkinsonism & Related Disorders: The 
reference for this publication is as follows: 
 
Daley DJ, Myint PK, Gray RJ, Deane KHO. Systematic review on factors 
associated with medication non-adherence in Parkinson's disease. Parkinsonism 
and Related Disorders 2012;18(10):1053-1061. 
 
This can be accessed at: 
http://www.sciencedirect.com/science/article/pii/S1353802012003458 
 
Both of these published papers can be seen in Appendix 41. 
 
11.5.3 Manuscripts Submitted 
The RCT findings have been submitted to Parkinsonism & Related Disorders. The 
manuscript is currently under review. 
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11.5.4 Manuscripts in Preparation 
The qualitative study paper and the Cochrane systematic review are both under 
preparation. 
 
11.6 Conclusion 
For many people the symptoms of PD are controllable, particularly in earlier stages 
of the disease. Thus, appropriately titrated anti-parkinsonian medication can help to 
optimise QoL. This can allow some individuals to remain active and ambulatory 
for many years. However, in spite of this, poor adherence to treatment is prevalent 
in PD.  
 
The work presented in this thesis identified which factors are associated with 
medication non-adherence in PD. These factors were acknowledged when 
developing a novel therapy for improving adherence in PD (i.e. AT). This PD 
specific intervention was tested in a RCT (CAAT-PARK). Findings showed that 
medication adherence and QoL significantly improved in participants who received 
AT. A qualitative study was conducted to determine the acceptability of AT in 
people with PD. Findings showed that AT was highly acceptable and a mechanism 
of action for AT in PD was proposed. Researchers should seek to both confirm this 
proposed mechanism and establish the effectiveness of AT when delivered on a 
larger scale by clinical team members (i.e. PD nurse specialists) as part of a wider 
NHS service.  
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